
<html lang="en"     class="pb-page"  data-request-id="04fbe58d-0377-41ed-8793-ffa4fbe7fd79"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm301537p;website:website:acspubs;issue:issue:10.1021/jmcmar.2013.56.issue-4;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Structure–Activity Relationship Studies of Pyrazolo[3,4-d]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity against Acute Myeloid Leukemia in Vitro and in Vivo" /></meta><meta name="dc.Creator" content="Ling-Ling  Yang" /></meta><meta name="dc.Creator" content="Guo-Bo  Li" /></meta><meta name="dc.Creator" content="Shuang  Ma" /></meta><meta name="dc.Creator" content="Chan  Zou" /></meta><meta name="dc.Creator" content="Shu  Zhou" /></meta><meta name="dc.Creator" content="Qi-Zheng  Sun" /></meta><meta name="dc.Creator" content="Chuan  Cheng" /></meta><meta name="dc.Creator" content="Xin  Chen" /></meta><meta name="dc.Creator" content="Li-Jiao  Wang" /></meta><meta name="dc.Creator" content="Shan  Feng" /></meta><meta name="dc.Creator" content="Lin-Li  Li" /></meta><meta name="dc.Creator" content="Sheng-Yong  Yang" /></meta><meta name="dc.Description" content="We describe the structural optimization of a hit compound, 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)phenyl)-3-(3-methoxyphenyl)urea (1), which exhibits inhibitory activity but low potency agains..." /></meta><meta name="Description" content="We describe the structural optimization of a hit compound, 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)phenyl)-3-(3-methoxyphenyl)urea (1), which exhibits inhibitory activity but low potency agains..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 19, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm301537p" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm301537p" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm301537p" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm301537p" /></link>
        
    
    

<title>Structure–Activity Relationship Studies of Pyrazolo[3,4-d]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity against Acute Myeloid Leukemia in Vitro and in Vivo | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm301537p" /></meta><meta property="og:title" content="Structure–Activity Relationship Studies of Pyrazolo[3,4-d]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity against Acute Myeloid Leukemia in Vitro and in Vivo" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0019.jpeg" /></meta><meta property="og:description" content="We describe the structural optimization of a hit compound, 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)phenyl)-3-(3-methoxyphenyl)urea (1), which exhibits inhibitory activity but low potency against FLT3 and VEGFR2. A series of pyrazolo[3,4-d]pyrimidine derivatives were synthesized, and structure–activity relationship analysis using cell- and transgenic-zebrafish-based assays led to the discovery of a number of compounds that exhibited both high potency against FLT3-driven human acute myeloid leukemia (AML) MV4-11 cells and a considerable antiangiogenic effect in transgenic-zebrafish-based assays. The compound 1-(4-(1H-pyrazolo[3,4-d]pyrimidin −4-yloxy)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea (33), which exhibited the highest activity in preliminary in vivo anti-AML assays, was chosen for further anti-AML studies. The results demonstrated that compound 33 is a multikinase inhibitor that potently inhibits FLT3 and VEGFR2. In an MV4-11 xenograft mouse model, a once-daily dose of compound 33 at 10 mg/kg for 18 days led to complete tumor regression without obvious toxicity. Western blot and immunohistochemical analyses were performed to determine the mechanism of action of compound 33." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm301537p"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm301537p">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm301537p&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm301537p&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm301537p&amp;href=/doi/10.1021/jm301537p" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1641-1655</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm301435z" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm3016377" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure–Activity Relationship Studies of Pyrazolo[3,4-<i>d</i>]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity against Acute Myeloid Leukemia in Vitro and in Vivo</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ling-Ling++Yang">Ling-Ling Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guo-Bo++Li">Guo-Bo Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shuang++Ma">Shuang Ma</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chan++Zou">Chan Zou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shu++Zhou">Shu Zhou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qi-Zheng++Sun">Qi-Zheng Sun</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chuan++Cheng">Chuan Cheng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xin++Chen">Xin Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li-Jiao++Wang">Li-Jiao Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shan++Feng">Shan Feng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lin-Li++Li">Lin-Li Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sheng-Yong++Yang">Sheng-Yong Yang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, and <sup>‡</sup>College of Chemical Engineering, Sichuan University, Sichuan 610041, China</span></div><div class="corresp-info"><strong>*</strong>Phone: +86-28-85164063. Fax: +86-28-85164060. E-mail: <a href="/cdn-cgi/l/email-protection#9ce5fdf2fbefe5dcefffe9b2f9f8e9b2fff2"><span class="__cf_email__" data-cfemail="235a424d44505a635040560d4647560d404d">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm301537p&amp;href=/doi/10.1021%2Fjm301537p" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1641–1655</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 30, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 October 2012</li><li><span class="item_label"><b>Published</b> online</span>19 February 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 February 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm301537p" title="DOI URL">https://doi.org/10.1021/jm301537p</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1641%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLing-Ling%2BYang%252C%2BGuo-Bo%2BLi%252C%2BShuang%2BMa%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D4%26contentID%3Djm301537p%26title%3DStructure%25E2%2580%2593Activity%2BRelationship%2BStudies%2Bof%2BPyrazolo%255B3%252C4-d%255Dpyrimidine%2BDerivatives%2BLeading%2Bto%2Bthe%2BDiscovery%2Bof%2Ba%2BNovel%2BMultikinase%2BInhibitor%2BThat%2BPotently%2BInhibits%2BFLT3%2Band%2BVEGFR2%2Band%2BEvaluation%2Bof%2BIts%2BActivity%2Bagainst%2BAcute%2BMyeloid%2BLeukemia%2Bin%2BVitro%2Band%2Bin%2BVivo%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1655%26publicationDate%3DFebruary%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm301537p"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4433</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">47</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm301537p" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure–Activity Relationship Studies of Pyrazolo[3,4-d]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity against Acute Myeloid Leukemia in Vitro and in Vivo&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ling-Ling&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Guo-Bo&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Shuang&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Chan&quot;,&quot;last_name&quot;:&quot;Zou&quot;},{&quot;first_name&quot;:&quot;Shu&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Qi-Zheng&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Chuan&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Xin&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Li-Jiao&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Shan&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Lin-Li&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Sheng-Yong&quot;,&quot;last_name&quot;:&quot;Yang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;1641-1655&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm301537p&quot;},&quot;abstract&quot;:&quot;We describe the structural optimization of a hit compound, 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)phenyl)-3-(3-methoxyphenyl)urea (1), which exhibits inhibitory activity but low potency against FLT3 and VEGFR2. A series of pyrazolo[3,4-d]pyrimidine derivatives were synthesized, and structure–activity relationship analysis using cell- and transgenic-zebrafish-based assays led to the discovery of a number of compounds that exhibited both high potency against FLT3-driven human acute myeloid leukemia (AML) MV4-11 cells and a considerable antiangiogenic effect in transgenic-zebrafish-based assays. The compound 1-(4-(1H-pyrazolo[3,4-d]pyrimidin −4-yloxy)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea (33), which exhibited the highest activity in preliminary in vivo anti-AML assays, was chosen for further anti-AML studies. The results demonstrated that compound 33 is a multikinase inhibitor that potently inhibits FLT3 and VEGFR2. In an MV4-11 xenograft mouse model, a once-daily dose of compound 33 at 10 mg/k&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301537p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301537p" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301537p&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301537p" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301537p&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301537p" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm301537p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301537p&amp;href=/doi/10.1021/jm301537p" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm301537p" /></input><a href="/doi/pdf/10.1021/jm301537p" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm301537p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm301537p%26sid%3Dliteratum%253Aachs%26pmid%3D23362959%26genre%3Darticle%26aulast%3DYang%26date%3D2013%26atitle%3DStructure%25E2%2580%2593Activity%2BRelationship%2BStudies%2Bof%2BPyrazolo%255B3%252C4-d%255Dpyrimidine%2BDerivatives%2BLeading%2Bto%2Bthe%2BDiscovery%2Bof%2Ba%2BNovel%2BMultikinase%2BInhibitor%2BThat%2BPotently%2BInhibits%2BFLT3%2Band%2BVEGFR2%2Band%2BEvaluation%2Bof%2BIts%2BActivity%2Bagainst%2BAcute%2BMyeloid%2BLeukemia%2Bin%2BVitro%2Band%2Bin%2BVivo%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D4%26spage%3D1641%26epage%3D1655%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291917" title="Pyrimidine">Pyrimidine</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jmcmar.2013.56.issue-4/production/jmcmar.2013.56.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We describe the structural optimization of a hit compound, 1-(4-(1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-ylamino)phenyl)-3-(3-methoxyphenyl)urea (<b>1</b>), which exhibits inhibitory activity but low potency against FLT3 and VEGFR2. A series of pyrazolo[3,4-<i>d</i>]pyrimidine derivatives were synthesized, and structure–activity relationship analysis using cell- and transgenic-zebrafish-based assays led to the discovery of a number of compounds that exhibited both high potency against FLT3-driven human acute myeloid leukemia (AML) MV4-11 cells and a considerable antiangiogenic effect in transgenic-zebrafish-based assays. The compound 1-(4-(1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin −4-yloxy)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea (<b>33</b>), which exhibited the highest activity in preliminary in vivo anti-AML assays, was chosen for further anti-AML studies. The results demonstrated that compound <b>33</b> is a multikinase inhibitor that potently inhibits FLT3 and VEGFR2. In an MV4-11 xenograft mouse model, a once-daily dose of compound <b>33</b> at 10 mg/kg for 18 days led to complete tumor regression without obvious toxicity. Western blot and immunohistochemical analyses were performed to determine the mechanism of action of compound <b>33</b>.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41505" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41505" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Acute myeloid leukemia (AML) is a malignant disorder of hematopoietic cells that is characterized by the rapid growth of abnormal white blood cells, which accumulate in the bone marrow and hinder the development of normal blood cells.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> AML has become one of the leading causes of cancer-related mortality worldwide. Recent studies regarding the pathogenesis of AML have revealed that mutations and/or aberrant expression of specific protein tyrosine kinases (PTKs) are frequently responsible for the development of AML.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5">(2-5)</a> Of special note is the FMS-like tyrosine kinase 3 (FLT3), which is a class III receptor tyrosine kinase. Activating mutations in FLT3 kinase are found in up to one-third of AML cases; the most prevalent activating mutations are “internal tandem duplications” (ITDs) in the juxtamembrane domain that lead to constitutive, ligand-independent activation of the kinase.<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6-8)</a> Numerous studies have demonstrated that FLT3-ITD mutations represent a driving mutation for the development of AML and are associated with a poor prognosis for overall survival.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9-11)</a> Therefore, FLT3 has been considered a valid therapeutic target for AML treatment, and many pharmaceutical companies and research institutes have been involved in the discovery of FLT3 inhibitors.</div><div class="NLM_p">A number of small-molecule FLT3 inhibitors have been reported, and several, such as SU-11248, CHIR-258, PKC412, CEP-701, MLN518, and AC220, have been investigated in clinical trials.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15 ref16 ref17 ref18">(12-18)</a> However, with few exceptions, such as AC220, the clinical efficacy of these FLT3 inhibitors in patients with AML has been unimpressive, with responses characterized by transient clearance of leukemia blast cells, followed by progressive disease or resistance to the treatment.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The causes of this unimpressive efficacy are complex, but a critical factor may be aberrant VEGF signaling in the bone marrow of AML patients, which promotes autocrine AML blast cell proliferation, survival, and chemotherapy resistance and mediates paracrine vascular endothelial cell-controlled angiogenesis in AML.<a onclick="showRef(event, 'ref19 ref20 ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21 ref22 ref23 ref24">(19-24)</a> More recently, researchers focusing on bone marrow stem cell niches have demonstrated a role for VEGF signaling in the preservation of several cell types within these niches.<a onclick="showRef(event, 'ref23 ref25 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref23 ref25 ref26 ref27 ref28">(23, 25-28)</a> Bone marrow niches have been proposed to be a protective microenvironment for AML cells that could be responsible for relapses in AML patients.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> These studies have indicated that therapeutics targeting VEGF signaling could potentially prevent relapses of AML. Because VEGFR2 is the key receptor of VEGF, we hypothesized that a dual FLT3/VEGFR2 tyrosine kinase inhibitor could function in both clearing leukemia blast cells and preventing relapses of AML.</div><div class="NLM_p">To identify potent dual FLT3/VEGFR2 inhibitors, we recently performed virtual screening against several commercial chemical databases and an in-house chemical library, followed by an in vitro kinase inhibition assay. From the hit compounds obtained, we chose the compound 1-(4-(1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-ylamino)phenyl)-3-(3-methoxyphenyl)urea (<b>1</b>; Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>a) for further structural optimization. Compound <b>1</b> was chosen because the 1-(4-(1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-ylamino)phenyl)-3-phenylurea scaffold is novel for FLT3 and VEGFR2 inhibitors (no FLT3 or VEGFR2 inhibitors possess this scaffold) and has a relatively low molecular weight (375 Da).<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a> Compound <b>1</b> inhibits both FLT3 and VEGFR2 with a half-maximal inhibitory concentration (IC<sub>50</sub>) of 1.278 μM for FLT3 and 0.305 μM for VEGFR2. Thus, the potency of compound <b>1</b> against FLT3 and VEGFR2 is poor and must be optimized further. The purpose of this study was to perform structural modifications to optimize the potency of compound <b>1</b> against both FLT3 and VEGFR2. A series of novel pyrazolo[3,4-<i>d</i>]pyrimidine derivatives were synthesized and tested for their in vitro anti-AML activity and antiangiogenic effect. The most potent derivatives were then subjected to further in vitro and in vivo assays. In this paper, we report the chemical synthesis and structure–activity relationship (SAR) studies of this novel series of compounds, as well as the in vitro and in vivo anti-AML activities of the most active compounds.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0013.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Structure of compound <b>1</b>. (b) Schematic showing subgroups or atoms that were the focus of structural modifications.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">2 Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63188" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63188" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To explore the SAR of the pyrazolo[3,4-<i>d</i>]pyrimidine compound class, a series of derivatives were synthesized according to the synthetic routes outlined in Schemes <a class="ref internalNav" href="#sch1" aria-label="1">1</a>–<a class="ref internalNav" href="#sch6" aria-label="6">6</a>. All of the target compounds were prepared from the general intermediate 4-chloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine (<b>35</b>), which was obtained through reaction of phosphorus oxychloride with commercially available 1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4(5<i>H</i>)-one (<b>34</b>) with a yield of 56% (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) phosphorus oxychloride, DIEA, toluene, reflux, 56%.</p></p></figure><div class="NLM_p">All the target compounds can be classified into two categories: 4-<i>N</i>-pyrazolopyrimidine derivatives <b>1</b>–<b>5</b> and 4-<i>O</i>-pyrazolopyrimidine derivatives <b>6</b>–<b>33</b>. Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a> depicts the general synthetic route for the 4-<i>N</i>-pyrazolopyrimidine derivatives <b>1</b>–<b>5</b>. First, intermediates <b>38</b>–<b>42</b> were prepared by a synthetic method similar to that described previously.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Target compounds <b>1</b>–<b>5</b> were then obtained by a classic nucleophilic substitution reaction between <b>38</b>–<b>42</b> and the previously synthesized intermediate <b>35</b> in 1-butanol in the presence of concentrated HCl in 74–80% yield.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (b) triphosgene, Et<sub>3</sub>N, THF, rt; (c) RNH<sub>2</sub>, THF, 45 °C, 72–96% for two steps; (d) Fe, NH<sub>4</sub>Cl, EtOH, H<sub>2</sub>O, 91–98%; (e) HCl, 1-BuOH, 100 °C, 74–80%.</p></p></figure><div class="NLM_p">The 4-<i>O</i>-pyrazolopyrimidine derivatives <b>6</b>–<b>9</b>, <b>20</b>, and <b>25</b>–<b>33</b> were obtained via the two routes outlined in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>.<a onclick="showRef(event, 'ref31 ref33'); return false;" href="javascript:void(0);" class="ref ref31 ref33">(31, 33)</a> In route 1, condensation of 4-aminophenol with the corresponding isocyanates in THF provided the desired urea derivative intermediates <b>62</b>–<b>75</b> in high yields with short reaction times. Subsequent nucleophilic substitution of intermediate <b>35</b> with the phenolic hydroxyl group of the urea derivatives <b>62</b>–<b>75</b> in the presence of sodium hydroxide produced the target compounds <b>6</b>–<b>9</b>, <b>20</b>, and <b>25</b>–<b>33</b> in low yield (see Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). In route 2, 4-aminophenol initially forms 4-aminophenolate in a sodium hydroxide solution. Selective nucleophilic substitution reaction of phenolate anion (bearing an oxygen anion) with the chloride of compound <b>35</b> resulted in intermediate <b>76</b> in a yield of 32% since the nucleophilicity of the oxygen anion is relatively stronger than that of nitrogen in 4-aminophenol.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Then target compounds <b>6</b>–<b>9</b>, <b>20</b>, and <b>25</b>–<b>33</b> were produced in excellent yield by the reaction of intermediate <b>76</b> with the corresponding isocyanates under reflux in acetonitrile (see Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). The second route gave high yields and thus was adopted here. In addition, intermediate <b>76</b> was reacted with commercially available 4-bromobenzoic acid and 2-(4-bromophenyl)acetic acid to give compounds <b>18</b> and <b>19</b>, respectively, which contain an amide or acetamide moiety (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>).</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (f) triphosgene, THF, Et<sub>3</sub>N, rt; 4-aminophenol, THF, 45 °C, 64–99%; (g) sodium hydroxide, H<sub>2</sub>O, THF, 60 °C, 21–34%; (h) 4-aminophenol, sodium hydroxide, H<sub>2</sub>O, THF, 60 °C, 32%; (i) substituted anilines, triphosgene, THF, Et<sub>3</sub>N, rt; acetonitrile, reflux, 61–84%; (j) HOBT, EDCI, DIEA, THF, rt to reflux, 66–73%.</p></p></figure><div class="NLM_p">Compounds <b>10</b> and <b>11</b>, which contain a methyl substituent at the 1-NH of pyrazolopyrimidine, were prepared from the corresponding analogues <b>6</b> and <b>9</b> (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>). In this reaction, sodium hydroxide was used to deprotonate the NH group in DMF at ambient temperature. Iodomethane was then added, and the mixture continued to react overnight.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (k) iodomethane (MeI), sodium hydroxide, DMF, rt, 65–70%.</p></p></figure><div class="NLM_p">The 4-<i>O</i>-pyrazolopyrimidine derivatives <b>12</b>–<b>17</b> were synthesized as outlined in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. Urea compounds <b>12</b> and <b>13</b> were obtained via the second route (see Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>), as described above. Compounds <b>14</b>–<b>17</b> were obtained following the condensation of commercially available carboxylic acids and intermediate <b>77</b> in a mixture of 1.0 equiv of HOBT, 1.0 equiv of EDCI, and 1.5 equiv of DIEA. Compounds <b>12</b>–<b>17</b> were all obtained in high yields.</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (h) 3-aminophenol, sodium hydroxide, THF, H<sub>2</sub>O, 60 °C, 38%; (i) for <b>12</b> and <b>13</b>, substituted aniline, triphosgene, THF, Et<sub>3</sub>N, rt; acetonitrile, reflux, 87–89%; for <b>14</b> and <b>15</b>, HOBT, EDCI, DIEA, THF, rt to reflux, 71–74%; (m) HOBT, EDCI, DIEA, THF, rt to reflux, 79–86%.</p></p></figure><div class="NLM_p">Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a> depicts the general reaction route of compounds <b>21</b>–<b>24</b>. Intermediate <b>76</b>, which was obtained via route 2 in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>, was reacted with various isocyanates to give the final products with yields ranging from 44% to quantitative.</div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (n) amine, triphosgene, THF, Et<sub>3</sub>N, rt; acetonitrile, reflux, 44–77%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">3 Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75845" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75845" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">3.1 SAR of Pyrazolo[3,4-<i>d</i>]pyrimidine Derivatives Using Cell- and Transgenic-Zebrafish-Based Assays</h3><div class="NLM_p">For SAR analysis, cell- and transgenic-zebrafish-based assays were used. To screen FLT3 kinase inhibitors, two tumor cell lines, MV4-11 and HeLa, were chosen. MV4-11 is a human AML cell line whose viability depends on the activation of mutated FLT3 kinase (FLT3-ITD).<a onclick="showRef(event, 'ref34 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36 ref37">(34-37)</a> HeLa is a human cancerous cervical tumor cell line whose viability is independent of FLT3; Hela cells were used to rule out activity due to non-FLT3-mediated effects (“off-target” or cellular toxic effects). Compounds are likely better FLT3 inhibitors if they have high potency against MV4-11 cells but low or no activity against HeLa cells. To screen VEGFR2 kinase inhibitors, an in vivo live fluorescent transgenic zebrafish (FLK-1:EGFP) assay was adopted; VEGFR2 is one of the key regulators of angiogenesis, and the transgenic zebrafish assay has been utilized as a less costly and more rapid in vivo method for the screening of agents with antiangiogenic activity.<a onclick="showRef(event, 'ref38 ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40 ref41">(38-41)</a> The combination of cell- and transgenic-zebrafish-based assays is an effective method for identifying dual inhibitors of FLT3 and VEGFR2. There are some advantages of performing SAR analysis with cell- and transgenic-zebrafish-based assays rather than enzymatic assays for hit/lead optimization. For example, SAR analysis based on cellular assays may permit the evaluation of both the intrinsic activity of the compounds against the protein target and the ability of the compounds to permeate the cell wall. The transgenic zebrafish assay combines the physiological complexity of an in vivo vertebrate model with the speed of high-throughput screening. Thus, SAR studies based on both cell (in vitro) and zebrafish (in vivo) assays can potentially accelerate the hit/lead optimization process to rapidly obtain an agent with bioactivity both in vitro and in vivo. Certainly, there may exist some possibility of off-target effects contributing to cell growth inhibitory potency or antiangiogenic activity, although some strategies, such as the use of Hela cells, have been adopted to rule out this possibility. Thus, enzymatic assays were also performed but only on compounds with higher potency in cell and zebrafish assays. The most active compounds in the enzyme, cell, and zebrafish assays were selected for further in vivo experiments to evaluate their anti-AML activity.</div><div class="NLM_p">The SAR analysis below focuses on four positions: the 4-position linker atom (Y), the N-1 position of pyrazolo[3,4-<i>d</i>]pyrimidine (R<sup>1</sup>), the bridge group that connects rings A and B, and the ring B moiety (see Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>b).</div><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i5" class="anchor-spacer"></div><h4 class="article-section__title" id="_i5">3.1.1 Impact of the 4-Position Linker Atom (Y) of Pyrazolo[3,4-<i>d</i>]pyrimidine</h4><div class="NLM_p">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> shows the bioactivities of two series of 1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine derivatives, namely, 4-anilino-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine and 4-phenoxy-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine derivatives, which contain a nitrogen (−NH) and oxygen (−O) atom at the 4-position linker site, respectively. The cell growth inhibitory activities (IC<sub>50</sub>) against MV4-11 of the 4-phenoxy-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine derivatives <b>6</b>, <b>7</b>, <b>8</b>, <b>9</b>, and <b>22</b> were 0.020, 0.083, 0.037, 0.005, and 1.077 μM, respectively, corresponding to a higher potency than that of the corresponding 4-anilino-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine derivatives <b>1</b>, <b>2</b>, <b>3</b>, <b>4,</b> and <b>5</b> (IC<sub>50</sub> = 1.65, 1.24, 1.69, 0.26, and 2.05 μM, respectively). Here one may argue that the lower MV4-11 cell growth inhibitory potency observed with compounds <b>1</b>–<b>5</b> might be due to poorer cell permeability. To clarify this issue, we tested the enzymatic inhibitory potency of compounds <b>1</b>–<b>5</b> against the FLT3 kinase, and the results showed that compounds <b>1</b>–<b>5</b> had a poor FLT3 kinase inhibitory potency (1 μM < IC<sub>50</sub> < 10 μM). These results together with the fact that many of their analogues displayed a higher MV4-11 cell growth inhibitory potency (see below) demonstrated that the lower MV4-11 cell growth inhibitory potency observed with compounds <b>1</b>–<b>5</b> should not be, at least not mainly, due to poorer cell permeability. All of the 1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine derivatives had IC<sub>50</sub> values greater than 10 μM against HeLa cells (the same phenomenon will be seen below), indicating that the cell growth inhibitory activities of these compounds against the MV4-11 cells were not due to cellular toxicity. By contrast, all of the 4-phenoxy-1<i>H</i>-pyrazolo[3,4-<i>d</i>] pyrimidine derivatives also exhibited slightly more potent antiangiogenic activity in zebrafish assays than did the corresponding 4-anilino-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine derivatives. Thus, we can conclude that the 4-phenoxy-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine derivatives are more potent than the 4-anilino-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine derivatives, in terms of their bioactivities in both cell and zebrafish assays.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Cell Growth Inhibitory Activities of Pyrazolo[3,4-<i>d</i>]pyrimidine Derivatives with Different 4-Position Linker Atoms (Y) and Different Substituents at the N-1 Position (R<sup>1</sup>) of Pyrazolo[3,4-<i>d</i>]pyrimidine against FLT3-ITD-Dependent MV4-11 Cells and FLT3-Independent HeLa Cells, as Well as Their Antiangiogenic Activities in Transgenic-Zebrafish-Based Assays</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0007.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0008.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean ± SD.</p></div></div><div></div></div></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i7" class="anchor-spacer"></div><h4 class="article-section__title" id="_i7">3.1.2 Substitution Effect of the N-1 Position (R<sup>1</sup>) of Pyrazolo[3,4-<i>d</i>]pyrimidine</h4><div class="NLM_p last">The possible influence of the substitution of the N-1 position (R<sup>1</sup>) of pyrazolo[3,4-<i>d</i>]pyrimidine was examined next. The N-1 hydrogen of the pyrazolo[3,4-<i>d</i>]pyrimidine moiety of the two most potent 4-phenoxy-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine derivatives (<b>6</b> and <b>9</b>) was replaced by a methyl group, yielding compounds <b>10</b> and <b>11</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), respectively. Compounds <b>10</b> and <b>11</b> exhibited much lower antiproliferative and antiangiogenic activities than their unsubstituted counterparts <b>6</b> and <b>9</b>, implying that substitution at the N-1 position of pyrazolo[3,4-<i>d</i>]pyrimidine is not beneficial for activity.</div></div><div id="sec3_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8">3.1.3 Influence of Different Bridge Groups Connecting Ring A and Ring B</h4><div class="NLM_p">The bioactivities of a series of 4-phenoxy-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine derivatives with different bridge groups connecting ring A and ring B, including <i>p</i>-urea, <i>m</i>-urea, <i>p</i>-amide, <i>m</i>-amide, <i>p</i>-acetamide, and <i>m</i>-acetamide, are presented in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Replacement of the urea group by an amide or acetamide led to a decreased bioactivity (<b>12</b> vs <b>14</b> and <b>16</b>; <b>13</b> vs <b>15</b> and <b>17</b>; <b>7</b> vs <b>18</b> and <b>19</b>) in the cellular assay. Furthermore, a comparison of the bioactivities of the compound pairs [<b>12</b> (4.53 μM), <b>9</b> (0.005 μM)] and [<b>13</b> (7.82 μM), <b>7</b> (0.083 μM)], in which the urea group is attached to the <i>para</i>- or <i>meta</i>-position, respectively, indicated that substitution at the <i>para</i>-position was preferred to substitution at the <i>meta</i>-position to increase bioactivity in the cellular assay.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. 4-Phenoxy-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine Derivatives with Different Bridge Groups Connecting Rings A and B, Together with Their Cell Growth Inhibitory Activities against FLT3-ITD-Dependent MV4-11 Cells and FLT3-Independent HeLa Cells and Their Zebrafish-Based Antiangiogenic Activities</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0009.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0010.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean ± SD.</p></div></div><div></div></div></div><div id="sec3_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10">3.1.4 Influence of Variation of the Ring B Moiety</h4><div class="NLM_p">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> presents the bioactivities of a series of 4-phenoxy-1<i>H</i>-pyrazolo[3,4-<i>d</i>] pyrimidine derivatives containing a variety of moieties at the ring B position. From Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, we can see that, compared with other moieties at the ring B position, including a six-membered heteroaromatic ring (<b>21</b>) and other six-membered cyclic groups (<b>22</b>–<b>24</b>), a phenyl group at the ring B position yielded a more potent compound (<b>20</b>) in both the cell and zebrafish assays. We then explored the influence of different substituents on the phenyl ring (ring B). It is clear that, compared with compound <b>20</b>, which has no substituent on ring B, substitution at the <i>meta</i>- and/or <i>para</i>-position of ring B considerably increased the potency of cell growth inhibition against MV4-11. Substitution on ring B also increased the antiangiogenic potency, with the exception of compound <b>26</b>, which contains a morpholine ring. Furthermore, for both the cell growth inhibitory activity against MV4-11 and antiangiogenic activity, compounds with substituents at the <i>meta</i>-position were identically potent or slightly more potent compared with compounds with substituents at the <i>para</i>-position (see <b>27</b> vs <b>9</b>, <b>29</b> vs <b>25</b>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. 4-Phenoxy-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine Derivatives Containing Various Moieties at the Ring B Position Together with Their Cell Growth Inhibitory Activities against FLT3-ITD-Dependent MV4-11 Cells and FLT3-Independent Hela Cells and Zebrafish-Based Antiangiogenic Activities</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0011.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0012.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean ± SD.</p></div></div><div></div></div><div class="NLM_p">Collectively, the structural optimization and SAR studies led to the discovery of a number of compounds that exhibited both high potency against FLT3-driven human AML MV4-11 cells and a considerable antiangiogenic effect in transgenic-zebrafish-based assays. The three most potent compounds, <b>9</b>, <b>27</b>, and <b>33</b>, displayed nanomolar potencies at the cellular level and low micromolar potencies in the zebrafish assay. The kinase inhibitory potencies (IC<sub>50</sub>) against FLT3 and VEGFR2, as well as the binding affinity (<i>K</i><sub>d</sub>, dissociation constant) for FLT3-ITD of the three compounds were then measured, and the results are presented in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. The three compounds are all potent FLT3 and VEGFR2 inhibitors, and their kinase inhibitory activities are at least as potent as that of sorafenib, which is a multikinase inhibitor and can potently inhibit VEGFR2 and FLT3; sorafenib is currently in clinical studies for the treatment of AML.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43, 44)</a> Of note is that compounds <b>27</b> and <b>33</b> showed lower nanomolar binding affinity (<i>K</i><sub>d</sub>) against the FLT3-ITD mutant, which is at least 10 times more potent compared with sorafenib. We subsequently performed a preliminary in vivo anti-AML study in a xenograft MV4-11 mouse model. Compound <b>33</b> was the most active in this study (see Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). This increased activity could be due to the potentially increased bioavailability of compound <b>33</b> compared with the other compounds. Further in-depth in vitro (including enzymatic and cellular assays) and in vivo anti-AML studies were subsequently performed with compound <b>33</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Kinase Inhibitory Potency against FLT3 and VEGFR2 for the Most Active Compounds in Cell and Zebrafish Assays</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">FLT3 IC<sub>50</sub>, μM</th><th class="colsep0 rowsep0" align="center" char=".">VEGFR2 IC<sub>50</sub>, μM</th><th class="colsep0 rowsep0" align="center" char=".">FLT3-ITD <i>K</i><sub>d</sub>, μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="char" char=".">0.032</td><td class="colsep0 rowsep0" align="char" char=".">0.038</td><td class="colsep0 rowsep0" align="char" char=".">0.91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="char" char=".">0.009</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="char" char=".">0.0066</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="char" char=".">0.039</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="char" char=".">0.0043</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sorafenib</td><td class="colsep0 rowsep0" align="char" char=".">0.033</td><td class="colsep0 rowsep0" align="char" char=".">0.090</td><td class="colsep0 rowsep0" align="char" char=".">0.079</td></tr></tbody></table></div></div><figure id="fig2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0014.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Preliminary in vivo anti-AML assays. Daily oral administration of compounds <b>9</b>, <b>27</b>, and <b>33</b> at concentrations of 5, 7.5, and 5 mg/kg/d, respectively, was initiated when the MV4-11 tumors reached approximately 400 mm<sup>3</sup> in volume (three mice per group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">3.2 Enzymatic Activity of Compound <b>33</b> against Various Kinases</h3><div class="NLM_p">The kinase inhibition profile of compound <b>33</b> against a panel of selected recombinant human protein kinases is presented in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Compound <b>33</b> potently inhibited FLT3 and VEGFR2 kinases (IC<sub>50</sub> = 0.039 μM for FLT3 and 0.012 μM for VEGFR2). Compound <b>33</b> also exhibits considerable potency against several other kinases, including c-RAF (0.072 μM), PDGFRα (0.223 μM), PDGFRβ (0.408 μM), c-Kit (0.507 μM), and FGFR2 (1.805 μM). Compound <b>33</b> displayed almost no inhibitory activity against 23 other tested protein kinases. These data demonstrate that compound <b>33</b> is a multikinase inhibitor that potently inhibits FLT3 and VEGFR2 kinases.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Kinase Inhibition Profile for Compound <b>33</b> against Human FLT3/VEGFR2 and a Panel of Other Selected Protein Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub>, μM</th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub>, μM</th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub>, μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt3</td><td class="colsep0 rowsep0" align="left">0.039</td><td class="colsep0 rowsep0" align="left">Pim-1</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="left">DMPK</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VEGFR2</td><td class="colsep0 rowsep0" align="left">0.012</td><td class="colsep0 rowsep0" align="left">Syk</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="left">ERN1</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-RAF</td><td class="colsep0 rowsep0" align="left">0.072</td><td class="colsep0 rowsep0" align="left">aurora A</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="left">IGF1R</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRα</td><td class="colsep0 rowsep0" align="left">0.223</td><td class="colsep0 rowsep0" align="left">aurora B</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="left">MLK1</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRβ</td><td class="colsep0 rowsep0" align="left">0.408</td><td class="colsep0 rowsep0" align="left">PLK1</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="left">MEK1</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Kit</td><td class="colsep0 rowsep0" align="left">0.507</td><td class="colsep0 rowsep0" align="left">CDK2</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="left">PAK1</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR2</td><td class="colsep0 rowsep0" align="left">1.805</td><td class="colsep0 rowsep0" align="left">CHEK1</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="left">PAK2</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">CAMK4</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="left">PAK4</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ErBB2</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">CTK</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="left">ERK</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ErBB4</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">DLK</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="left">Lck</td><td class="colsep0 rowsep0" align="center">>10</td></tr></tbody></table></div></div><div class="NLM_p last">Furthermore, a primary kinase selectivity assay was performed through measuring the binding affinities of compound <b>33</b> with a large set of representative kinases. A total of 131 kinases were selected; these kinases cover all of the kinase subfamilies, and most of them are common kinases. Compound <b>33</b> was screened against the kinase set at a fixed concentration of 10 μM. The results, shown in Figure S1 and Table S1 (see the <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>), indicate that compound <b>33</b> also has a considerable binding affinity for a few of the kinases in addition to FLT3 and VEGFR2. The calculated selectivity scores, S(1), S(10), and S(35), whose definitions are given in the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>, are 0.076, 0.122, and 0.206, respectively.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">3.3 In Vitro Cell Growth Inhibitory Activity of Compound <b>33</b></h3><div class="NLM_p">The cell growth inhibitory potency of compound <b>33</b> against various leukemia and solid tumor cell lines was examined, and the results are presented in Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>. As noted previously, compound <b>33</b> potently inhibits the viability of FLT3-driven AML MV4-11 cells, with an IC<sub>50</sub> value of 0.004 μM (also see Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>a). It exhibited weak inhibitory activity against several other cell lines, including Jurkat (leukemia, IC<sub>50</sub> = 8.72 μM), MKN45 (gastric cancer, IC<sub>50</sub> = 8.23 μM), MDA-MB-468 (breast cancer, IC<sub>50</sub> = 6.68 μM), and TT (thyroid cancer, IC<sub>50</sub> = 3.42 μM). Negligible activity against the remaining 16 human cancer cell lines was observed. These results indicate that compound <b>33</b> is relatively selective for the human AML cell line MV4-11.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Cell Growth Inhibitory Potency of Compound <b>33</b> against Various Leukemia and Solid Tumor Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">tumor type</th><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub>,<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> μM</th><th class="colsep0 rowsep0" align="center">tumor type</th><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub>,<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> μM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">leukemia, AML</td><td class="colsep0 rowsep0" align="left">MV4-11</td><td class="colsep0 rowsep0" align="left">0.004 ± 0.0004</td><td class="colsep0 rowsep0" align="left">liver cancer</td><td class="colsep0 rowsep0" align="left">Bel7402</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">leukemia, ALL</td><td class="colsep0 rowsep0" align="left">Jurkat</td><td class="colsep0 rowsep0" align="left">8.72 ± 0.440</td><td class="colsep0 rowsep0" align="left">liver cancer</td><td class="colsep0 rowsep0" align="left">SMMC7721</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">leukemia, APL</td><td class="colsep0 rowsep0" align="left">HL60</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">lung cancer</td><td class="colsep0 rowsep0" align="left">A549</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">leukemia, CML</td><td class="colsep0 rowsep0" align="left">K562</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">lymphoma</td><td class="colsep0 rowsep0" align="left">Raji</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cervical cancer</td><td class="colsep0 rowsep0" align="left">Hela</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">lymphoma</td><td class="colsep0 rowsep0" align="left">U937</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">colon cancer</td><td class="colsep0 rowsep0" align="left">HCT116</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">lymphoma</td><td class="colsep0 rowsep0" align="left">Karpass299</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gastric cancer</td><td class="colsep0 rowsep0" align="left">MKN45</td><td class="colsep0 rowsep0" align="left">8.23 ± 0.485</td><td class="colsep0 rowsep0" align="left">colorectal carcinoma</td><td class="colsep0 rowsep0" align="left">LoVo</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">breast cancer</td><td class="colsep0 rowsep0" align="left">MDA-MB-468</td><td class="colsep0 rowsep0" align="left">6.68 ± 0.652</td><td class="colsep0 rowsep0" align="left">prostate cancer</td><td class="colsep0 rowsep0" align="left">DU145</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">breast cancer</td><td class="colsep0 rowsep0" align="left">MCF-7</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">multiple myeloma</td><td class="colsep0 rowsep0" align="left">U266</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">thyroid cancer</td><td class="colsep0 rowsep0" align="left">TT</td><td class="colsep0 rowsep0" align="left">3.42</td><td class="colsep0 rowsep0" align="left">ovarian cancer</td><td class="colsep0 rowsep0" align="left">SKOV3</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ovarian cancer</td><td class="colsep0 rowsep0" align="left">SK</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Each compound was tested in triplicate; the data are presented as the mean ± SD.</p></div></div></div><figure id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0015.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Growth inhibitory profile of compound <b>33</b> against MV4-11 cells using the MTT assay method. (b) A flow cytometry assay was performed to examine cell apoptosis. MV4-11 cells (1 × 10<sup>5</sup>) were harvested after treatment with various drug concentrations for 24 h. Cells were stained with an Annexin V & PI Kit and analyzed by flow cytometry. Percentages in the bottom right quadrants are the ratio of cells in early apoptosis (annexin V positive and PI negative). Percentages in the upper right quadrants are the ratio of cells in late apoptosis (Annexin V positive and PI positive). (c) Western blot analysis was used to examine the phosphorylation of FLT3 and downstream signals in MV4-11 cells treated with different doses of compound <b>33</b> for 20 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">3.4 Apoptosis Assays and Signaling Inhibition in MV4-11 Cells</h3><div class="NLM_p">A flow cytometry assay was performed to examine cell apoptosis upon treatment with compound <b>33</b>. Compound <b>33</b> induced apoptosis in MV4-11 cells in a concentration-dependent manner (see Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>b). At a concentration of 0.10 μM, an apoptosis rate of 35.8% was observed.</div><div class="NLM_p">The ability of compound <b>33</b> to inhibit the activation of FLT3 and downstream signaling proteins in intact cells was assessed by Western blot analysis. After a 5 h treatment with increasing concentrations of compound <b>33</b>, MV4-11 cells were harvested and lysed for an IP/wt assay. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>c, compound <b>33</b> inhibited FLT3 phosphorylation in a dose-dependent manner. Consistent with the downregulation of the phosphorylation of FLT3, the phosphorylation of the downstream signaling proteins STAT5 and ERK1/2 was also significantly inhibited at concentrations of compound <b>33</b> >0.003 μM (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>c). The observed IC<sub>50</sub> value was approximately 0.003 μM for phosphorylation of FLT3, 0.003 μM for STAT5, and 0.001 μM for Erk1/2.</div><div class="NLM_p last">Here we have to point out that inhibition of VEGF signaling in intact MV4-11 cells was not measured because MV-411 cells express very low levels of VEGFR2, below that which can be detected by Western blot. VEGFR2 inhibition should not significantly contribute to the cell viability of MV4-11 cells. As mentioned before, aberrant VEGF signaling often exists in the bone marrow of AML patients, which has been demonstrated to be associated with drug resistance and relapses of AML after treatment with FLT3 inhibitors. Blockade of VEGF signaling is expected to play important roles in preventing drug resistance and relapses of AML. Thus, we shall in the next section examine the suppressive ability of compound <b>33</b> against the VEGF signaling using transgenic-zebrafish-based assays.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">3.5 Antiangiogenic Activity of Compound <b>33</b></h3><div class="NLM_p">The effect of compound <b>33</b> on embryonic angiogenesis in zebrafish was examined. Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>a shows 33hpf zebrafish embryos treated with 1.25, 2.5, and 5 μM <b>33</b>, as well as a blank control. Treatment of live fish embryos with compound <b>33</b> completely blocked the formation of intersegmental vessels (ISVs) at a concentration of 5 μM while preserving fluorescence in the doral aorta and major cranial vessels. At 1.25 or 2.5 μM <b>33</b>, the formation of intersegmental vessels was considerably inhibited compared with that of the vehicle control group, indicating a dose-dependent inhibition pattern. The IC<sub>50</sub> value was approximately 2.5 μM (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>b).</div><figure id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0016.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) 33hpf zebrafish embryos treated with blank control or 1.25, 2.5, or 5 μM <b>33</b>. ISV budding and outgrowth were almost completely inhibited by treatment with 5 μM <b>33</b>. (b) Statistics of ISV length in embryos treated with blank control and compound <b>33</b>. ISVs above the yolk extension were counted. Key: columns, mean; bars, SD (<i>n</i> = 11; ANOVA; **, <i>P</i> < 0.01 vs the control).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">3.6 In Vivo Effects of <b>33</b> against sc MV4-11 Tumor Xenografts</h3><div class="NLM_p">The in vivo anti-AML activity of compound <b>33</b> was evaluated using the FLT3-ITD-positive MV4-11 xenograft model. When the tumor grew to a volume of 300–500 mm<sup>3</sup>, the mice were grouped and treated orally once daily with 1, 3, or 10 mg/kg/d of compound <b>33</b> for 18 days. The tumor volumes were measured every 3 d. Treatment with compound <b>33</b> at 10 mg/kg/d resulted in rapid and complete tumor regression in all mice in this group. Compound <b>33</b> treatment at 3 mg/kg/d stopped tumor growth and resulted in a slight regression of tumor growth (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>a). Moreover, throughout the experiment, no significant weight loss or any other obvious signs of toxicity were observed for any of the compound <b>33</b>-treated mice (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>b).</div><figure id="fig5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0017.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Daily oral administration of compound <b>33</b> at concentrations of 1, 3, and 10 mg/kg/d and sorafenib at a dose of 3 mg/kg/d was initiated when the MV4-11 tumors reached approximately 500 mm<sup>3</sup> in volume (six mice per group). (b) Average body weights for <b>33</b>-treated mouse groups in the MV4-11 xenograft model. (c) Pharmacokinetics of compound <b>33</b> in SD rats (five rats per group). The rats were treated orally with 10 mg/kg/d of compound <b>33</b>, and plasma was collected via jugular vein cannulation. Finally, compound concentrations in the plasma were detected by liquid–liquid extraction followed by LC–MS detection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>33</b> was also evaluated for its effects on the tumor mitotic index (Ki67) and apoptosis, as well as the FLT3 signaling, using histological and immunohistochemical techniques. Similar to the tumor xenograft models, a dose of 10 mg/kg/d of compound <b>33</b> was administered by oral gavage for the MV4-11 model. After treatment for 3 or 4 d, tumors were collected and analyzed. Tumor tissues from the vehicle group stained strongly with Ki67, indicating a large number of highly proliferative cells. Conversely, the tumor tissues from the compound <b>33</b>-treated groups exhibited significantly fewer Ki67-positive cells (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>a). Furthermore, the TUNEL data demonstrated an obvious increase in the percentage of apoptotic cells in a time-dependent manner (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>b). In addition, the phosphorylation of STAT5, which is an important downstream signaling protein of FLT3 signaling, was also significantly reduced in MV4-11 tumor tissues of the compound <b>33</b>-treated group compared with the vehicle group (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>c), indicating that the observed efficacy in vivo was consistent with FLT3 signaling inhibition.</div><figure id="fig6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0018.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Ki67, TUNEL, and p-STAT5 detection of MV4-11 tumor tissues after treatment with compound <b>33</b> for 72 or 96 h. At 24 h after the final dose of compound <b>33</b>, the tumor samples were collected for analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">It is important to mention again that the MV4-11 cell line expresses very low levels of VEGFR2. VEGFR2 inhibition should not have a significant effect on the AML cell viability, but is expected to contribute to blockade of aberrant VEGF signaling that often exists in the bone marrow of AML patients, which may be helpful in preventing relapses of AML. We acknowledged that the in vivo MV4-11 xenograft model used here is not suitable for examining the effects of compound <b>33</b> on preventing relapses of AML. Other more sophisticated models such as orthotopic AML models should be adopted for this purpose; the related studies are still under way.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20">3.7 Pharmacokinetic Characteristics of Compound <b>33</b></h3><div class="NLM_p last">The preliminary pharmacokinetic characteristics of compound <b>33</b> following po administration to rats were also analyzed. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>c, the compound was absorbed well, achieving a maximum plasma level (<i>C</i><sub>max</sub>) of 15.12 μg/mL within 7 h after oral administration at a dose of 10 mg/kg/d. The measured plasma protein binding value was 87.96%. Furthermore, the apparent plasma half-life was approximately 12.6 h, the AUC<sub>0–24h</sub> was approximately 318817.4 μg/(L·h), and the oral bioavailability was about 66.7%. All of these indicated that compound <b>33</b> has good pharmacokinetic properties.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">4 Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this paper, a series of pyrazolo[3,4-<i>d</i>]pyrimidine derivatives was synthesized, and an SAR analysis of these compounds based on cell and zebrafish assays led to the identification of three pyrazolo[3,4-<i>d</i>]pyrimidine derivatives with considerable potency. Further in-depth in vitro and in vivo assays were performed with compound <b>33</b>, which exhibited the highest in vivo anti-AML activity in a preliminary in vivo assay. The kinase inhibition profile revealed that compound <b>33</b> was a multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and showed good kinase spectrum selectivity. Western blot analysis demonstrated that compound <b>33</b> significantly inhibited FLT3 phosphorylation and the activation of downstream signaling proteins. In vivo anti-AML activity assays showed that an oral, once-daily dose of compound <b>33</b> at 10 mg/kg for 18 days led to complete tumor regression in the MV4-11 xenograft model. Preliminary pharmacokinetic studies indicated that compound <b>33</b> possesses good pharmacokinetic properties. By the way, since the AML MV4-11 cell line used in this study expresses very low levels of VEGFR2, inhibition of VEGFR2 should not significantly contribute to the suppression of tumor cell growth, but might play some important roles in preventing relapses of AML due to the fact that aberrant VEGF signaling often exists in the bone marrow of AML patients. Issues related to the VEGFR2 inhibition and its roles in preventing the relapses of AML still need further intense studies.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">5 Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62065" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62065" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">5.1 Chemistry Methods</h3><div class="NLM_p">All reagents were purchased and used without further purification unless otherwise indicated. Reactions were monitored by thin-layer chromatography (TLC) on Merck silica gel 60 F-254 thin-layer plates. All of the final compounds were purified to >95% purity, as determined by high-performance liquid chromatography (HPLC). HPLC analysis was performed on a Waters 2695 HPLC system with the use of a Kromasil C18 column (4.6 mm × 250 mm, 5 um). <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker AV-400 spectrometer at 400 and 100 MHz, respectively. Chemical shifts (δ) are listed in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard. Multiplicities are given as s (singlet), d (doublet), dd (double–doublet), t (triplet), q (quadruplet), m (multiplet), and br s (broad signal). Low-resolution and high-resolution mass spectral (MS) data were acquired on an Agilent 1100 series LC–MS instrument with UV detection at 254 nm in low-resonance electrospray mode (ESI).</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24">5.1.1 4-Chloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine (<b>35</b>)</h4><div class="NLM_p last">To a cooled solution of 1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4(5<i>H</i>)-one (<b>34</b>; 5.0 g, 36.7 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (3.0 mL, 18.4 mmol) in toluene was slowly added phosphorus oxychloride (16.8 mL, 183.5 mmol). The reaction mixture was warmed to room temperature and refluxed for 5 h. After evaporation of the organic solvent, the residue was cooled to room temperature and treated with excess ice–water. At this time, a buff solid was formed and collected by filtration. The crude product was dried in a vacuum oven to give the title compound <b>35</b> (3.2 g, 56%). This product was used in the next step without purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.12 (s, 1H), 9.32 (s, 1H), 7.55 (s, 1H). LC–MS: <i>m</i>/<i>z</i> 155.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25">5.1.2 1-(4-(1<i>H</i>-Pyrazolo[3,4-<i>d</i>]pyrimidin-4-ylamino)phenyl)-3-(3-methoxyphenyl)urea (<b>1</b>)</h4><div class="NLM_p">To a mixture of 1-(4-aminophenyl)-3-(3-methoxyphenyl)urea (180 mg, 0.7 mmol) in 1-butanol (10 mL) was added 6 N HCl (0.2 mL). The reaction mixture was stirred at room temperature for 20 min. Then a solution of <b>35</b> (108 mg, 0.7 mmol) in 1-butanol (10 mL) was added to the reaction mixture, followed by heating to 100 °C for 3.5 h. The solvent was removed by rotary evaporation. The crude mixture was added to 100 mL of water, and the pH was adjusted to 7–8 with K<sub>2</sub>CO<sub>3</sub>. The aqueous layer was extracted with ethyl acetate (2 × 120 mL). Then the combined organic layers were dried over MgSO<sub>4</sub> and concentrated. The residue was purified by column chromatography (eluent gradient CH<sub>2</sub>Cl<sub>2</sub>:MeOH = 35:1 to 20:1) and recrystallized from EtOAc and petroleum to afford the product <b>1</b> (205 mg, 78% yield, 98% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.59 (s, 1H), 9.93 (s, 1H), 8.69 (d, <i>J</i> = 5.6 Hz, 2H), 8.35 (s, 1H), 8.15 (br s, 1H), 7.71 (d, <i>J</i> = 8.0 Hz, 2H), 7.47 (d, <i>J</i> = 8.8 Hz, 2H), 7.21–7.16 (m, 2H), 6.93 (d, <i>J</i> = 8.0 Hz, 1H), 6.55 (dd, <i>J</i> = 2.4 Hz, <i>J</i> = 5.6 Hz, 1H), 3.74 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 160.2, 155.8, 155.0, 153.0, 141.5, 133.8, 132.9, 130.0, 122.8, 119.1, 110.9, 107.6, 104.3, 100.8, 55.4. LC–MS: <i>m</i>/<i>z</i> 376.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>2</b>–<b>5</b> were synthesized using the same methodology. Experimental data for compound <b>2</b>–<b>5</b> are given in the <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26">5.1.3 General Procedure for the Synthesis of Ureas <b>62</b>–<b>75</b></h4><div class="NLM_p last">A solution of substituted anilines (10.0 mmol) dissolved in THF (80 mL) was slowly dripped into a stirred solution of triphosgene (2.98 g, 10.0 mmol) in THF (10 mL) by using a constant-pressure dropping funnel. NEt<sub>3</sub> (3 mL, 21.0 mmol) was then added slowly to the reaction mixture after the anilines were added. After evaporation of the solvent, the residue was taken up in THF (80 mL), and 4-aminophenol (0.93 g, 8.5 mmol) was added directly to the residue. The reaction mixture was stirred at 45 °C for 2 h, and the solvent was subsequently removed in vacuo. The residue obtained was dissolved in acetone (4 mL), and upon addition of water, a solid precipitated. This solid was collected, washed with water and Et<sub>2</sub>O, and dried under vacuum to give the products <b>62</b>–<b>75</b> (64–99%).</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27">5.1.4 4-(1<i>H</i>-Pyrazolo[3,4-<i>d</i>]pyrimidin-4-yloxy)aniline (<b>76</b>)</h4><div class="NLM_p last">To a solution of 4-aminophenol (3.53 g, 32.4 mmol) in H<sub>2</sub>O (40 mL) was added a sodium hydroxide solution (1.30 g, 32.4 mmol in 40 mL of water). The mixture was stirred at room temperature for 30 min. Then the intermediate <b>35</b> (5.00 g, 32.4 mmol) in THF (40 mL) was slowly added, and the reaction mixture was heated to 60 °C for 1.5 h. The solvent was then partially evaporated on a rotary evaporator. The crude mixture was extracted with ethyl acetate (2 × 120 mL) and water. The combined organic layers were dried over MgSO<sub>4</sub> and concentrated. The obtained residue was purified by column chromatography (eluent gradient CH<sub>2</sub>Cl<sub>2</sub>:MeOH = 100:1 to 60:1) without final recrystallization to give the product <b>76</b> (2.35 g, 32%) as a brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.07 (s, 1H), 8.50 (s, 1H), 7.67 (s, 1H), 6.96 (d, <i>J</i> = 8.8 Hz, 2H), 6.64 (d, <i>J</i> = 8.8 Hz, 2H), 5.20 (s, 2H). LC–MS: <i>m</i>/<i>z</i> 228.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28">5.1.5 1-(4-(1<i>H</i>-Pyrazolo[3,4-<i>d</i>]pyrimidin-4-yloxy)phenyl)-3-(3-methoxyphenyl)urea (<b>6</b>)</h4><div class="NLM_p last">Two methods were used to obtain the final product. Method A: A suspension of 1-(4-hydroxyphenyl)-3-(3-methoxyphenyl)urea (0.35 g, 1.35 mmol) and sodium hydroxide (0.065 g, 1.62 mmol) in THF (10 mL) and water (2 mL) was stirred at room temperature for 30 min. Then the intermediate <b>35</b> (0.31 g, 2.0 mol) was added, and the resulting mixture was heated to 60 °C for 6 h. The solvent was concentrated in vacuo, treated with water (100 mL), and extracted with EtOAc (3 × 60 mL). The combined organic layers were removed in vacuo. The residue obtained was purified by column chromatography (eluent gradient CH<sub>2</sub>Cl<sub>2</sub>:MeOH = 70:1) and recrystallized from EtOAc and petroleum ether to provide <b>6</b> (0.13 g, 26.3% yield, 98% HPLC purity). Method B: A solution of 3-methoxyaniline (0.62 g, 5.0 mmol) dissolved in THF (40 mL) was slowly dripped into a stirred solution of triphosgene (1.49g, 5.0 mmol) in THF (10 mL) by using a constant-pressure dropping funnel. NEt<sub>3</sub> (1.5 mL, 10.5 mmol) was then added slowly to the reaction mixture after the aniline was added. After evaporation of the solvent, the residue was taken up in acetonitrile (80 mL), and compound <b>76</b> (1.02 g, 4.5 mmol) was added directly to the residue. Next the reaction mixture was stirred at 90 °C for 6 h, and the solvent was removed in vacuo. The residue obtained was purified by column chromatography (eluent gradient CH<sub>2</sub>Cl<sub>2</sub>:MeOH = 70:1) and recrystallized from EtOAc and petroleum ether to provide <b>6</b> (1.37 g, yield 81%, 98% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.14 (s, 1H), 8.79 (s, 1H), 8.73 (s, 1H), 8.51 (s, 1H), 8.03 (s, 1H), 7.60 (d, <i>J</i> = 8.8 Hz 2H), 7.26–7.21 (m, 4H), 6.96 (d, <i>J</i> = 8.0 Hz, 1H), 6.57 (dd, <i>J</i> = 2.0 Hz, <i>J</i> = 6.0 Hz, 1H), 3.74 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 163.2, 159.6, 156.7, 154.9, 152.5, 146.4, 140.8, 137.5, 131.8, 129.5, 122.2, 119.4, 110.5, 107.2, 104.0, 101.3, 54.9. LC–MS: <i>m</i>/<i>z</i> 377.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29">5.1.6 1-(4-(1<i>H</i>-Pyrazolo[3,4-<i>d</i>]pyrimidin-4-yloxy)phenyl)-3-(4-(trifluoromethyl)phenyl)urea (<b>9</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>76</b> and 4-(trifluoromethyl)aniline using method B, purified by column chromatography (eluent gradient CH<sub>2</sub>Cl<sub>2</sub>:MeOH = 70:1), and recrystallized from EtOAc and petroleum ether. Yield: 83%. HPLC purity: 98%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.15 (s, 1H), 9.13 (s, 1H), 8.97 (s, 1H), 8.51 (s, 1H), 8.04 (s, 1H), 7.60–7.51 (m, 5H), 7.32 (d, <i>J</i> = 7.2 Hz, 1H), 7.26 (d, <i>J</i> = 8.8 Hz, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 163.2, 155.8, 155.0, 152.6, 146.6, 140.5, 137.3, 131.8, 130.0, 129.6, 122.3, 121.8, 119.7, 118.1, 114.1, 101.3. HRMS: <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>13</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 415.1052, found 415.1064.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30">5.1.7 1-(3-Methoxyphenyl)-3-(4-((1-methyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)urea (<b>10</b>)</h4><div class="NLM_p last">A suspension of compound <b>6</b> (752 mg, 2.0 mmol) and sodium hydroxide (80 mg, 2.0 mmol) in dry DMF (10 mL) was stirred at room temperature for 30 min. Iodomethane (0.15 mL, 2.4 mmol) was added, and the resulting mixture was stirred overnight. The reaction mixture was treated with water (100 mL) and extracted with EtOAc (3 × 60 mL). The combined organic layers were removed in vacuo. The residue obtained was purified by column chromatography (eluent gradient CH<sub>2</sub>Cl<sub>2</sub>: MeOH = 90:1) and recrystallized from EtOAc and petroleum ether to provide <b>10</b> (546 mg, 70%, 98% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.82 (s, 1H), 8.75 (s, 1H), 8.55 (s, 1H), 8.05 (s, 1H), 7.55 (d, <i>J</i> = 8.8 Hz, 2H), 7.26–7.17 (m, 4H), 6.95 (d, <i>J</i> = 8.4 Hz, 1H), 6.57 (d, <i>J</i> = 8.4 Hz, 1H), 4.04(s, 3H), 3.74(s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 163.3, 159.7, 154.9, 154.8, 152.5, 146.4, 140.8, 137.6, 130.9, 129.5, 122.1, 119.4, 110.5, 107.2, 104.0, 101.7, 54.9, 34.0. LC–MS: <i>m</i>/<i>z</i> 391.4 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31">5.1.8 1-(3-(1<i>H</i>-Pyrazolo[3,4-<i>d</i>]pyrimidin-4-yloxy)phenyl)-3-(4-(trifluoromethyl)phenyl)urea (<b>12</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>77</b> and 4-(trifluoromethyl)aniline using method B, purified by column chromatography (eluent gradient CH<sub>2</sub>Cl<sub>2</sub>:MeOH = 75:1), and recrystallized from EtOAc and petroleum ether. Yield: 89%. PHLC purity: 97%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.16 (s, 1H), 9.17 (s, 1H), 9.03 (s, 1H), 8.53 (s, 1H), 8.10 (s, 1H), 7.66–7.57 (m, 5H), 7.42 (t, <i>J</i> = 8.0 Hz, 1H), 7.33 (d, <i>J</i> = 8.8 Hz, 1H), 6.97 (d, <i>J</i> = 7.2 Hz, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 162.8, 156.7, 154.9, 152.3, 152.1, 143.2, 140.8, 131.9, 130.0, 126.1, 123.1, 122.0, 121.7, 117.9, 115.9, 115.5, 111.7, 101.4. LC–MS: <i>m</i>/<i>z</i> 415.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32">5.1.9 <i>N-</i>(4-(1<i>H</i>-Pyrazolo[3,4-<i>d</i>]pyrimidin-4-yloxy)phenyl)-4-bromobenzamide (<b>18</b>)</h4><div class="NLM_p last">A mixture of 4-bromobenzoic acid (265 mg, 1.32 mmol), 1-hydroxybenzotriazole (HOBT; 178.8 mg, 1.32 mmol), 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (EDCI; 254.6 mg, 1.32 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (DIEA; 0.33 mL, 2.0 mmol) in THF (25 mL) was stirred at room temperature for 0.5 h. Next compound <b>76</b> (300 mg, 1.32 mmol) was added to the mixture, which was heated to reflux for 12 h. Then the mixture was cooled to room temperature, and water (5 mL) was added. The precipitate was filtered and washed with ice–water and THF to obtain compound <b>18</b> (390 mg, 73%). The white precipitate was purified by recrystallization from EtOAc and petroleum ether (97% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.18 (s, 1H), 10.49 (s, 1H), 8.53 (s, 1H), 8.11 (br s, 1H), 7.95 (d, <i>J</i> = 8.4 Hz, 2H), 7.88 (d, <i>J</i> = 8.8 Hz, 2H), 7.79 (d, <i>J</i> = 8.4 Hz, 2H), 7.34 (d, <i>J</i> = 9.2 Hz, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ164.7, 162.8, 156.8, 154.9, 152.2, 141.0, 133.7, 131.7, 131.4, 129.8, 125.5, 122.3, 117.7, 117.2, 113.7, 101.4. LC–MS: <i>m</i>/<i>z</i> 411.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33">5.1.10 1-(4-(1<i>H</i>-Pyrazolo[3,4-<i>d</i>]pyrimidin-4-yloxy)phenyl)-3-(3-(trifluoromethyl)phenyl)urea (<b>27</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>76</b> and 3-(trifluoromethyl)aniline using method B, purified by column chromatography (eluent gradient CH<sub>2</sub>Cl<sub>2</sub>:MeOH = 70:1), and recrystallized from EtOAc and petroleum ether. Yield: 84%. HPLC purity: 98%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.14 (s, 1H), 9.10 (s, 1H), 8.93 (s, 1H), 8.51 (s, 1H), 8.04 (s, 2H), 7.61–7.51 (m, 4H), 7.32 (d, <i>J</i> = 7.6 Hz, 1H), 7.26 (d, <i>J</i> = 8.8 Hz, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 163.2, 156.7, 154.9, 152.6, 146.6, 140.5, 137.2, 131.8, 129.9, 122.3, 121.8, 119.7, 101.3. HRMS: <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>13</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 415.1052, found 415.1062.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34">5.1.11 1-(4-(1<i>H</i>-Pyrazolo[3,4-<i>d</i>]pyrimidin-4-yloxy)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea (<b>33</b>)</h4><div class="NLM_p">The title compound was prepared from <b>76</b> and 4-chloro-3-(trifluoromethyl)aniline using method B, purified by column chromatography (eluent gradient CH<sub>2</sub>Cl<sub>2</sub>:MeOH = 75:1), and recrystallized from EtOAc and petroleum ether. Yield: 82%. HPLC purity: 99%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.14 (s, 1H), 9.22 (s, 1H), 8.99 (s, 1H), 8.51 (s, 1H), 8.13 (s, 1H), 8.05 (s, 1H), 7.64 (q, <i>J</i> = 6.8 Hz, 2H), 7.56 (d, <i>J</i> = 8.4 Hz, 2H), 7.25 (d, <i>J</i> = 8.4 Hz, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 163.2, 156.7, 154.9, 152.5, 146.7, 139.3, 137.1, 131.9, 131.8, 123.0, 122.3, 119.9, 101.3. HRMS: <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>12</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup> 449.0662, found 449.0680.</div><div class="NLM_p last">Experimental data for compound <b>7</b>, <b>8</b>, <b>11</b>, <b>13</b>–<b>17</b>, <b>19</b>–<b>26</b>, and <b>28</b>–<b>32</b> are given in the <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35">5.2 Kinase Inhibition, Binding Affinity Assays, and Kinase Selectivity</h3><div class="NLM_p last">The kinase inhibition assays were performed according to the KinaseProfiler assay protocols of Upstate Biotechnology (Millipore). The Ambit in vitro KINOMEscan kinase binding assays (Ambit Biosciences) were employed to determine the binding affinity of the compounds. The kinase selectivity is described by the selectivity score, <i>S</i>-score, which is calculated by dividing the number of kinases that compounds bind to by the total number of distinct kinases tested, excluding mutant variants. Here <i>S</i>-score is defined as follows: <i>S</i>(<i>X</i>) = (number of nonmutant kinases with %Ctrl < <i>X</i>)/(number of nonmutant kinases tested).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36">5.3 Cell Lines and Cell Culture</h3><div class="NLM_p last">All cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, VA). MV4-11 was maintained in IMDM culture medium according to ATCC guidelines. The other cell lines were grown in RPMI 1640 or DMEM culture medium containing 10% fetal bovine serum (v/v) in 5% CO<sub>2</sub> at 37 °C.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37">5.4 Cell Viability Assays</h3><div class="NLM_p last">The MTT assay was used to detect the viability of cells. Leukemia cells were collected and seeded in a 96-well plate at (1–4) × 10<sup>4</sup> cells per well. Different concentrations of inhibitors were added to the cells and incubated at 37 °C for 72 h. Then 20 μL of 5 mg/mL MTT reagent was added to each well and incubated for 2–4 h, and 50 μL of 20% acidified SDS was used to lyse the oxidative product. The other cell lines were seeded in 96-well plates at a density of (2–5) × 10<sup>3</sup> cells per well, and after 24 h, the medium in the plates was replaced by medium containing serial dilutions of inhibitors. Following a 72 h incubation, the MTT reagent was added for a 2–4 h incubation, and 100% DMSO was used to dissolve the oxidative product. Finally, the light absorption (OD) of the dissolved cells was measured at 570 nm using a SpectraMAX M5 microplate spectrophotometer (Molecular Devices). All experiments were performed in triplicate. The IC<sub>50</sub> values were calculated using GraphPad Prism software.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38">5.5 Western Blot Analysis</h3><div class="NLM_p last">After treatment with a series of concentrations of compound <b>33</b> for 20 h at 37 °C, MV4-11 cells were harvested, washed with ice-cold physiological saline, and lysed with RIPA lysis buffer (Beyotime) including 1% cocktail (Sigma-Aldrich). Cell lysates were separated by SDS–PAGE and electrotransferred onto PVDF membranes (Millipore). The PVDF membranes were incubated with each antibody and detected according to the immunoblot analysis principle. The antibodies were purchased from Cell Signaling Technology, with the exception of the anti-FLT3 antibody, which was obtained from Abcam.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39">5.6 Apoptosis Analysis in MV4-11 Cells</h3><div class="NLM_p last">A total of 4 × 10<sup>5</sup> MV4-11 cells were plated in a six-well plate and treated with compound <b>33</b> for 24 h at 37 °C. After incubation, the cells were harvested and washed with PBS. The apoptosis ratio was analyzed using an Annexin V-FITC Apoptosis Analysis Kit (Tianjin Suangene Biotech Co.) and BD FACSCalibur.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40">5.7 In Vivo Models</h3><div class="NLM_p last">For the subcutaneous xenograft model, MV4-11 cells were harvested and washed three times with serum-free medium, followed by resuspension at a concentration of 1 × 10<sup>8</sup> per mL. A total of 100 μL of cell suspension was injected into NOD-SCID mice (5–6 weeks) subcutaneously. When the tumors had grown to 300–500 mm<sup>3</sup>, all the mice were grouped and administered different doses of compound or vehicle. The compounds were dissolved in 12.5% (v/v) castor oil (Sigma-Aldrich), 12.5% ethanol, and 75% distilled water. Tumor growth was measured every 3, and the volume was calculated as follows: tumor size = long diameter × (short diameter)<sup>2</sup>/2.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41">5.8 Histopathology</h3><div class="NLM_p last">NOD-SCID mice bearing tumors were administered compound <b>33</b> at a dose of 10 mg/kg/d orally. Two or three days later, the mice were killed, and the tumors were fixed in formalin. Proliferation was assessed by immunostaining with Ki67 (Thermo Fisher Scientific, Fremont, CA). Apoptosis was determined using transferase-mediated dUTP nick-end labeling (TUNEL) staining (Roche Applied Science). The p-STAT5 staining was performed using the p-STAT5 antibody from Cell Signaling Technology. Images were acquired on an Olympus digital camera attached to a light microscope.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42">5.9 In Vivo Live Fluorescent Zebrafish Assay</h3><div class="NLM_p last">Transgenic zebrafish (FLK-1:EGFP) embryos were grown and maintained according to the same protocols as given in ref <a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">41</a>. The screen was carried out in 24-well plates. Each compound was prepared initially as 10 mmol/L stock solution in dimethyl sulfoxide (DMSO). Stock solution was diluted in the relevant assay concentration with fish water, and 0.3% DMSO served as a vehicle control. The embryos were distributed to 24-well plates with 10 embryos placed in each well. Then a diluted solution of each compound was added. The embryos were exposed to compound solution and incubated at 28.5 °C from 15 h postfertilization (hpf) until 31 hpf. At 31 hpf, zebrafish were anesthetized with 0.01% tricaine and imaged under a fluorescence microscope (Carl Zeiss Microimaging Inc.) equipped with an AxioCam MRc5 digital CCD camera (Carl Zeiss Microimaging Inc.).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43"><a href="/doi/suppl/10.1021/jm301537p">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13867" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13867" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Table S1 listing the binding affinities of compound <b>33</b> with various kinases, Figure S1 showing the TREE<i>spot</i> interaction maps for compound <b>33</b>, experimental details of the synthesis and analytical characterization of compounds <b>2</b>–<b>5</b>, <b>7</b>, <b>8</b>, <b>11</b>, <b>13</b>–<b>17</b>, <b>19</b>–<b>26</b>, and <b>28</b>–<b>32</b> described in this paper, and purity data for the final compounds. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm301537p/suppl_file/jm301537p_si_001.pdf">jm301537p_si_001.pdf (289.52 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm301537p" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82510" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82510" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sheng-Yong Yang</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, and ‡College of Chemical Engineering, Sichuan University, Sichuan 610041,
China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#bec7dfd0d9cdc7fecdddcb90dbdacb90ddd0"><span class="__cf_email__" data-cfemail="4a332b242d39330a39293f642f2e3f642924">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ling-Ling Yang</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, and ‡College of Chemical Engineering, Sichuan University, Sichuan 610041,
China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guo-Bo Li</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, and ‡College of Chemical Engineering, Sichuan University, Sichuan 610041,
China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuang Ma</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, and ‡College of Chemical Engineering, Sichuan University, Sichuan 610041,
China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chan Zou</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, and ‡College of Chemical Engineering, Sichuan University, Sichuan 610041,
China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shu Zhou</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, and ‡College of Chemical Engineering, Sichuan University, Sichuan 610041,
China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qi-Zheng Sun</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, and ‡College of Chemical Engineering, Sichuan University, Sichuan 610041,
China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chuan Cheng</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, and ‡College of Chemical Engineering, Sichuan University, Sichuan 610041,
China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xin Chen</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, and ‡College of Chemical Engineering, Sichuan University, Sichuan 610041,
China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li-Jiao Wang</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, and ‡College of Chemical Engineering, Sichuan University, Sichuan 610041,
China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shan Feng</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, and ‡College of Chemical Engineering, Sichuan University, Sichuan 610041,
China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lin-Li Li</span> - <span class="hlFld-Affiliation affiliation">†State
Key Laboratory of Biotherapy and Cancer Center, West China Hospital,
West China Medical School, and ‡College of Chemical Engineering, Sichuan University, Sichuan 610041,
China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>These authors contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e2979-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11321" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11321" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Natural Science Foundation of China (Grant 81172987), the 973 Program (Grant 2013CB967204), and the 863 Hi-Tech Program (Grants 2012AA020301 and 2012AA0203).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i46" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i46"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i47" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i47"> Abbreviations Used</h2><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">FMS-like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">VEGFR2</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor 2</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">PTK</td><td class="NLM_def"><p class="first last">protein tyrosine kinase</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">ITDs</td><td class="NLM_def"><p class="first last">internal tandem duplications</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr><tr><td class="NLM_term">STAT5</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 5</p></td></tr><tr><td class="NLM_term">HOBT</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67283" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67283" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 44 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Lowenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downing, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnett, A.</span><span> </span><span class="NLM_article-title">Acute myeloid leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">1051</span><span class="NLM_x">–</span> <span class="NLM_lpage">1062</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1056%2FNEJM199909303411407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=10502596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A280%3ADyaK1MvhslSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=1999&pages=1051-1062&author=B.+Lowenbergauthor=J.+R.+Downingauthor=A.+Burnett&title=Acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Acute myeloid leukemia</span></div><div class="casAuthors">Lowenberg B; Downing J R; Burnett A</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1051-62</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvdpRq9xav842y4bB4mnvYfW6udTcc2eZ0lg0-Cwrf5bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1MvhslSrtg%253D%253D&md5=7cd5e8c3edc8a431afbad11822153c23</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJM199909303411407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199909303411407%26sid%3Dliteratum%253Aachs%26aulast%3DLowenberg%26aufirst%3DB.%26aulast%3DDowning%26aufirst%3DJ.%2BR.%26aulast%3DBurnett%26aufirst%3DA.%26atitle%3DAcute%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1999%26volume%3D341%26spage%3D1051%26epage%3D1062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Schlenk, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dohner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbacioglu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullinger, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habdank, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlegelberger, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heil, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dohner, H.</span><span> </span><span class="NLM_article-title">German-Austrian Acute Myeloid Leukemia Study, G. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">1909</span><span class="NLM_x">–</span> <span class="NLM_lpage">1918</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1056%2FNEJMoa074306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=18450602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Ggu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=1909-1918&author=R.+F.+Schlenkauthor=K.+Dohnerauthor=J.+Krauterauthor=S.+Frohlingauthor=A.+Corbaciogluauthor=L.+Bullingerauthor=M.+Habdankauthor=D.+Spathauthor=M.+Morganauthor=A.+Bennerauthor=B.+Schlegelbergerauthor=G.+Heilauthor=A.+Ganserauthor=H.+Dohner&title=German-Austrian+Acute+Myeloid+Leukemia+Study%2C+G.+Mutations+and+treatment+outcome+in+cytogenetically+normal+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia</span></div><div class="casAuthors">Schlenk, Richard F.; Doehner, Konstanze; Krauter, Jurgen; Frohling, Stefan; Corbacioglu, Andrea; Bullinger, Lars; Habdank, Marianne; Spith, Daniela; Morgan, Michael; Benner, Axel; Schlegelberger, Brigitte; Heil, Gerhard; Ganser, Arnold; Doehner, Hartmut; Schlimok, G.; Arnold, R.; Pezzutto, A.; Glasmacher, A.; Germing, U.; Heit, W.; Hoelzer, D.; Derigs, H. G.; Luebbert, M.; Pralle, H.; Runde, V.; Griesinger, F.; Fiedler, W.; Salwender, H.; Kirchner, H.; Hensel, M.; Hartmann, F.; Fischer, J. T.; Kneba, M.; Hinke, A.; Kremers, S.; Goetze, K.; Waterhouse, C.; del Valle, F.; Matzdorff, A.; Grimminger, W.; Mergenthaler, H. G.; Kirchen, H.; Brossart, P.; Bergmann, L.; Raghavachar, Aruna; Petzer, A.; Koller, E.; Neons, L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1909-1918</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations occur in several genes in cytogenetically normal acute myeloid leukemia (AML) cells: the nucleophosmin gene (NPM1), the fms-related tyrosine kinase 3 gene (FLT3), the CCAAT/enhancer binding protein a gene (CEPBA), the myeloid-lymphoid or mixed-lineage leukemia gene (MLL), and the neuroblastoma RAS viral oncogene homolog (NRAS).  We evaluated the assocns. of these mutations with clin. outcomes in patients.  We compared the mutational status of the NPM1, FLT3, CEBPA, MLL, and NRAS genes in leukemia cells with the clin. outcome in 872 adults younger than 60 years of age with cytogenetically normal AML.  Patients had been entered into one of four trials of therapy for AML.  In each study, patients with an HLA-matched related donor were assigned to undergo stem-cell transplantation.  A total of 53% of patients had NPM1 mutations, 31% had FLT3 internal tandem duplications (ITDs), 11% had FLT3 tyrosine kinase-domain mutations, 13% had CEBPA mutations, 7% had MLL partial tandem duplications (PTDs), and 13% had NRAS mutations.  The overall complete-remission rate was 77%.  The genotype of mutant NPM1 without FLT3-ITD, the mutant CEBPA genotype, and younger age were each significantly assocd. with complete remission.  Of the 663 patients who received postremission therapy, 150 underwent hematopoietic stem-cell transplantation from an HLA-matched related donor.  Significant assocns. were found between the risk of relapse or the risk of death during complete remission and the leukemia genotype of mutant NPM1 without FLT3-ITD (hazard ratio, 0.44; 95% confidence interval [CI], 0.32 to 0.61), the mutant CEBPA genotype (hazard ratio, 0.48; 95% CI, 0.30 to 0.75), and the MLL-PTD genotype (hazard ratio, 1.56; 95% CI, 1.00 to 2.43), as well as receipt of a transplant from an HLA-matched related donor (hazard ratio, 0.60; 95% CI, 0.44 to 0.82).  The benefit of the transplant was limited to the subgroup of patients with the prognostically adverse genotype FLT3-ITD or the genotype consisting of wild-type NPM1 and CEBPA without FLT3-ITD.  Genotypes defined by the mutational status of NPM1, FLT3, CEBPA, and MLL are assocd. with the outcome of treatment for patients with cytogenetically normal AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6JpbRc9OYmrVg90H21EOLACvtfcHk0lh9edLlg4fL_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Ggu70%253D&md5=4109ec9d7141f2405163dfc31a9dd660</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa074306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa074306%26sid%3Dliteratum%253Aachs%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DDohner%26aufirst%3DK.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DFrohling%26aufirst%3DS.%26aulast%3DCorbacioglu%26aufirst%3DA.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DHabdank%26aufirst%3DM.%26aulast%3DSpath%26aufirst%3DD.%26aulast%3DMorgan%26aufirst%3DM.%26aulast%3DBenner%26aufirst%3DA.%26aulast%3DSchlegelberger%26aufirst%3DB.%26aulast%3DHeil%26aufirst%3DG.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DDohner%26aufirst%3DH.%26atitle%3DGerman-Austrian%2520Acute%2520Myeloid%2520Leukemia%2520Study%252C%2520G.%2520Mutations%2520and%2520treatment%2520outcome%2520in%2520cytogenetically%2520normal%2520acute%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D358%26spage%3D1909%26epage%3D1918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Meshinchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonzo, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirewalt, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwaan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhardt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaspers, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerema, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerbing, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lange, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radich, J. P.</span><span> </span><span class="NLM_article-title">Clinical implications of FLT3 mutations in pediatric AML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3654</span><span class="NLM_x">–</span> <span class="NLM_lpage">3661</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3654-3661&author=S.+Meshinchiauthor=T.+A.+Alonzoauthor=D.+L.+Stirewaltauthor=M.+Zwaanauthor=M.+Zimmermanauthor=D.+Reinhardtauthor=G.+J.+Kaspersauthor=N.+A.+Heeremaauthor=R.+Gerbingauthor=B.+J.+Langeauthor=J.+P.+Radich&title=Clinical+implications+of+FLT3+mutations+in+pediatric+AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeshinchi%26aufirst%3DS.%26aulast%3DAlonzo%26aufirst%3DT.%2BA.%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26aulast%3DZwaan%26aufirst%3DM.%26aulast%3DZimmerman%26aufirst%3DM.%26aulast%3DReinhardt%26aufirst%3DD.%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DGerbing%26aufirst%3DR.%26aulast%3DLange%26aufirst%3DB.%2BJ.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26atitle%3DClinical%2520implications%2520of%2520FLT3%2520mutations%2520in%2520pediatric%2520AML%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3654%26epage%3D3661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholl, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernard, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">4788</span><span class="NLM_x">–</span> <span class="NLM_lpage">4796</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=4788-4796&author=M.+M.+Loriauxauthor=R.+L.+Levineauthor=J.+W.+Tynerauthor=S.+Frohlingauthor=C.+Schollauthor=E.+P.+Stoffregenauthor=G.+Wernigauthor=H.+Ericksonauthor=C.+A.+Eideauthor=R.+Bergerauthor=O.+A.+Bernardauthor=J.+D.+Griffinauthor=R.+M.+Stoneauthor=B.+Leeauthor=M.+Meyersonauthor=M.+C.+Heinrichauthor=M.+W.+Deiningerauthor=D.+G.+Gillilandauthor=B.+J.+Druker&title=High-throughput+sequence+analysis+of+the+tyrosine+kinome+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DFrohling%26aufirst%3DS.%26aulast%3DScholl%26aufirst%3DC.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DWernig%26aufirst%3DG.%26aulast%3DErickson%26aufirst%3DH.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DBernard%26aufirst%3DO.%2BA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DHigh-throughput%2520sequence%2520analysis%2520of%2520the%2520tyrosine%2520kinome%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D4788%26epage%3D4796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willis, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttropp, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oost, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">2238</span><span class="NLM_x">–</span> <span class="NLM_lpage">2245</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=2238-2245&author=J.+W.+Tynerauthor=D.+K.+Waltersauthor=S.+G.+Willisauthor=M.+Luttroppauthor=J.+Oostauthor=M.+Loriauxauthor=H.+Ericksonauthor=A.+S.+Corbinauthor=T.+O%E2%80%99Hareauthor=M.+C.+Heinrichauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=RNAi+screening+of+the+tyrosine+kinome+identifies+therapeutic+targets+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DWalters%26aufirst%3DD.%2BK.%26aulast%3DWillis%26aufirst%3DS.%2BG.%26aulast%3DLuttropp%26aufirst%3DM.%26aulast%3DOost%26aufirst%3DJ.%26aulast%3DLoriaux%26aufirst%3DM.%26aulast%3DErickson%26aufirst%3DH.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DRNAi%2520screening%2520of%2520the%2520tyrosine%2520kinome%2520identifies%2520therapeutic%2520targets%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D2238%26epage%3D2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">The roles of FLT3 in hematopoiesis and leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">1532</span><span class="NLM_x">–</span> <span class="NLM_lpage">1542</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1182%2Fblood-2002-02-0492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=12176867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=1532-1542&author=D.+G.+Gillilandauthor=J.+D.+Griffin&title=The+roles+of+FLT3+in+hematopoiesis+and+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of FLT3 in hematopoiesis and leukemia</span></div><div class="casAuthors">Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1532-1542</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system.  The ligand for FLT3 is expressed by marrow stromal cells and other cells and synergized with other growth factors to stimulate proliferation of stem cells, progenitor cells, dendritic cells, and natural killer cells.  Mutations of FLT3 have been detected in about 30% of patients with acute myelogenous leukemia and a small no. of patients with acute lymphocytic leukemia or myelodysplastic syndrome.  Patients with FLT3 mutations tend to have a poor prognosis.  The mutations most often involve small tandem duplications of amino acids within the juxtamembrane domain of the receptor and result in constitutive tyrosine kinase activity.  Expression of a mutant FLT3 receptor in murine marrow cells results in a lethal myeloproliferative syndrome and preliminary studies suggest that mutant FLT3 cooperates with other leukemia oncogenes to confer a more aggressive phenotype.  Taken together, these results suggest that FLT3 is an attractive therapeutic target for kinase inhibitors or other approaches for patients with mutations of this gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYQc2WkC8EQbVg90H21EOLACvtfcHk0lh5ffEcROGU4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D&md5=f6d04b227f5c5baf5c22cfba6e693ff1</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-02-0492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-02-0492%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520roles%2520of%2520FLT3%2520in%2520hematopoiesis%2520and%2520leukemia%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26spage%3D1532%26epage%3D1542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Kottaridis, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frew, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langabeer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belton, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheatley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowen, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnett, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstone, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linch, D. C.</span><span> </span><span class="NLM_article-title">The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">1752</span><span class="NLM_x">–</span> <span class="NLM_lpage">1759</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=1752-1759&author=P.+D.+Kottaridisauthor=R.+E.+Galeauthor=M.+E.+Frewauthor=G.+Harrisonauthor=S.+E.+Langabeerauthor=A.+A.+Beltonauthor=H.+Walkerauthor=K.+Wheatleyauthor=D.+T.+Bowenauthor=A.+K.+Burnettauthor=A.+H.+Goldstoneauthor=D.+C.+Linch&title=The+presence+of+a+FLT3+internal+tandem+duplication+in+patients+with+acute+myeloid+leukemia+%28AML%29+adds+important+prognostic+information+to+cytogenetic+risk+group+and+response+to+the+first+cycle+of+chemotherapy%3A+analysis+of+854+patients+from+the+United+Kingdom+Medical+Research+Council+AML+10+and+12+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKottaridis%26aufirst%3DP.%2BD.%26aulast%3DGale%26aufirst%3DR.%2BE.%26aulast%3DFrew%26aufirst%3DM.%2BE.%26aulast%3DHarrison%26aufirst%3DG.%26aulast%3DLangabeer%26aufirst%3DS.%2BE.%26aulast%3DBelton%26aufirst%3DA.%2BA.%26aulast%3DWalker%26aufirst%3DH.%26aulast%3DWheatley%26aufirst%3DK.%26aulast%3DBowen%26aufirst%3DD.%2BT.%26aulast%3DBurnett%26aufirst%3DA.%2BK.%26aulast%3DGoldstone%26aufirst%3DA.%2BH.%26aulast%3DLinch%26aufirst%3DD.%2BC.%26atitle%3DThe%2520presence%2520of%2520a%2520FLT3%2520internal%2520tandem%2520duplication%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%2520adds%2520important%2520prognostic%2520information%2520to%2520cytogenetic%2520risk%2520group%2520and%2520response%2520to%2520the%2520first%2520cycle%2520of%2520chemotherapy%253A%2520analysis%2520of%2520854%2520patients%2520from%2520the%2520United%2520Kingdom%2520Medical%2520Research%2520Council%2520AML%252010%2520and%252012%2520trials%26jtitle%3DBlood%26date%3D2001%26volume%3D98%26spage%3D1752%26epage%3D1759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Andersson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitelman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billstrom, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fioretos, T.</span><span> </span><span class="NLM_article-title">Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients</span> <span class="citation_source-journal">Eur. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1111%2Fj.1600-0609.2004.00225.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=15059064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Kgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2004&pages=307-313&author=A.+Anderssonauthor=B.+Johanssonauthor=C.+Lassenauthor=F.+Mitelmanauthor=R.+Billstromauthor=T.+Fioretos&title=Clinical+impact+of+internal+tandem+duplications+and+activating+point+mutations+in+FLT3+in+acute+myeloid+leukemia+in+elderly+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients</span></div><div class="casAuthors">Andersson, Anna; Johansson, Bertil; Lassen, Carin; Mitelman, Felix; Billstroem, Rolf; Fioretos, Thoas</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Haematology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">307-313</span>CODEN:
                <span class="NLM_cas:coden">EJHAEC</span>;
        ISSN:<span class="NLM_cas:issn">0902-4441</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The FLT3 gene is frequently mutated in acute myeloid leukemia (AML), either by an internal tandem duplication (ITD) of the juxtamembrane domain or by activating point mutations in the second tyrosine kinase domain (ATKD).  Only a few investigations have focused on the prognostic significance of FLT3 alterations in AML among the elderly, yielding conflicting results.  In the present study, the frequency and clin. relevance of FLT3 abnormalities were ascertained in a cohort of elderly AML patients.  A total of 109 AMLs, occurring in patients above the age of 60 yr (median 71.5), were investigated.  DNA was extd. from fresh bone marrow cells or from cells in fixative and investigated for the presence of ITD of exons 14 and 15 and the ATKD D835 in exon 20.  ITDs and ATKDs were identified in 20 (18%) and 11 (10%) of the cases, resp.  Three cases displayed both an ITD and an ATKD.  FLT3 abnormalities were assocd. with leukocytosis (ITD P < 0.01; ATKD P = 0.069), and the monocytic FAB subtypes M4 and M5 [ITD (P < 0.05), ATKD (P = 0.05)], and ITD and ATKD were significantly (P < 0.05) more common in cases with a normal karyotype.  There was no correlation between the presence of FLT3 abnormalities and complete remission rates or overall survival.  A correlation was obsd. between FLT3 abnormalities and leukocytosis, a normal karyotype, and the M4/M5 subtypes of leukemia.  However, no clear-cut prognostic impact of FLT3 abnormalities was identified in elderly AML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqywfTjAtj3ULVg90H21EOLACvtfcHk0liXWd5WdmIQrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Kgu74%253D&md5=1eb23898d331d2321b640467b1355ae2</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0609.2004.00225.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0609.2004.00225.x%26sid%3Dliteratum%253Aachs%26aulast%3DAndersson%26aufirst%3DA.%26aulast%3DJohansson%26aufirst%3DB.%26aulast%3DLassen%26aufirst%3DC.%26aulast%3DMitelman%26aufirst%3DF.%26aulast%3DBillstrom%26aufirst%3DR.%26aulast%3DFioretos%26aufirst%3DT.%26atitle%3DClinical%2520impact%2520of%2520internal%2520tandem%2520duplications%2520and%2520activating%2520point%2520mutations%2520in%2520FLT3%2520in%2520acute%2520myeloid%2520leukemia%2520in%2520elderly%2520patients%26jtitle%3DEur.%2520J.%2520Haematol.%26date%3D2004%26volume%3D72%26spage%3D307%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salerno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perl, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travers, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadt, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasarskis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span> </span><span class="NLM_article-title">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">485</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1038%2Fnature11016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=22504184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=485&publication_year=2012&pages=260-263&author=C.+C.+Smithauthor=Q.+Wangauthor=C.+S.+Chinauthor=S.+Salernoauthor=L.+E.+Damonauthor=M.+J.+Levisauthor=A.+E.+Perlauthor=K.+J.+Traversauthor=S.+Wangauthor=J.+P.+Huntauthor=P.+P.+Zarrinkarauthor=E.+E.+Schadtauthor=A.+Kasarskisauthor=J.+Kuriyanauthor=N.+P.+Shah&title=Validation+of+ITD+mutations+in+FLT3+as+a+therapeutic+target+in+human+acute+myeloid+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukemia</span></div><div class="casAuthors">Smith, Catherine C.; Wang, Qi; Chin, Chen-Shan; Salerno, Sara; Damon, Lauren E.; Levis, Mark J.; Perl, Alexander E.; Travers, Kevin J.; Wang, Susana; Hunt, Jeremy P.; Zarrinkar, Patrick P.; Schadt, Eric E.; Kasarskis, Andrew; Kuriyan, John; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">485</span>
        (<span class="NLM_cas:issue">7397</span>),
    <span class="NLM_cas:pages">260-263</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Effective targeted cancer therapeutic development depends upon distinguishing disease-assocd. driver' mutations, which have causative roles in malignancy pathogenesis, from passenger' mutations, which are dispensable for cancer initiation and maintenance.  Translational studies of clin. active targeted therapeutics can definitively discriminate driver from passenger lesions and provide valuable insights into human cancer biol.  Activating internal tandem duplication (ITD) mutations in FLT3 (FLT3-ITD) are detected in approx. 20% of acute myeloid leukemia (AML) patients and are assocd. with a poor prognosis.  Abundant scientific and clin. evidence, including the lack of convincing clin. activity of early FLT3 inhibitors, suggests that FLT3-ITD probably represents a passenger lesion.  Here we report point mutations at three residues within the kinase domain of FLT3-ITD that confer substantial in vitro resistance to AC220 (quizartinib), an active investigational inhibitor of FLT3, KIT, PDGFRA, PDGFRB and RET; evolution of AC220-resistant substitutions at two of these amino acid positions was obsd. in eight of eight FLT3-ITD-pos. AML patients with acquired resistance to AC220.  Our findings demonstrate that FLT3-ITD can represent a driver lesion and valid therapeutic target in human AML.  AC220-resistant FLT3 kinase domain mutants represent high-value targets for future FLT3 inhibitor development efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq0PeqhlWLObVg90H21EOLACvtfcHk0liXWd5WdmIQrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D&md5=228dae85b08e65918f74ee8c5d20ddb0</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature11016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11016%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DChin%26aufirst%3DC.%2BS.%26aulast%3DSalerno%26aufirst%3DS.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DTravers%26aufirst%3DK.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DSchadt%26aufirst%3DE.%2BE.%26aulast%3DKasarskis%26aufirst%3DA.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DValidation%2520of%2520ITD%2520mutations%2520in%2520FLT3%2520as%2520a%2520therapeutic%2520target%2520in%2520human%2520acute%2520myeloid%2520leukaemia%26jtitle%3DNature%26date%3D2012%26volume%3D485%26spage%3D260%26epage%3D263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Thiede, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steudel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schakel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Platzbecker, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wermke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornhauser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehninger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illmer, T.</span><span> </span><span class="NLM_article-title">Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">4326</span><span class="NLM_x">–</span> <span class="NLM_lpage">4335</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=4326-4335&author=C.+Thiedeauthor=C.+Steudelauthor=B.+Mohrauthor=M.+Schaichauthor=U.+Schakelauthor=U.+Platzbeckerauthor=M.+Wermkeauthor=M.+Bornhauserauthor=M.+Ritterauthor=A.+Neubauerauthor=G.+Ehningerauthor=T.+Illmer&title=Analysis+of+FLT3-activating+mutations+in+979+patients+with+acute+myelogenous+leukemia%3A+association+with+FAB+subtypes+and+identification+of+subgroups+with+poor+prognosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThiede%26aufirst%3DC.%26aulast%3DSteudel%26aufirst%3DC.%26aulast%3DMohr%26aufirst%3DB.%26aulast%3DSchaich%26aufirst%3DM.%26aulast%3DSchakel%26aufirst%3DU.%26aulast%3DPlatzbecker%26aufirst%3DU.%26aulast%3DWermke%26aufirst%3DM.%26aulast%3DBornhauser%26aufirst%3DM.%26aulast%3DRitter%26aufirst%3DM.%26aulast%3DNeubauer%26aufirst%3DA.%26aulast%3DEhninger%26aufirst%3DG.%26aulast%3DIllmer%26aufirst%3DT.%26atitle%3DAnalysis%2520of%2520FLT3-activating%2520mutations%2520in%2520979%2520patients%2520with%2520acute%2520myelogenous%2520leukemia%253A%2520association%2520with%2520FAB%2520subtypes%2520and%2520identification%2520of%2520subgroups%2520with%2520poor%2520prognosis%26jtitle%3DBlood%26date%3D2002%26volume%3D99%26spage%3D4326%26epage%3D4335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Sallmyr, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Datta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rassool, F.</span><span> </span><span class="NLM_article-title">Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">3173</span><span class="NLM_x">–</span> <span class="NLM_lpage">3182</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=3173-3182&author=A.+Sallmyrauthor=J.+Fanauthor=K.+Dattaauthor=K.+T.+Kimauthor=D.+Grosuauthor=P.+Shapiroauthor=D.+Smallauthor=F.+Rassool&title=Internal+tandem+duplication+of+FLT3+%28FLT3%2FITD%29+induces+increased+ROS+production%2C+DNA+damage%2C+and+misrepair%3A+implications+for+poor+prognosis+in+AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSallmyr%26aufirst%3DA.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DDatta%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DK.%2BT.%26aulast%3DGrosu%26aufirst%3DD.%26aulast%3DShapiro%26aufirst%3DP.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DRassool%26aufirst%3DF.%26atitle%3DInternal%2520tandem%2520duplication%2520of%2520FLT3%2520%2528FLT3%252FITD%2529%2520induces%2520increased%2520ROS%2520production%252C%2520DNA%2520damage%252C%2520and%2520misrepair%253A%2520implications%2520for%2520poor%2520prognosis%2520in%2520AML%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D3173%26epage%3D3182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">O’Farrell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngai, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smolich, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span> </span><span class="NLM_article-title">SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">3597</span><span class="NLM_x">–</span> <span class="NLM_lpage">3605</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=3597-3605&author=A.+M.+O%E2%80%99Farrellauthor=T.+J.+Abramsauthor=H.+A.+Yuenauthor=T.+J.+Ngaiauthor=S.+G.+Louieauthor=K.+W.+Yeeauthor=L.+M.+Wongauthor=W.+Hongauthor=L.+B.+Leeauthor=A.+Townauthor=B.+D.+Smolichauthor=W.+C.+Manningauthor=L.+J.+Murrayauthor=M.+C.+Heinrichauthor=J.+M.+Cherrington&title=SU11248+is+a+novel+FLT3+tyrosine+kinase+inhibitor+with+potent+activity+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DA.%2BM.%26aulast%3DAbrams%26aufirst%3DT.%2BJ.%26aulast%3DYuen%26aufirst%3DH.%2BA.%26aulast%3DNgai%26aufirst%3DT.%2BJ.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DYee%26aufirst%3DK.%2BW.%26aulast%3DWong%26aufirst%3DL.%2BM.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DSmolich%26aufirst%3DB.%2BD.%26aulast%3DManning%26aufirst%3DW.%2BC.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26atitle%3DSU11248%2520is%2520a%2520novel%2520FLT3%2520tyrosine%2520kinase%2520inhibitor%2520with%2520potent%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26spage%3D3597%26epage%3D3605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Lopes de Menezes, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shephard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldbeck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aukerman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C.</span><span> </span><span class="NLM_article-title">CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5281</span><span class="NLM_x">–</span> <span class="NLM_lpage">5291</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1158%2F1078-0432.CCR-05-0358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=16033847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt12qurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=5281-5291&author=D.+E.+Lopes+de+Menezesauthor=J.+Pengauthor=E.+N.+Garrettauthor=S.+G.+Louieauthor=S.+H.+Leeauthor=M.+Wiesmannauthor=Y.+Tangauthor=L.+Shephardauthor=C.+Goldbeckauthor=Y.+Oeiauthor=H.+Yeauthor=S.+L.+Aukermanauthor=C.+Heise&title=CHIR-258%3A+a+potent+inhibitor+of+FLT3+kinase+in+experimental+tumor+xenograft+models+of+human+acute+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia</span></div><div class="casAuthors">Lopes de Menezes, Daniel E.; Peng, Jing; Garrett, Evelyn N.; Louie, Sharianne G.; Lee, Sang H.; Wiesmann, Marion; Tang, Yan; Shephard, Lee; Goldbeck, Cheryl; Oei, Yoko; Ye, Helen; Aukerman, Sharon L.; Heise, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5281-5291</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Fms-like tyrosine kinase 3 (FLT3) encodes a receptor tyrosine kinase (RTK) for which activating mutations have been identified in a proportion of acute myelogenous leukemia (AML) patients and assocd. with poor clin. prognosis.  Given the relevance of FLT3 mutations in AML, we investigated the activity of CHIR-258, an orally active, multitargeted small mol., with potent activity against FLT3 kinase and class III, IV, and V RTKs involved in endothelial and tumor cell proliferation in AML models.  Exptl. Design: CHIR-258 was tested on two human leukemic cell lines in vitro and in vivo with differing FLT3 mutational status [MV4;11 cells express FLT3 internal tandem duplications (ITD) vs. RS4;11 cells with wild-type (WT) FLT3].  Results: Antiproliferative activity of CHIR-258 against MV4;11 was ∼24-fold greater compared with RS4;11, indicating more potent inhibition against cells with constitutively activated FLT3 ITD.  Dose-dependent down modulation of receptor phosphorylation and downstream signaling [signal transducer and activator of transcription 5 (STAT5) and extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase] in MV4;11 cells with CHIR-258 confirmed the mol. mechanism of action.  Target modulation of phospho-FLT3, phospho-STAT5, and phospho-ERK in MV4;11 tumors was achieved at biol. active doses of CHIR-258.  Tumor regressions and eradication of AML cells from the bone marrow were shown in s.c. and bone marrow engraftment leukemic xenograft models.  Tumor responses were characterized by decreased cellular proliferation and pos. immunohistochem. staining for active caspase-3 and cleaved poly(ADP-ribose) polymerase, suggesting cell death was mediated in part via apoptosis.  Conclusions: These data indicate that CHIR-258 may be an effective therapy in FLT3-assocd. AML and warrants clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqguTG7oB17arVg90H21EOLACvtfcHk0liHqBuC41mpbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt12qurc%253D&md5=81dc564d120f28420fdd69f685f877c2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0358%26sid%3Dliteratum%253Aachs%26aulast%3DLopes%2Bde%2BMenezes%26aufirst%3DD.%2BE.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DGarrett%26aufirst%3DE.%2BN.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DShephard%26aufirst%3DL.%26aulast%3DGoldbeck%26aufirst%3DC.%26aulast%3DOei%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DAukerman%26aufirst%3DS.%2BL.%26aulast%3DHeise%26aufirst%3DC.%26atitle%3DCHIR-258%253A%2520a%2520potent%2520inhibitor%2520of%2520FLT3%2520kinase%2520in%2520experimental%2520tumor%2520xenograft%2520models%2520of%2520human%2520acute%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D5281%26epage%3D5291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Angelo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galinsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klimek, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial</span> <span class="citation_source-journal">Ann. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2004&pages=89-90&author=R.+M.+Stoneauthor=J.+De+Angeloauthor=I.+Galinskyauthor=E.+Esteyauthor=V.+Klimekauthor=W.+Grandinauthor=D.+Lebwohlauthor=A.+Yapauthor=P.+Cohenauthor=E.+Foxauthor=D.+Neubergauthor=J.+Clarkauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=PKC+412+FLT3+inhibitor+therapy+in+AML%3A+results+of+a+phase+II+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DDe%2BAngelo%26aufirst%3DJ.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DKlimek%26aufirst%3DV.%26aulast%3DGrandin%26aufirst%3DW.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DYap%26aufirst%3DA.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DFox%26aufirst%3DE.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DPKC%2520412%2520FLT3%2520inhibitor%2520therapy%2520in%2520AML%253A%2520results%2520of%2520a%2520phase%2520II%2520trial%26jtitle%3DAnn.%2520Hematol.%26date%3D2004%26volume%3D83%26spage%3D89%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauses, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allebach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">3669</span><span class="NLM_x">–</span> <span class="NLM_lpage">3676</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2004&pages=3669-3676&author=B.+D.+Smithauthor=M.+Levisauthor=M.+Beranauthor=F.+Gilesauthor=H.+Kantarjianauthor=K.+Bergauthor=K.+M.+Murphyauthor=T.+Dausesauthor=J.+Allebachauthor=D.+Small&title=Single-agent+CEP-701%2C+a+novel+FLT3+inhibitor%2C+shows+biologic+and+clinical+activity+in+patients+with+relapsed+or+refractory+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DBeran%26aufirst%3DM.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DBerg%26aufirst%3DK.%26aulast%3DMurphy%26aufirst%3DK.%2BM.%26aulast%3DDauses%26aufirst%3DT.%26aulast%3DAllebach%26aufirst%3DJ.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DSingle-agent%2520CEP-701%252C%2520a%2520novel%2520FLT3%2520inhibitor%252C%2520shows%2520biologic%2520and%2520clinical%2520activity%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2004%26volume%3D103%26spage%3D3669%26epage%3D3676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaney, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klisovic, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecerf, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karol, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holford, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span> </span><span class="NLM_article-title">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3674</span><span class="NLM_x">–</span> <span class="NLM_lpage">3681</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1182%2Fblood-2006-02-005702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=16902153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3674-3681&author=D.+J.+DeAngeloauthor=R.+M.+Stoneauthor=M.+L.+Heaneyauthor=S.+D.+Nimerauthor=R.+L.+Paquetteauthor=R.+B.+Klisovicauthor=M.+A.+Caligiuriauthor=M.+R.+Cooperauthor=J.+M.+Lecerfauthor=M.+D.+Karolauthor=S.+Shengauthor=N.+Holfordauthor=P.+T.+Curtinauthor=B.+J.+Drukerauthor=M.+C.+Heinrich&title=Phase+1+clinical+results+with+tandutinib+%28MLN518%29%2C+a+novel+FLT3+antagonist%2C+in+patients+with+acute+myelogenous+leukemia+or+high-risk+myelodysplastic+syndrome%3A+safety%2C+pharmacokinetics%2C+and+pharmacodynamics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span></div><div class="casAuthors">DeAngelo, Daniel J.; Stone, Richard M.; Heaney, Mark L.; Nimer, Stephen D.; Paquette, Ronald L.; Klisovic, Rebecca B.; Caligiuri, Michael A.; Cooper, Michael R.; Lecerf, Jean-Michel; Karol, Michael D.; Sheng, Shihong; Holford, Nick; Curtin, Peter T.; Druker, Brian J.; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3674-3681</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptor (PDGFR), and KIT.  Because of the correlation between FLT3 internal tandem duplication (ITD) mutations and poor prognosis in acute myelogenous leukemia (AML), we conducted a phase 1 trial of tandutinib in 40 patients with either AML or high-risk myelodysplastic syndrome (MDS).  Tandutinib was given orally in doses ranging from 50 mg to 700 mg twice daily The principal dose-limiting toxicity (DLT) of tandutinib was reversible generalized muscular weakness, fatigue, or both, occurring at doses of 525 mg and 700 mg twice daily.  Tandutinib's pharmacokinetics were characterized by slow elimination, with achievement of steady-state plasma concns. requiring greater than 1 wk of dosing.  Western blotting showed that tandutinib inhibited phosphorylation of FLT3 in circulating leukemic blasts.  Eight patients had FLT3-ITD mutations; 5 of these were evaluable for assessment of tandutinib's antileukemic effect.  Two of the 5 patients, treated at 525 mg and 700 mg twice daily, showed evidence of antileukemic activity, with decreases in both peripheral and bone marrow blasts.  Tandutinib at the MTD (525 mg twice daily) should be evaluated more extensively in patients with AML with FLT3-ITD mutations to better define its antileukemic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraXRBv_Gv-TLVg90H21EOLACvtfcHk0lhadtYPrJ8XXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM&md5=42c0b5a4c193955023198d6c6d12c463</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-02-005702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-02-005702%26sid%3Dliteratum%253Aachs%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DHeaney%26aufirst%3DM.%2BL.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKlisovic%26aufirst%3DR.%2BB.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DCooper%26aufirst%3DM.%2BR.%26aulast%3DLecerf%26aufirst%3DJ.%2BM.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26aulast%3DSheng%26aufirst%3DS.%26aulast%3DHolford%26aufirst%3DN.%26aulast%3DCurtin%26aufirst%3DP.%2BT.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DPhase%25201%2520clinical%2520results%2520with%2520tandutinib%2520%2528MLN518%2529%252C%2520a%2520novel%2520FLT3%2520antagonist%252C%2520in%2520patients%2520with%2520acute%2520myelogenous%2520leukemia%2520or%2520high-risk%2520myelodysplastic%2520syndrome%253A%2520safety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3674%26epage%3D3681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brigham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprankle, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S. S.</span><span> </span><span class="NLM_article-title">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">2984</span><span class="NLM_x">–</span> <span class="NLM_lpage">2992</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=2984-2992&author=P.+P.+Zarrinkarauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=D.+Brighamauthor=B.+Belliauthor=M.+W.+Karamanauthor=K.+W.+Pratzauthor=G.+Pallaresauthor=Q.+Chaoauthor=K.+G.+Sprankleauthor=H.+K.+Patelauthor=M.+Levisauthor=R.+C.+Armstrongauthor=J.+Jamesauthor=S.+S.+Bhagwat&title=AC220+is+a+uniquely+potent+and+selective+inhibitor+of+FLT3+for+the+treatment+of+acute+myeloid+leukemia+%28AML%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DAC220%2520is%2520a%2520uniquely%2520potent%2520and%2520selective%2520inhibitor%2520of%2520FLT3%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D2984%26epage%3D2992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprankle, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S. S.</span><span> </span><span class="NLM_article-title">Identification of <i>N</i>-(5-<i>tert</i>-butylisoxazol-3-yl)-<i>N</i>′-{4-[7-(2-morpholin-4-ylethoxy)imidazo[2,1-<i>b</i>][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7808</span><span class="NLM_x">–</span> <span class="NLM_lpage">7816</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9007533" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7808-7816&author=Q.+Chaoauthor=K.+G.+Sprankleauthor=R.+M.+Grotzfeldauthor=A.+G.+Laiauthor=T.+A.+Carterauthor=A.+M.+Velascoauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=J.+Jamesauthor=P.+P.+Zarrinkarauthor=H.+K.+Patelauthor=S.+S.+Bhagwat&title=Identification+of+N-%285-tert-butylisoxazol-3-yl%29-N%E2%80%B2-%7B4-%5B7-%282-morpholin-4-ylethoxy%29imidazo%5B2%2C1-b%5D%5B1%2C3%5Dbenzothiazol-2-yl%5Dphenyl%7Durea+dihydrochloride+%28AC220%29%2C+a+uniquely+potent%2C+selective%2C+and+efficacious+FMS-like+tyrosine+kinase-3+%28FLT3%29+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm9007533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9007533%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DIdentification%2520of%2520N-%25285-tert-butylisoxazol-3-yl%2529-N%25E2%2580%25B2-%257B4-%255B7-%25282-morpholin-4-ylethoxy%2529imidazo%255B2%252C1-b%255D%255B1%252C3%255Dbenzothiazol-2-yl%255Dphenyl%257Durea%2520dihydrochloride%2520%2528AC220%2529%252C%2520a%2520uniquely%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520FMS-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7808%26epage%3D7816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Kampen, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ter Elst, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bont, E. S.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor signaling in acute myeloid leukemia</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><div class="note"><p class="first last">in press</p></div><span class="refDoi"> DOI: 10.1007/s00018-012-1085-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1007%2Fs00018-012-1085-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=K.+R.+Kampenauthor=A.+Ter+Elstauthor=E.+S.+de+Bont&title=Vascular+endothelial+growth+factor+signaling+in+acute+myeloid+leukemia&doi=10.1007%2Fs00018-012-1085-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00018-012-1085-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-012-1085-3%26sid%3Dliteratum%253Aachs%26aulast%3DKampen%26aufirst%3DK.%2BR.%26aulast%3DTer%2BElst%26aufirst%3DA.%26aulast%3Dde%2BBont%26aufirst%3DE.%2BS.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520signaling%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2013%26doi%3D10.1007%2Fs00018-012-1085-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Ter Elst, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherpen, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Jonge, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douwes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierenga, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuringa, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamps, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bont, E. S.</span><span> </span><span class="NLM_article-title">Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">2761</span><span class="NLM_x">–</span> <span class="NLM_lpage">2771</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=2761-2771&author=A.+Ter+Elstauthor=B.+Maauthor=F.+J.+Scherpenauthor=H.+J.+de+Jongeauthor=J.+Douwesauthor=A.+T.+Wierengaauthor=J.+J.+Schuringaauthor=W.+A.+Kampsauthor=E.+S.+de+Bont&title=Repression+of+vascular+endothelial+growth+factor+expression+by+the+runt-related+transcription+factor+1+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTer%2BElst%26aufirst%3DA.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DScherpen%26aufirst%3DF.%2BJ.%26aulast%3Dde%2BJonge%26aufirst%3DH.%2BJ.%26aulast%3DDouwes%26aufirst%3DJ.%26aulast%3DWierenga%26aufirst%3DA.%2BT.%26aulast%3DSchuringa%26aufirst%3DJ.%2BJ.%26aulast%3DKamps%26aufirst%3DW.%2BA.%26aulast%3Dde%2BBont%26aufirst%3DE.%2BS.%26atitle%3DRepression%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520expression%2520by%2520the%2520runt-related%2520transcription%2520factor%25201%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D2761%26epage%3D2771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Savic, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cemerikic-Martinovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dovat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajic, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urosevic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekulic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kvrgic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popovic, S.</span><span> </span><span class="NLM_article-title">Angiogenesis and survival in patients with myelodysplastic syndrome</span> <span class="citation_source-journal">Pathol. Oncol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">681</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1007%2Fs12253-012-9495-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=22270865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsF2msLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=681-690&author=A.+Savicauthor=V.+Cemerikic-Martinovicauthor=S.+Dovatauthor=N.+Rajicauthor=I.+Urosevicauthor=B.+Sekulicauthor=V.+Kvrgicauthor=S.+Popovic&title=Angiogenesis+and+survival+in+patients+with+myelodysplastic+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis and Survival in Patients with Myelodysplastic Syndrome</span></div><div class="casAuthors">Savic, Aleksandar; Cemerikic-Martinovic, Vesna; Dovat, Sinisa; Rajic, Nebojsa; Urosevic, Ivana; Sekulic, Borivoj; Kvrgic, Vanja; Popovic, Stevan</div><div class="citationInfo"><span class="NLM_cas:title">Pathology & Oncology Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">681-690</span>CODEN:
                <span class="NLM_cas:coden">POREFR</span>;
        ISSN:<span class="NLM_cas:issn">1219-4956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Angiogenesis has been implicated in the pathogenesis and prognosis of myelodysplastic syndrome (MDS).  In this study, we investigated the relationship between microvessel d. (MVD), vascular endothelial growth factor (VEGF) expression, common morphol. and clin. factors, and survival in patients with MDS.  We examd. the MVD of paraffin-embedded bone marrow sections from 70 MDS patients and 31 controls.  VEGF expression was detd. in 50 patients and 20 controls.  The median MVD in MDS patients was significantly higher than that in controls (p = 0.025), whereas there was no difference in VEGF expression between MDS patients and controls.  In univariate anal., increased MVD was assocd. with a shorter survival time (p = 0.023).  However, in multivariate anal., MVD was not an independent predictor of survival.  The VEGF expression did not influence survival in univariate anal.  Survival was independently influenced by platelet count (p = 0.0073), cytogenetic risk category (p = 0.022), and transfusion dependence (p = 0.0073).  Neither MVD nor VEGF expression were predictors for progression to acute myeloid leukemia in univariate anal.  Progression to acute myeloid leukemia was independently influenced only by the cytogenetic risk category (p = 0.022).  This study confirmed increased MVD in MDS.  It does not support an independent prognostic role of angiogenesis in MDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBEH9qNr3gD7Vg90H21EOLACvtfcHk0lga-FA07uxtSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsF2msLY%253D&md5=92901e8c2460b32e964195c734c23490</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs12253-012-9495-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12253-012-9495-y%26sid%3Dliteratum%253Aachs%26aulast%3DSavic%26aufirst%3DA.%26aulast%3DCemerikic-Martinovic%26aufirst%3DV.%26aulast%3DDovat%26aufirst%3DS.%26aulast%3DRajic%26aufirst%3DN.%26aulast%3DUrosevic%26aufirst%3DI.%26aulast%3DSekulic%26aufirst%3DB.%26aulast%3DKvrgic%26aufirst%3DV.%26aulast%3DPopovic%26aufirst%3DS.%26atitle%3DAngiogenesis%2520and%2520survival%2520in%2520patients%2520with%2520myelodysplastic%2520syndrome%26jtitle%3DPathol.%2520Oncol.%2520Res.%26date%3D2012%26volume%3D18%26spage%3D681%26epage%3D690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Padro, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Retzlaff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrera, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kienast, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Tidow, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serve, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdel, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesters, R. M.</span><span> </span><span class="NLM_article-title">Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1302</span><span class="NLM_x">–</span> <span class="NLM_lpage">1310</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=1302-1310&author=T.+Padroauthor=R.+Biekerauthor=S.+Ruizauthor=M.+Steinsauthor=S.+Retzlaffauthor=H.+Burgerauthor=T.+Buchnerauthor=T.+Kesslerauthor=F.+Herreraauthor=J.+Kienastauthor=C.+Muller-Tidowauthor=H.+Serveauthor=W.+E.+Berdelauthor=R.+M.+Mesters&title=Overexpression+of+vascular+endothelial+growth+factor+%28VEGF%29+and+its+cellular+receptor+KDR+%28VEGFR-2%29+in+the+bone+marrow+of+patients+with+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPadro%26aufirst%3DT.%26aulast%3DBieker%26aufirst%3DR.%26aulast%3DRuiz%26aufirst%3DS.%26aulast%3DSteins%26aufirst%3DM.%26aulast%3DRetzlaff%26aufirst%3DS.%26aulast%3DBurger%26aufirst%3DH.%26aulast%3DBuchner%26aufirst%3DT.%26aulast%3DKessler%26aufirst%3DT.%26aulast%3DHerrera%26aufirst%3DF.%26aulast%3DKienast%26aufirst%3DJ.%26aulast%3DMuller-Tidow%26aufirst%3DC.%26aulast%3DServe%26aufirst%3DH.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DMesters%26aufirst%3DR.%2BM.%26atitle%3DOverexpression%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520%2528VEGF%2529%2520and%2520its%2520cellular%2520receptor%2520KDR%2520%2528VEGFR-2%2529%2520in%2520the%2520bone%2520marrow%2520of%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2002%26volume%3D16%26spage%3D1302%26epage%3D1310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Trujillo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cogle, C. R.</span><span> </span><span class="NLM_article-title">Angiogenesis in acute myeloid leukemia and opportunities for novel therapies</span> <span class="citation_source-journal">J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1155%2F2012%2F128608" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=1-9&author=A.+Trujilloauthor=C.+McGeeauthor=C.+R.+Cogle&title=Angiogenesis+in+acute+myeloid+leukemia+and+opportunities+for+novel+therapies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1155%2F2012%2F128608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2012%252F128608%26sid%3Dliteratum%253Aachs%26aulast%3DTrujillo%26aufirst%3DA.%26aulast%3DMcGee%26aufirst%3DC.%26aulast%3DCogle%26aufirst%3DC.%2BR.%26atitle%3DAngiogenesis%2520in%2520acute%2520myeloid%2520leukemia%2520and%2520opportunities%2520for%2520novel%2520therapies%26jtitle%3DJ.%2520Oncol.%26date%3D2012%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Fiedler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graeven, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ergun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verago, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilic, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockschlader, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hossfeld, D. K.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">1870</span><span class="NLM_x">–</span> <span class="NLM_lpage">1875</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=1870-1875&author=W.+Fiedlerauthor=U.+Graevenauthor=S.+Ergunauthor=S.+Veragoauthor=N.+Kilicauthor=M.+Stockschladerauthor=D.+K.+Hossfeld&title=Vascular+endothelial+growth+factor%2C+a+possible+paracrine+growth+factor+in+human+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DGraeven%26aufirst%3DU.%26aulast%3DErgun%26aufirst%3DS.%26aulast%3DVerago%26aufirst%3DS.%26aulast%3DKilic%26aufirst%3DN.%26aulast%3DStockschlader%26aufirst%3DM.%26aulast%3DHossfeld%26aufirst%3DD.%2BK.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%252C%2520a%2520possible%2520paracrine%2520growth%2520factor%2520in%2520human%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D1997%26volume%3D89%26spage%3D1870%26epage%3D1875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Deckers, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Bezooijen, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Horst, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoogendam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Der Bent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papapoulos, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowik, C. W.</span><span> </span><span class="NLM_article-title">Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">143</span><span class="NLM_x">, </span> <span class="NLM_fpage">1545</span><span class="NLM_x">–</span> <span class="NLM_lpage">1553</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2002&pages=1545-1553&author=M.+M.+Deckersauthor=R.+L.+van+Bezooijenauthor=G.+van+der+Horstauthor=J.+Hoogendamauthor=C.+van+Der+Bentauthor=S.+E.+Papapoulosauthor=C.+W.+Lowik&title=Bone+morphogenetic+proteins+stimulate+angiogenesis+through+osteoblast-derived+vascular+endothelial+growth+factor+A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDeckers%26aufirst%3DM.%2BM.%26aulast%3Dvan%2BBezooijen%26aufirst%3DR.%2BL.%26aulast%3Dvan%2Bder%2BHorst%26aufirst%3DG.%26aulast%3DHoogendam%26aufirst%3DJ.%26aulast%3Dvan%2BDer%2BBent%26aufirst%3DC.%26aulast%3DPapapoulos%26aufirst%3DS.%2BE.%26aulast%3DLowik%26aufirst%3DC.%2BW.%26atitle%3DBone%2520morphogenetic%2520proteins%2520stimulate%2520angiogenesis%2520through%2520osteoblast-derived%2520vascular%2520endothelial%2520growth%2520factor%2520A%26jtitle%3DEndocrinology%26date%3D2002%26volume%3D143%26spage%3D1545%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Kodama, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshiko, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohama, K.</span><span> </span><span class="NLM_article-title">Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice</span> <span class="citation_source-journal">J. Bone Miner. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">200</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1359%2FJBMR.0301229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=14969389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1emu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2004&pages=200-206&author=I.+Kodamaauthor=S.+Niidaauthor=M.+Sanadaauthor=Y.+Yoshikoauthor=M.+Tsudaauthor=N.+Maedaauthor=K.+Ohama&title=Estrogen+regulates+the+production+of+VEGF+for+osteoclast+formation+and+activity+in+op%2Fop+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice</span></div><div class="casAuthors">Kodama, Ichiro; Niida, Shumpei; Sanada, Mitsuhiro; Yoshiko, Yuji; Tsuda, Mikio; Maeda, Norihiko; Ohama, Koso</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bone and Mineral Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">200-206</span>CODEN:
                <span class="NLM_cas:coden">JBMREJ</span>;
        ISSN:<span class="NLM_cas:issn">0884-0431</span>.
    
            (<span class="NLM_cas:orgname">American Society for Bone and Mineral Research</span>)
        </div><div class="casAbstract">Op/op mice have a severe deficiency of osteoclasts because of lacking functional M-CSF that is an essential factor of osteoclast differentiation and function.  The authors now report that OVX induces osteoclast formation and cures osteopetrosis by increasing the VEGF that regulates osteoclast formation in these mice.  The authors have found that estrogen deficiency induced by ovariectomy (OVX) upregulated osteoclast formation in op/op mice.  The authors have recently demonstrated that vascular endothelial growth factor (VEGF) could substitute for macrophage colony-stimulating factor (M-CSF) in the support of osteoclastic bone resorption in these mice.  Therefore, in this study, the authors wished to assess the effects of VEGF on bone loss induced by OVX in these mice.  Eight-week-old op/op mice were bilateral OVX or sham-operated.  Mice were killed at 8, 10, and 12 wk of age, and femurs were removed for prepns.  Some OVX mice were treated with three consecutive injections of 120 μl/body of VEGF-neutralizing antibody at 12-h intervals starting from 36 h before death at 4 wk after OVX.  VEGFR-1/Fc chimeric protein (600 μg/kg/day) or 17β-estradiol (0.16 μg/day) was administered in a dorsal s.c. pocket of the mice at the time of OVX.  These mice were killed 2 wk after surgery.  Changes of serum levels of VEGF were measured by ELISA.  Changes of mRNA levels of VEGF, Flt-1, interleukin-6, and osteoclast differentiation factor (ODF/TRANCE/RANKL) in bone tissue were measured by reverse transcriptase-polymerase chain reaction.  In OVX op/op mice, trabecular bone vol. of the femur was decreased, and the no. of osteoclasts was significantly increased.  Serum levels of VEGF were demonstrated to be higher in OVX mice than in sham-operated mice.  VEGF mRNA, Flt-1 mRNA, interleukin-6 mRNA, and RANKL mRNA levels in bone tissue were elevated in OVX mice over that in sham-operated mice.  The increase in osteoclast no. was inhibited by VEGF antagonist treatment in OVX mice.  Thus, the authors have demonstrated that the prodn. of VEGF and RANKL stimulated by OVX results in increased osteoclast formation in op/op mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNdUCvdWoEv7Vg90H21EOLACvtfcHk0li1Tsg1CS4J_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1emu7o%253D&md5=d61bdc6a122829993f4ff2843ebda085</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1359%2FJBMR.0301229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1359%252FJBMR.0301229%26sid%3Dliteratum%253Aachs%26aulast%3DKodama%26aufirst%3DI.%26aulast%3DNiida%26aufirst%3DS.%26aulast%3DSanada%26aufirst%3DM.%26aulast%3DYoshiko%26aufirst%3DY.%26aulast%3DTsuda%26aufirst%3DM.%26aulast%3DMaeda%26aufirst%3DN.%26aulast%3DOhama%26aufirst%3DK.%26atitle%3DEstrogen%2520regulates%2520the%2520production%2520of%2520VEGF%2520for%2520osteoclast%2520formation%2520and%2520activity%2520in%2520op%252Fop%2520mice%26jtitle%3DJ.%2520Bone%2520Miner.%2520Res.%26date%3D2004%26volume%3D19%26spage%3D200%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Knowles, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Athanasou, N. A.</span><span> </span><span class="NLM_article-title">Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">215</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">66</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1002%2Fpath.2319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=18283716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtFKrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=2008&pages=56-66&author=H.+J.+Knowlesauthor=N.+A.+Athanasou&title=Hypoxia-inducible+factor+is+expressed+in+giant+cell+tumour+of+bone+and+mediates+paracrine+effects+of+hypoxia+on+monocyte-osteoclast+differentiation+via+induction+of+VEGF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF</span></div><div class="casAuthors">Knowles, H. J.; Athanasou, N. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">215</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-66</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Hypoxia is an important regulator of bone biol. and stimulates osteoclast differentiation from monocytic precursors.  Hypoxia-inducible factor (HIF) is a key pro-tumorigenic transcription factor mediating pathways of hypoxia-inducible gene expression.  We have described expression of HIF-1α and HIF-2α in the multi-nucleated, osteoclast-like giant cells and the mononuclear stromal component of giant cell tumor of bone (GCTB), a locally osteolytic primary bone tumor.  HIF induction was obsd. in culture in the osteoblastic MG-63 cell line, primary GCTB stromal cells, and monocyte-derived osteoclasts following stimulation with hypoxia (0.1% O2) or the osteoclastogenic cytokines hepatocyte growth factor (HGF) and macrophage colony-stimulating factor (M-CSF).  This was accompanied by increased expression of the downstream target genes Bcl-2/adenovirus E1B 19 kD-interacting protein 3 (BNIP3), Glut-1, and vascular endothelial growth factor (VEGF).  As VEGF can substitute for M-CSF to support osteoclastogenesis in the presence of receptor activator for nuclear factor κB ligand (RANKL), we assessed the effect of MG-63 hypoxic conditioned media on osteoclast differentiation.  In the presence of RANKL, hypoxic conditioned media induced the formation of active osteoclasts, as assessed from the nos. of TRAP-pos. multi-nucleated cells and the area of lacunar bone resorption, which was inhibited by co-incubation with a neutralizing anti-VEGF antibody.  Targeted siRNA ablated HIF-1α and/or HIF-2α expression in MG-63 cells and reduced hypoxic secretion of VEGF.  Hypoxic conditioned media from cells treated with siRNA for (HIF-1α + HIF-2α) produced a significant decrease in osteoclast no. (p < 0.005) and activity (p < 0.05) in comparison with the scrambled siRNA control.  These results suggest that local hypoxia could indirectly influence osteoclastogenesis via autocrine and paracrine secretion of VEGF under the control of HIF.  This is potentially an important mechanism of pathogenesis for GCTB and other osteolytic lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhbgp3zroAPbVg90H21EOLACvtfcHk0li1Tsg1CS4J_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtFKrsr8%253D&md5=9b7490c27469b2d52e4c4e50f23701a3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fpath.2319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.2319%26sid%3Dliteratum%253Aachs%26aulast%3DKnowles%26aufirst%3DH.%2BJ.%26aulast%3DAthanasou%26aufirst%3DN.%2BA.%26atitle%3DHypoxia-inducible%2520factor%2520is%2520expressed%2520in%2520giant%2520cell%2520tumour%2520of%2520bone%2520and%2520mediates%2520paracrine%2520effects%2520of%2520hypoxia%2520on%2520monocyte-osteoclast%2520differentiation%2520via%2520induction%2520of%2520VEGF%26jtitle%3DJ.%2520Pathol.%26date%3D2008%26volume%3D215%26spage%3D56%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyce, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, L.</span><span> </span><span class="NLM_article-title">VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">13491</span><span class="NLM_x">–</span> <span class="NLM_lpage">13499</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=13491-13499&author=Q.+Zhangauthor=R.+Guoauthor=Y.+Luauthor=L.+Zhaoauthor=Q.+Zhouauthor=E.+M.+Schwarzauthor=J.+Huangauthor=D.+Chenauthor=Z.+G.+Jinauthor=B.+F.+Boyceauthor=L.+Xing&title=VEGF-C%2C+a+lymphatic+growth+factor%2C+is+a+RANKL+target+gene+in+osteoclasts+that+enhances+osteoclastic+bone+resorption+through+an+autocrine+mechanism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGuo%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DSchwarz%26aufirst%3DE.%2BM.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DJin%26aufirst%3DZ.%2BG.%26aulast%3DBoyce%26aufirst%3DB.%2BF.%26aulast%3DXing%26aufirst%3DL.%26atitle%3DVEGF-C%252C%2520a%2520lymphatic%2520growth%2520factor%252C%2520is%2520a%2520RANKL%2520target%2520gene%2520in%2520osteoclasts%2520that%2520enhances%2520osteoclastic%2520bone%2520resorption%2520through%2520an%2520autocrine%2520mechanism%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D13491%26epage%3D13499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Holzer, P.; Imbach, P.; Furet, P.; Schmiedeberg, N.</span><span> </span><span class="NLM_article-title">3-(Substituted amino)-pyrazolo[3,4-d]pyrimidines as Ephb and VEGFR2 Kinase Inhibitors</span>. PCT WO 2007/062805 A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=P.+Holzer&author=P.+Imbach&author=P.+Furet&author=N.+Schmiedeberg&title=3-%28Substituted+amino%29-pyrazolo%5B3%2C4-d%5Dpyrimidines+as+Ephb+and+VEGFR2+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHolzer%26aufirst%3DP.%26atitle%3D3-%2528Substituted%2520amino%2529-pyrazolo%255B3%252C4-d%255Dpyrimidines%2520as%2520Ephb%2520and%2520VEGFR2%2520Kinase%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Bannen, L. C.; Chan, D. S.; Dalrymple, L. E.; Jammalamadaka, V.; Khoury, R. G.; Mac, M. B.; Mann, G.; Mann, L. W.; Nuss, J. M.; Parks, J. J.; Wang, Y.; Xu, W.</span><span> </span><span class="NLM_article-title">C-met Modulators and Method of Use</span>. PCT WO 2006/014325 A2,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=L.+C.+Bannen&author=D.+S.+Chan&author=L.+E.+Dalrymple&author=V.+Jammalamadaka&author=R.+G.+Khoury&author=M.+B.+Mac&author=G.+Mann&author=L.+W.+Mann&author=J.+M.+Nuss&author=J.+J.+Parks&author=Y.+Wang&author=W.+Xu&title=C-met+Modulators+and+Method+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBannen%26aufirst%3DL.%2BC.%26atitle%3DC-met%2520Modulators%2520and%2520Method%2520of%2520Use%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murooka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasegawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isoe, T.</span><span> </span><span class="NLM_article-title">Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure–activity relationships, and antitumor activities of <i>N</i>-phenyl-<i>N</i>′-{4-(4-quinolyloxy)phenyl}ureas</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1359</span><span class="NLM_x">–</span> <span class="NLM_lpage">1366</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030427r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1359-1366&author=K.+Kuboauthor=T.+Shimizuauthor=S.+Ohyamaauthor=H.+Murookaauthor=A.+Iwaiauthor=K.+Nakamuraauthor=K.+Hasegawaauthor=Y.+Kobayashiauthor=N.+Takahashiauthor=K.+Takahashiauthor=S.+Katoauthor=T.+Izawaauthor=T.+Isoe&title=Novel+potent+orally+active+selective+VEGFR-2+tyrosine+kinase+inhibitors%3A+synthesis%2C+structure%E2%80%93activity+relationships%2C+and+antitumor+activities+of+N-phenyl-N%E2%80%B2-%7B4-%284-quinolyloxy%29phenyl%7Dureas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm030427r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030427r%26sid%3Dliteratum%253Aachs%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DOhyama%26aufirst%3DS.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DIwai%26aufirst%3DA.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DHasegawa%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DS.%26aulast%3DIzawa%26aufirst%3DT.%26aulast%3DIsoe%26aufirst%3DT.%26atitle%3DNovel%2520potent%2520orally%2520active%2520selective%2520VEGFR-2%2520tyrosine%2520kinase%2520inhibitors%253A%2520synthesis%252C%2520structure%25E2%2580%2593activity%2520relationships%252C%2520and%2520antitumor%2520activities%2520of%2520N-phenyl-N%25E2%2580%25B2-%257B4-%25284-quinolyloxy%2529phenyl%257Dureas%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1359%26epage%3D1366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Yang, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Q. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S. Y.</span><span> </span><span class="NLM_article-title">Discovery of N6-phenyl-1<i>H</i>-pyrazolo[3,4-d]pyrimidine-3,6- diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">30</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=30-38&author=L.+L.+Yangauthor=G.+B.+Liauthor=H.+X.+Yanauthor=Q.+Z.+Sunauthor=S.+Maauthor=P.+Jiauthor=Z.+R.+Wangauthor=S.+Fengauthor=J.+Zouauthor=S.+Y.+Yang&title=Discovery+of+N6-phenyl-1H-pyrazolo%5B3%2C4-d%5Dpyrimidine-3%2C6-+diamine+derivatives+as+novel+CK1+inhibitors+using+common-feature+pharmacophore+model+based+virtual+screening+and+hit-to-lead+optimization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%2BL.%26aulast%3DLi%26aufirst%3DG.%2BB.%26aulast%3DYan%26aufirst%3DH.%2BX.%26aulast%3DSun%26aufirst%3DQ.%2BZ.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DJi%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%2BR.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DDiscovery%2520of%2520N6-phenyl-1H-pyrazolo%255B3%252C4-d%255Dpyrimidine-3%252C6-%2520diamine%2520derivatives%2520as%2520novel%2520CK1%2520inhibitors%2520using%2520common-feature%2520pharmacophore%2520model%2520based%2520virtual%2520screening%2520and%2520hit-to-lead%2520optimization%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D56%26spage%3D30%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Garofalo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farce, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemoine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Six, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavatte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goossens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depreux, P.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1189</span><span class="NLM_x">–</span> <span class="NLM_lpage">1204</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2013453" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1189-1204&author=A.+Garofaloauthor=A.+Farceauthor=S.+Ravezauthor=A.+Lemoineauthor=P.+Sixauthor=P.+Chavatteauthor=L.+Goossensauthor=P.+Depreux&title=Synthesis+and+structure%E2%80%93activity+relationships+of+%28aryloxy%29quinazoline+ureas+as+novel%2C+potent%2C+and+selective+vascular+endothelial+growth+factor+receptor-2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm2013453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2013453%26sid%3Dliteratum%253Aachs%26aulast%3DGarofalo%26aufirst%3DA.%26aulast%3DFarce%26aufirst%3DA.%26aulast%3DRavez%26aufirst%3DS.%26aulast%3DLemoine%26aufirst%3DA.%26aulast%3DSix%26aufirst%3DP.%26aulast%3DChavatte%26aufirst%3DP.%26aulast%3DGoossens%26aufirst%3DL.%26aulast%3DDepreux%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520%2528aryloxy%2529quinazoline%2520ureas%2520as%2520novel%252C%2520potent%252C%2520and%2520selective%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1189%26epage%3D1204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Quentmeier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhardt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaborski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drexler, H. G.</span><span> </span><span class="NLM_article-title">FLT3 mutations in acute myeloid leukemia cell lines</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=120-124&author=H.+Quentmeierauthor=J.+Reinhardtauthor=M.+Zaborskiauthor=H.+G.+Drexler&title=FLT3+mutations+in+acute+myeloid+leukemia+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuentmeier%26aufirst%3DH.%26aulast%3DReinhardt%26aufirst%3DJ.%26aulast%3DZaborski%26aufirst%3DM.%26aulast%3DDrexler%26aufirst%3DH.%2BG.%26atitle%3DFLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%2520cell%2520lines%26jtitle%3DLeukemia%26date%3D2003%26volume%3D17%26spage%3D120%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Li, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Q. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S. Y.</span><span> </span><span class="NLM_article-title">Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-<i>p</i>-tolylurea and its anti-acute myeloid leukemia (AML) activities <i>in vitro</i> and <i>in vivo</i></span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3852</span><span class="NLM_x">–</span> <span class="NLM_lpage">3866</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300042x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3852-3866&author=W.+W.+Liauthor=X.+Y.+Wangauthor=R.+L.+Zhengauthor=H.+X.+Yanauthor=Z.+X.+Caoauthor=L.+Zhongauthor=Z.+R.+Wangauthor=P.+Jiauthor=L.+L.+Yangauthor=L.+J.+Wangauthor=Y.+Xuauthor=J.+J.+Liuauthor=J.+Yangauthor=C.+H.+Zhangauthor=S.+Maauthor=S.+Fengauthor=Q.+Z.+Sunauthor=Y.+Q.+Weiauthor=S.+Y.+Yang&title=Discovery+of+the+novel+potent+and+selective+FLT3+inhibitor+1-%7B5-%5B7-%283-+morpholinopropoxy%29quinazolin-4-ylthio%5D-%5B1%2C3%2C4%5Dthiadiazol-2-yl%7D-3-p-tolylurea+and+its+anti-acute+myeloid+leukemia+%28AML%29+activities+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm300042x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300042x%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%2BW.%26aulast%3DWang%26aufirst%3DX.%2BY.%26aulast%3DZheng%26aufirst%3DR.%2BL.%26aulast%3DYan%26aufirst%3DH.%2BX.%26aulast%3DCao%26aufirst%3DZ.%2BX.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%2BR.%26aulast%3DJi%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DL.%2BL.%26aulast%3DWang%26aufirst%3DL.%2BJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%2BJ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DQ.%2BZ.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DDiscovery%2520of%2520the%2520novel%2520potent%2520and%2520selective%2520FLT3%2520inhibitor%25201-%257B5-%255B7-%25283-%2520morpholinopropoxy%2529quinazolin-4-ylthio%255D-%255B1%252C3%252C4%255Dthiadiazol-2-yl%257D-3-p-tolylurea%2520and%2520its%2520anti-acute%2520myeloid%2520leukemia%2520%2528AML%2529%2520activities%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3852%26epage%3D3866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Davies, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forster, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnost, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galullo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henkel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidary, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuver-Moody, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namchuk, M.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7184</span><span class="NLM_x">–</span> <span class="NLM_lpage">7192</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200712h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7184-7192&author=R.+J.+Daviesauthor=A.+C.+Pierceauthor=C.+Forsterauthor=R.+Greyauthor=J.+Xuauthor=M.+Arnostauthor=D.+Choquetteauthor=V.+Galulloauthor=S.+K.+Tianauthor=G.+Henkelauthor=G.+Chenauthor=D.+K.+Heidaryauthor=J.+Maauthor=C.+Stuver-Moodyauthor=M.+Namchuk&title=Design%2C+synthesis%2C+and+evaluation+of+a+novel+dual+FMS-like+tyrosine+kinase+3%2Fstem+cell+factor+receptor+%28FLT3%2Fc-KIT%29+inhibitor+for+the+treatment+of+acute+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm200712h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200712h%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DR.%2BJ.%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DForster%26aufirst%3DC.%26aulast%3DGrey%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DArnost%26aufirst%3DM.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DTian%26aufirst%3DS.%2BK.%26aulast%3DHenkel%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DHeidary%26aufirst%3DD.%2BK.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DStuver-Moody%26aufirst%3DC.%26aulast%3DNamchuk%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520a%2520novel%2520dual%2520FMS-like%2520tyrosine%2520kinase%25203%252Fstem%2520cell%2520factor%2520receptor%2520%2528FLT3%252Fc-KIT%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520acute%2520myelogenous%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7184%26epage%3D7192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Bavetsias, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crumpler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avery, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atrash, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faisal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmopoulou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldrake, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayliss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardopoulos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span> </span><span class="NLM_article-title">Optimization of imidazo[4,5-<i>b</i>]pyridine-based kinase inhibitors: identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8721</span><span class="NLM_x">–</span> <span class="NLM_lpage">8734</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300952s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8721-8734&author=V.+Bavetsiasauthor=S.+Crumplerauthor=C.+Sunauthor=S.+Averyauthor=B.+Atrashauthor=A.+Faisalauthor=A.+S.+Mooreauthor=M.+Kosmopoulouauthor=N.+Brownauthor=P.+W.+Sheldrakeauthor=K.+Bushauthor=A.+Henleyauthor=G.+Boxauthor=M.+Valentiauthor=A.+de+Haven+Brandonauthor=F.+I.+Raynaudauthor=P.+Workmanauthor=S.+A.+Ecclesauthor=R.+Baylissauthor=S.+Linardopoulosauthor=J.+Blagg&title=Optimization+of+imidazo%5B4%2C5-b%5Dpyridine-based+kinase+inhibitors%3A+identification+of+a+dual+FLT3%2Faurora+kinase+inhibitor+as+an+orally+bioavailable+preclinical+development+candidate+for+the+treatment+of+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm300952s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300952s%26sid%3Dliteratum%253Aachs%26aulast%3DBavetsias%26aufirst%3DV.%26aulast%3DCrumpler%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DAvery%26aufirst%3DS.%26aulast%3DAtrash%26aufirst%3DB.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DA.%2BS.%26aulast%3DKosmopoulou%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DN.%26aulast%3DSheldrake%26aufirst%3DP.%2BW.%26aulast%3DBush%26aufirst%3DK.%26aulast%3DHenley%26aufirst%3DA.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DBayliss%26aufirst%3DR.%26aulast%3DLinardopoulos%26aufirst%3DS.%26aulast%3DBlagg%26aufirst%3DJ.%26atitle%3DOptimization%2520of%2520imidazo%255B4%252C5-b%255Dpyridine-based%2520kinase%2520inhibitors%253A%2520identification%2520of%2520a%2520dual%2520FLT3%252Faurora%2520kinase%2520inhibitor%2520as%2520an%2520orally%2520bioavailable%2520preclinical%2520development%2520candidate%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8721%26epage%3D8734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span> </span><span class="NLM_article-title">SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4439</span><span class="NLM_x">–</span> <span class="NLM_lpage">4450</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1158%2F1078-0432.CCR-10-3109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=21622720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1SmtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=4439-4450&author=S.+Zhangauthor=Z.+Caoauthor=H.+Tianauthor=G.+Shenauthor=Y.+Maauthor=H.+Xieauthor=Y.+Liuauthor=C.+Zhaoauthor=S.+Dengauthor=Y.+Yangauthor=R.+Zhengauthor=W.+Liauthor=N.+Zhangauthor=S.+Liuauthor=W.+Wangauthor=L.+Daiauthor=S.+Shiauthor=L.+Chengauthor=Y.+Panauthor=S.+Fengauthor=X.+Zhaoauthor=H.+Dengauthor=S.+Yangauthor=Y.+Wei&title=SKLB1002%2C+a+novel+potent+inhibitor+of+VEGF+receptor+2+signaling%2C+inhibits+angiogenesis+and+tumor+growth+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth In Vivo</span></div><div class="casAuthors">Zhang, Shuang; Cao, Zhixing; Tian, Hongwei; Shen, Guobo; Ma, Yongping; Xie, Huanzhang; Liu, Yalin; Zhao, Chengjian; Deng, Senyi; Yang, Yang; Zheng, Renlin; Li, Weiwei; Zhang, Na; Liu, Shengyong; Wang, Wei; Dai, Lixia; Shi, Shuai; Cheng, Lin; Pan, Youli; Feng, Shan; Zhao, Xia; Deng, Hongxin; Yang, Shengyong; Wei, Yuquan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4439-4450</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: VEGF receptor 2 (VEGFR2) inhibitors, as efficient antiangiogenesis agents, have been applied in the cancer treatment.  However, currently most of these anticancer drugs suffer some adverse effects.  Discovery of novel VEGFR2 inhibitors as anticancer drug candidates is still needed.  Exptl. Design: In this investigation, we adopted a restricted de novo design method to design VEGFR2 inhibitors.  We selected the most potent compd. SKLB1002 and analyzed its inhibitory effects on human umbilical vein endothelial cells (HUVEC) in vitro.  Tumor xenografts in zebrafish and athymic mice were used to examine the in vivo activity of SKLB1002.  RESULTS: The use of the restricted de novo design method indeed led to a new potent VEGFR2 inhibitor, SKLB1002, which could significantly inhibit HUVEC proliferation, migration, invasion, and tube formation.  Western blot anal. was conducted, which indicated that SKLB1002 inhibited VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal-regulated kinase, focal adhesion kinase, and Src.  In vivo zebrafish model expts. showed that SKLB1002 remarkably blocked the formation of intersegmental vessels in zebrafish embryos.  It was further found to inhibit a new microvasculature in zebrafish embryos induced by inoculated tumor cells.  Finally, compared with the solvent control, administration of 100 mg/kg/d SKLB1002 reached more than 60% inhibition against human tumor xenografts in athymic mice.  The antiangiogenic effect was indicated by CD31 immunohistochem. staining and alginate-encapsulated tumor cell assay.  CONCLUSIONS: Our findings suggest that SKLB1002 inhibits angiogenesis and may be a potential drug candidate in anticancer therapy.  Clin Cancer Res; 17(13); 4439-50.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIgqK6UNG6yrVg90H21EOLACvtfcHk0lh6y0PuekXLRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1SmtLo%253D&md5=a15e4fe2fd1e62134a8c48cf2d4a2547</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-3109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-3109%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DDai%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26atitle%3DSKLB1002%252C%2520a%2520novel%2520potent%2520inhibitor%2520of%2520VEGF%2520receptor%25202%2520signaling%252C%2520inhibits%2520angiogenesis%2520and%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D4439%26epage%3D4450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Song, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span> </span><span class="NLM_article-title">A critical role of vascular endothelial growth factor D in zebrafish embryonic vasculogenesis and angiogenesis</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">357</span><span class="NLM_x">, </span> <span class="NLM_fpage">924</span><span class="NLM_x">–</span> <span class="NLM_lpage">930</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2007&pages=924-930&author=M.+Songauthor=H.+Yangauthor=S.+Yaoauthor=F.+Maauthor=Z.+Liauthor=Y.+Dengauthor=H.+Dengauthor=Q.+Zhouauthor=S.+Linauthor=Y.+Wei&title=A+critical+role+of+vascular+endothelial+growth+factor+D+in+zebrafish+embryonic+vasculogenesis+and+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26atitle%3DA%2520critical%2520role%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520D%2520in%2520zebrafish%2520embryonic%2520vasculogenesis%2520and%2520angiogenesis%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2007%26volume%3D357%26spage%3D924%26epage%3D930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Cao, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S. Y.</span><span> </span><span class="NLM_article-title">SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1892</span><span class="NLM_x">–</span> <span class="NLM_lpage">1895</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=1892-1895&author=Z.+X.+Caoauthor=J.+J.+Liuauthor=R.+L.+Zhengauthor=J.+Yangauthor=L.+Zhongauthor=Y.+Xuauthor=L.+J.+Wangauthor=C.+H.+Zhangauthor=B.+L.+Wangauthor=S.+Maauthor=Z.+R.+Wangauthor=H.+Z.+Xieauthor=Y.+Q.+Weiauthor=S.+Y.+Yang&title=SKLB1028%2C+a+novel+oral+multikinase+inhibitor+of+EGFR%2C+FLT3+and+Abl%2C+displays+exceptional+activity+in+models+of+FLT3-driven+AML+and+considerable+potency+in+models+of+CML+harboring+Abl+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DZ.%2BX.%26aulast%3DLiu%26aufirst%3DJ.%2BJ.%26aulast%3DZheng%26aufirst%3DR.%2BL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%2BJ.%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DWang%26aufirst%3DB.%2BL.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%2BR.%26aulast%3DXie%26aufirst%3DH.%2BZ.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DSKLB1028%252C%2520a%2520novel%2520oral%2520multikinase%2520inhibitor%2520of%2520EGFR%252C%2520FLT3%2520and%2520Abl%252C%2520displays%2520exceptional%2520activity%2520in%2520models%2520of%2520FLT3-driven%2520AML%2520and%2520considerable%2520potency%2520in%2520models%2520of%2520CML%2520harboring%2520Abl%2520mutants%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D1892%26epage%3D1895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Tran, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sneed, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haider, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blavo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aiyejorun, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baranowski, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubinstein, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doan, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingledine, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandberg, E. M.</span><span> </span><span class="NLM_article-title">Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">11386</span><span class="NLM_x">–</span> <span class="NLM_lpage">11392</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11386-11392&author=T.+C.+Tranauthor=B.+Sneedauthor=J.+Haiderauthor=D.+Blavoauthor=A.+Whiteauthor=T.+Aiyejorunauthor=T.+C.+Baranowskiauthor=A.+L.+Rubinsteinauthor=T.+N.+Doanauthor=R.+Dingledineauthor=E.+M.+Sandberg&title=Automated%2C+quantitative+screening+assay+for+antiangiogenic+compounds+using+transgenic+zebrafish"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTran%26aufirst%3DT.%2BC.%26aulast%3DSneed%26aufirst%3DB.%26aulast%3DHaider%26aufirst%3DJ.%26aulast%3DBlavo%26aufirst%3DD.%26aulast%3DWhite%26aufirst%3DA.%26aulast%3DAiyejorun%26aufirst%3DT.%26aulast%3DBaranowski%26aufirst%3DT.%2BC.%26aulast%3DRubinstein%26aufirst%3DA.%2BL.%26aulast%3DDoan%26aufirst%3DT.%2BN.%26aulast%3DDingledine%26aufirst%3DR.%26aulast%3DSandberg%26aufirst%3DE.%2BM.%26atitle%3DAutomated%252C%2520quantitative%2520screening%2520assay%2520for%2520antiangiogenic%2520compounds%2520using%2520transgenic%2520zebrafish%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11386%26epage%3D11392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Nourry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dijkstra, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaulon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suijkerbuijk, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlos, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span> </span><span class="NLM_article-title">BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1964</span><span class="NLM_x">–</span> <span class="NLM_lpage">1978</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901509a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1964-1978&author=A.+Nourryauthor=A.+Zambonauthor=L.+Daviesauthor=I.+Niculescu-Duvazauthor=H.+P.+Dijkstraauthor=D.+Menardauthor=C.+Gaulonauthor=D.+Niculescu-Duvazauthor=B.+M.+Suijkerbuijkauthor=F.+Friedlosauthor=H.+A.+Manneauthor=R.+Kirkauthor=S.+Whittakerauthor=R.+Maraisauthor=C.+J.+Springer&title=BRAF+inhibitors+based+on+an+imidazo%5B4%2C5%5Dpyridin-2-one+scaffold+and+a+meta+substituted+middle+ring"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm901509a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901509a%26sid%3Dliteratum%253Aachs%26aulast%3DNourry%26aufirst%3DA.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DL.%26aulast%3DNiculescu-Duvaz%26aufirst%3DI.%26aulast%3DDijkstra%26aufirst%3DH.%2BP.%26aulast%3DMenard%26aufirst%3DD.%26aulast%3DGaulon%26aufirst%3DC.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DSuijkerbuijk%26aufirst%3DB.%2BM.%26aulast%3DFriedlos%26aufirst%3DF.%26aulast%3DManne%26aufirst%3DH.%2BA.%26aulast%3DKirk%26aufirst%3DR.%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26atitle%3DBRAF%2520inhibitors%2520based%2520on%2520an%2520imidazo%255B4%252C5%255Dpyridin-2-one%2520scaffold%2520and%2520a%2520meta%2520substituted%2520middle%2520ring%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1964%26epage%3D1978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Vizirianakis, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatzopoulou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonovolias, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolaou, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demopoulos, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsiftsoglou, A. S.</span><span> </span><span class="NLM_article-title">Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6779</span><span class="NLM_x">–</span> <span class="NLM_lpage">6810</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100189a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6779-6810&author=I.+S.+Vizirianakisauthor=M.+Chatzopoulouauthor=I.+D.+Bonovoliasauthor=I.+Nicolaouauthor=V.+J.+Demopoulosauthor=A.+S.+Tsiftsoglou&title=Toward+the+development+of+innovative+bifunctional+agents+to+induce+differentiation+and+to+promote+apoptosis+in+leukemia%3A+clinical+candidates+and+perspectives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm100189a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100189a%26sid%3Dliteratum%253Aachs%26aulast%3DVizirianakis%26aufirst%3DI.%2BS.%26aulast%3DChatzopoulou%26aufirst%3DM.%26aulast%3DBonovolias%26aufirst%3DI.%2BD.%26aulast%3DNicolaou%26aufirst%3DI.%26aulast%3DDemopoulos%26aufirst%3DV.%2BJ.%26aulast%3DTsiftsoglou%26aufirst%3DA.%2BS.%26atitle%3DToward%2520the%2520development%2520of%2520innovative%2520bifunctional%2520agents%2520to%2520induce%2520differentiation%2520and%2520to%2520promote%2520apoptosis%2520in%2520leukemia%253A%2520clinical%2520candidates%2520and%2520perspectives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6779%26epage%3D6810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Metzelder, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotze, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linn, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salih, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinicke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuhlmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giagounidis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vohringer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schafer-Eckart, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultheis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldus, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burchert, A.</span><span> </span><span class="NLM_article-title">High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">2353</span><span class="NLM_x">–</span> <span class="NLM_lpage">2359</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=2353-2359&author=S.+K.+Metzelderauthor=T.+Schroederauthor=A.+Finckauthor=S.+Schollauthor=M.+Feyauthor=K.+Gotzeauthor=Y.+C.+Linnauthor=M.+Krogerauthor=A.+Reiterauthor=H.+R.+Salihauthor=T.+Heinickeauthor=R.+Stuhlmannauthor=L.+Mullerauthor=A.+Giagounidisauthor=R.+G.+Meyerauthor=W.+Bruggerauthor=M.+Vohringerauthor=P.+Dregerauthor=M.+Moriauthor=N.+Basaraauthor=K.+Schafer-Eckartauthor=B.+Schultheisauthor=C.+Baldusauthor=A.+Neubauerauthor=A.+Burchert&title=High+activity+of+sorafenib+in+FLT3-ITD-positive+acute+myeloid+leukemia+synergizes+with+allo-immune+effects+to+induce+sustained+responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMetzelder%26aufirst%3DS.%2BK.%26aulast%3DSchroeder%26aufirst%3DT.%26aulast%3DFinck%26aufirst%3DA.%26aulast%3DScholl%26aufirst%3DS.%26aulast%3DFey%26aufirst%3DM.%26aulast%3DGotze%26aufirst%3DK.%26aulast%3DLinn%26aufirst%3DY.%2BC.%26aulast%3DKroger%26aufirst%3DM.%26aulast%3DReiter%26aufirst%3DA.%26aulast%3DSalih%26aufirst%3DH.%2BR.%26aulast%3DHeinicke%26aufirst%3DT.%26aulast%3DStuhlmann%26aufirst%3DR.%26aulast%3DMuller%26aufirst%3DL.%26aulast%3DGiagounidis%26aufirst%3DA.%26aulast%3DMeyer%26aufirst%3DR.%2BG.%26aulast%3DBrugger%26aufirst%3DW.%26aulast%3DVohringer%26aufirst%3DM.%26aulast%3DDreger%26aufirst%3DP.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DBasara%26aufirst%3DN.%26aulast%3DSchafer-Eckart%26aufirst%3DK.%26aulast%3DSchultheis%26aufirst%3DB.%26aulast%3DBaldus%26aufirst%3DC.%26aulast%3DNeubauer%26aufirst%3DA.%26aulast%3DBurchert%26aufirst%3DA.%26atitle%3DHigh%2520activity%2520of%2520sorafenib%2520in%2520FLT3-ITD-positive%2520acute%2520myeloid%2520leukemia%2520synergizes%2520with%2520allo-immune%2520effects%2520to%2520induce%2520sustained%2520responses%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D2353%26epage%3D2359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 47 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yueshan Li, Yu Xiong, Guo Zhang, Liting Zhang, Wei Yang, Jiao Yang, Luyi Huang, Zeen Qiao, Zhuang Miao, Guifeng Lin, Qiu Sun, Ting Niu, Lijuan Chen, Dawen Niu, Linli Li, <span class="NLM_string-name hlFld-ContribAuthor">Shengyong Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of 5-(2,3-Dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (24)
                                     , 11398-11414. <a href="https://doi.org/10.1021/acs.jmedchem.8b01652" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01652</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01652%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252B5-%2525282%25252C3-Dihydro-1H-indol-5-yl%252529-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-amine%252BDerivatives%252Bas%252Ba%252BNew%252BClass%252Bof%252BReceptor-Interacting%252BProtein%252BKinase%252B1%252B%252528RIPK1%252529%252BInhibitors%25252C%252BWhich%252BShowed%252BPotent%252BActivity%252Bin%252Ba%252BTumor%252BMetastasis%252BModel%26aulast%3DLi%26aufirst%3DYueshan%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D24102018%26date%3D10122018%26date%3D27112018%26volume%3D61%26issue%3D24%26spage%3D11398%26epage%3D11414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guo-Bo  Li</span>, <span class="hlFld-ContribAuthor ">Zhu-Jun  Yu</span>, <span class="hlFld-ContribAuthor ">Sha  Liu</span>, <span class="hlFld-ContribAuthor ">Lu-Yi  Huang</span>, <span class="hlFld-ContribAuthor ">Ling-Ling  Yang</span>, <span class="hlFld-ContribAuthor ">Christopher T.  Lohans</span>, and <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>  . </span><span class="cited-content_cbyCitation_article-title">IFPTarget: A Customized Virtual Target Identification Method Based on Protein–Ligand Interaction Fingerprinting Analyses. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (7)
                                     , 1640-1651. <a href="https://doi.org/10.1021/acs.jcim.7b00225" title="DOI URL">https://doi.org/10.1021/acs.jcim.7b00225</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.7b00225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.7b00225%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DIFPTarget%25253A%252BA%252BCustomized%252BVirtual%252BTarget%252BIdentification%252BMethod%252BBased%252Bon%252BProtein%2525E2%252580%252593Ligand%252BInteraction%252BFingerprinting%252BAnalyses%26aulast%3DLi%26aufirst%3DGuo-Bo%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D21042017%26date%3D10072017%26date%3D24072017%26date%3D29062017%26volume%3D57%26issue%3D7%26spage%3D1640%26epage%3D1651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guo-Bo  Li</span>, <span class="hlFld-ContribAuthor ">Shuang  Ma</span>, <span class="hlFld-ContribAuthor ">Ling-Ling  Yang</span>, <span class="hlFld-ContribAuthor ">Sen  Ji</span>, <span class="hlFld-ContribAuthor ">Zhen  Fang</span>, <span class="hlFld-ContribAuthor ">Guo  Zhang</span>, <span class="hlFld-ContribAuthor ">Li-Jiao  Wang</span>, <span class="hlFld-ContribAuthor ">Jie-Min  Zhong</span>, <span class="hlFld-ContribAuthor ">Yu  Xiong</span>, <span class="hlFld-ContribAuthor ">Jiang-Hong  Wang</span>, <span class="hlFld-ContribAuthor ">Shen-Zhen  Huang</span>, <span class="hlFld-ContribAuthor ">Lin-Li  Li</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>, <span class="hlFld-ContribAuthor ">Dawen  Niu</span>, <span class="hlFld-ContribAuthor ">Ying-Chun  Chen</span>, and <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>  . </span><span class="cited-content_cbyCitation_article-title">Drug Discovery against Psoriasis: Identification of a New Potent FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor, 1-(4-((1H-Pyrazolo[3,4-d]pyrimidin-4-yl)oxy)-3-fluorophenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea, That Showed Potent Activity in a Psoriatic Animal Model. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (18)
                                     , 8293-8305. <a href="https://doi.org/10.1021/acs.jmedchem.6b00604" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00604</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00604%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrug%252BDiscovery%252Bagainst%252BPsoriasis%25253A%252BIdentification%252Bof%252Ba%252BNew%252BPotent%252BFMS-like%252BTyrosine%252BKinase%252B3%252B%252528FLT3%252529%252BInhibitor%25252C%252B1-%2525284-%252528%2525281H-Pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-4-yl%252529oxy%252529-3-fluorophenyl%252529-3-%2525285-%252528tert-butyl%252529isoxazol-3-yl%252529urea%25252C%252BThat%252BShowed%252BPotent%252BActivity%252Bin%252Ba%252BPsoriatic%252BAnimal%252BModel%26aulast%3DLi%26aufirst%3DGuo-Bo%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D19042016%26date%3D02092016%26date%3D22092016%26date%3D18082016%26volume%3D59%26issue%3D18%26spage%3D8293%26epage%3D8305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhi-Ping  Zeng</span>, <span class="hlFld-ContribAuthor ">Qiong  Wu</span>, <span class="hlFld-ContribAuthor ">Fen-Yong  Sun</span>, <span class="hlFld-ContribAuthor ">Kang-Di  Zheng</span>, and <span class="hlFld-ContribAuthor ">Wen-Jie  Mei</span>  . </span><span class="cited-content_cbyCitation_article-title">Imaging Nuclei of MDA-MB-231 Breast Cancer Cells by Chiral Ruthenium(II) Complex Coordinated by 2-(4-Phenyacetylenephenyl)-1H-imidazo[4,5f][1,10]phenanthroline. </span><span class="cited-content_cbyCitation_journal-name">Inorganic Chemistry</span><span> <strong>2016,</strong> <em>55 </em>
                                    (11)
                                     , 5710-5718. <a href="https://doi.org/10.1021/acs.inorgchem.6b00824" title="DOI URL">https://doi.org/10.1021/acs.inorgchem.6b00824</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.inorgchem.6b00824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.inorgchem.6b00824%26sid%3Dliteratum%253Aachs%26jtitle%3DInorganic%2520Chemistry%26atitle%3DImaging%252BNuclei%252Bof%252BMDA-MB-231%252BBreast%252BCancer%252BCells%252Bby%252BChiral%252BRuthenium%252528II%252529%252BComplex%252BCoordinated%252Bby%252B2-%2525284-Phenyacetylenephenyl%252529-1H-imidazo%25255B4%25252C5f%25255D%25255B1%25252C10%25255Dphenanthroline%26aulast%3DZeng%26aufirst%3DZhi-Ping%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D03042016%26date%3D18052016%26date%3D06062016%26volume%3D55%26issue%3D11%26spage%3D5710%26epage%3D5718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Li</span>, <span class="hlFld-ContribAuthor ">Zhixiong  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhihai  Liu</span>, <span class="hlFld-ContribAuthor ">Minyi  Su</span>, and <span class="hlFld-ContribAuthor ">Renxiao  Wang</span>  . </span><span class="cited-content_cbyCitation_article-title">AutoT&T v.2: An Efficient and Versatile Tool for Lead Structure Generation and Optimization. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (2)
                                     , 435-453. <a href="https://doi.org/10.1021/acs.jcim.5b00691" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00691</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00691%26sid%3Dliteratum%253Aachs%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D1474%26epage%3D1491%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DAutoT%252526T%252Bv.2%25253A%252BAn%252BEfficient%252Band%252BVersatile%252BTool%252Bfor%252BLead%252BStructure%252BGeneration%252Band%252BOptimization%26aulast%3DLi%26aufirst%3DYan%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D17112015%26date%3D03022016%26date%3D22022016%26date%3D22012016%26volume%3D56%26issue%3D2%26spage%3D435%26epage%3D453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefania  Sartini</span>, <span class="hlFld-ContribAuthor ">Vito  Coviello</span>, <span class="hlFld-ContribAuthor ">Agostino  Bruno</span>, <span class="hlFld-ContribAuthor ">Valeria  La Pietra</span>, <span class="hlFld-ContribAuthor ">Luciana  Marinelli</span>, <span class="hlFld-ContribAuthor ">Francesca  Simorini</span>, <span class="hlFld-ContribAuthor ">Sabrina  Taliani</span>, <span class="hlFld-ContribAuthor ">Silvia  Salerno</span>, <span class="hlFld-ContribAuthor ">Anna Maria  Marini</span>, <span class="hlFld-ContribAuthor ">Anna  Fioravanti</span>, <span class="hlFld-ContribAuthor ">Paola  Orlandi</span>, <span class="hlFld-ContribAuthor ">Alessandro  Antonelli</span>, <span class="hlFld-ContribAuthor ">Federico  Da Settimo</span>, <span class="hlFld-ContribAuthor ">Ettore  Novellino</span>, <span class="hlFld-ContribAuthor ">Guido  Bocci</span>, and <span class="hlFld-ContribAuthor ">Concettina  La Motta</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies.. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (4)
                                     , 1225-1235. <a href="https://doi.org/10.1021/jm401358b" title="DOI URL">https://doi.org/10.1021/jm401358b</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401358b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401358b%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BOptimization%252Bof%252BTyrosine%252BKinase%252BInhibitor%252BCLM3.%252BDesign%25252C%252BSynthesis%25252C%252BFunctional%252BEvaluation%25252C%252Band%252BMolecular%252BModeling%252BStudies.%26aulast%3DSartini%26aufirst%3DStefania%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D02082013%26date%3D05022014%26date%3D27022014%26date%3D21012014%26volume%3D57%26issue%3D4%26spage%3D1225%26epage%3D1235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianbo  Zhang</span>, <span class="hlFld-ContribAuthor ">Chen  Liu</span>, <span class="hlFld-ContribAuthor ">Wen  Shi</span>, <span class="hlFld-ContribAuthor ">Lingling  Yang</span>, <span class="hlFld-ContribAuthor ">Quansheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianlin  Cui</span>, <span class="hlFld-ContribAuthor ">Yangwu  Fang</span>, <span class="hlFld-ContribAuthor ">Yuhao  Li</span>, <span class="hlFld-ContribAuthor ">Guosheng  Ren</span>, <span class="hlFld-ContribAuthor ">Shuang  Yang</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2106,</strong> <em>7 </em>
                                    (27)
                                     , 41067-41080. <a href="https://doi.org/10.18632/oncotarget.9392" title="DOI URL">https://doi.org/10.18632/oncotarget.9392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.9392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.9392%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DThe%252Bnovel%252BVEGF%252Breceptor%252B2%252Binhibitor%252BYLL545%252Binhibits%252Bangiogenesis%252Band%252Bgrowth%252Bin%252Bbreast%252Bcancer%26aulast%3DZhang%26aufirst%3DJianbo%26date%3D2106%26date%3D2016%26volume%3D7%26issue%3D27%26spage%3D41067%26epage%3D41080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eman Z.  Elrazaz</span>, <span class="hlFld-ContribAuthor ">Rabah A.T.  Serya</span>, <span class="hlFld-ContribAuthor ">Nasser S.M.  Ismail</span>, <span class="hlFld-ContribAuthor ">Amgad  Albohy</span>, <span class="hlFld-ContribAuthor ">Dalal A.  Abou El Ella</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent thieno[2,3-d]pyrimidine VEGFR-2 inhibitors: Design, synthesis and enzyme inhibitory evaluation supported by molecular dynamics simulations. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>113 </em>, 105019. <a href="https://doi.org/10.1016/j.bioorg.2021.105019" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105019%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252Bthieno%25255B2%25252C3-d%25255Dpyrimidine%252BVEGFR-2%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Benzyme%252Binhibitory%252Bevaluation%252Bsupported%252Bby%252Bmolecular%252Bdynamics%252Bsimulations%26aulast%3DElrazaz%26aufirst%3DEman%2BZ.%26date%3D2021%26volume%3D113%26spage%3D105019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanling  Tao</span>, <span class="hlFld-ContribAuthor ">Jingjing  Zhang</span>, <span class="hlFld-ContribAuthor ">Lulu  Chen</span>, <span class="hlFld-ContribAuthor ">Xin  Liu</span>, <span class="hlFld-ContribAuthor ">Mingkang  Yao</span>, <span class="hlFld-ContribAuthor ">Hao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">LncRNA CD27-AS1 promotes acute myeloid leukemia progression through the miR-224-5p/PBX3 signaling circuit. </span><span class="cited-content_cbyCitation_journal-name">Cell Death & Disease</span><span> <strong>2021,</strong> <em>12 </em>
                                    (6)
                                     <a href="https://doi.org/10.1038/s41419-021-03767-9" title="DOI URL">https://doi.org/10.1038/s41419-021-03767-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41419-021-03767-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41419-021-03767-9%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Death%2520%2526%2520Disease%26atitle%3DLncRNA%252BCD27-AS1%252Bpromotes%252Bacute%252Bmyeloid%252Bleukemia%252Bprogression%252Bthrough%252Bthe%252BmiR-224-5p%25252FPBX3%252Bsignaling%252Bcircuit%26aulast%3DTao%26aufirst%3DYanling%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting  Guo</span>, <span class="hlFld-ContribAuthor ">Shutao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , 600-620. <a href="https://doi.org/10.1002/cmdc.202000658" title="DOI URL">https://doi.org/10.1002/cmdc.202000658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000658%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDiscovery%252Bof%252BMultitargeted%252BTyrosine%252BKinase%252BInhibitors%252Bas%252BAnticancer%252BAgents%26aulast%3DGuo%26aufirst%3DTing%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D4%26spage%3D600%26epage%3D620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kai  Yang</span>, <span class="hlFld-ContribAuthor ">Jian-Qiong  Yang</span>, <span class="hlFld-ContribAuthor ">Shi-He  Luo</span>, <span class="hlFld-ContribAuthor ">Wen-Jie  Mei</span>, <span class="hlFld-ContribAuthor ">Jian-Yun  Lin</span>, <span class="hlFld-ContribAuthor ">Jia-Qi  Zhan</span>, <span class="hlFld-ContribAuthor ">Zhao-Yang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of N-2(5H)-furanonyl sulfonyl hydrazone derivatives and their biological evaluation in vitro and in vivo activity against MCF-7 breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>107 </em>, 104518. <a href="https://doi.org/10.1016/j.bioorg.2020.104518" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104518</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104518%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BN-2%2525285H%252529-furanonyl%252Bsulfonyl%252Bhydrazone%252Bderivatives%252Band%252Btheir%252Bbiological%252Bevaluation%252Bin%252Bvitro%252Band%252Bin%252Bvivo%252Bactivity%252Bagainst%252BMCF-7%252Bbreast%252Bcancer%252Bcells%26aulast%3DYang%26aufirst%3DKai%26date%3D2021%26volume%3D107%26spage%3D104518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neha  Upadhyay</span>, <span class="hlFld-ContribAuthor ">Kalpana  Tilekar</span>, <span class="hlFld-ContribAuthor ">Fulvio  Loiodice</span>, <span class="hlFld-ContribAuthor ">Natalia Yu.  Anisimova</span>, <span class="hlFld-ContribAuthor ">Tatiana S.  Spirina</span>, <span class="hlFld-ContribAuthor ">Darina V.  Sokolova</span>, <span class="hlFld-ContribAuthor ">Galina B.  Smirnova</span>, <span class="hlFld-ContribAuthor ">Jun-yong  Choe</span>, <span class="hlFld-ContribAuthor ">Franz-Josef  Meyer-Almes</span>, <span class="hlFld-ContribAuthor ">Vadim S.  Pokrovsky</span>, <span class="hlFld-ContribAuthor ">Antonio  Lavecchia</span>, <span class="hlFld-ContribAuthor ">CS  Ramaa</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore hybridization approach to discover novel pyrazoline-based hydantoin analogs with anti-tumor efficacy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>107 </em>, 104527. <a href="https://doi.org/10.1016/j.bioorg.2020.104527" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104527%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DPharmacophore%252Bhybridization%252Bapproach%252Bto%252Bdiscover%252Bnovel%252Bpyrazoline-based%252Bhydantoin%252Banalogs%252Bwith%252Banti-tumor%252Befficacy%26aulast%3DUpadhyay%26aufirst%3DNeha%26date%3D2021%26volume%3D107%26spage%3D104527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neha  Upadhyay</span>, <span class="hlFld-ContribAuthor ">Kalpana  Tilekar</span>, <span class="hlFld-ContribAuthor ">Sabreena  Safuan</span>, <span class="hlFld-ContribAuthor ">Alan P.  Kumar</span>, <span class="hlFld-ContribAuthor ">Markus  Schweipert</span>, <span class="hlFld-ContribAuthor ">Franz-Josef  Meyer-Almes</span>, <span class="hlFld-ContribAuthor ">Ramaa  C S</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.1039/D1MD00125F" title="DOI URL">https://doi.org/10.1039/D1MD00125F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00125F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00125F%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DMulti-target%252Bweapons%25253A%252Bdiaryl-pyrazoline%252Bthiazolidinediones%252Bsimultaneously%252Btargeting%252BVEGFR-2%252Band%252BHDAC%252Bcancer%252Bhallmarks%26aulast%3DUpadhyay%26aufirst%3DNeha%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lexian  Tong</span>, <span class="hlFld-ContribAuthor ">Xuemei  Li</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in FLT3 inhibitors for acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 961-981. <a href="https://doi.org/10.4155/fmc-2019-0365" title="DOI URL">https://doi.org/10.4155/fmc-2019-0365</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0365%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252BFLT3%252Binhibitors%252Bfor%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DTong%26aufirst%3DLexian%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D961%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Reem F.  Abutayeh</span>, <span class="hlFld-ContribAuthor ">Jehad  Almaliti</span>, <span class="hlFld-ContribAuthor ">Mutasem O.  Taha</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of New Sulfonamides-Based Flt3 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry</span><span> <strong>2020,</strong> <em>16 </em>
                                    (3)
                                     , 403-412. <a href="https://doi.org/10.2174/1573406415666190401144053" title="DOI URL">https://doi.org/10.2174/1573406415666190401144053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1573406415666190401144053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1573406415666190401144053%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BNew%252BSulfonamides-Based%252BFlt3%252BInhibitors%26aulast%3DAbutayeh%26aufirst%3DReem%2BF.%26date%3D2020%26volume%3D16%26issue%3D3%26spage%3D403%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Asmaa E.  Kassab</span>, <span class="hlFld-ContribAuthor ">Yara  El‐Dash</span>, <span class="hlFld-ContribAuthor ">Ehab M.  Gedawy</span>. </span><span class="cited-content_cbyCitation_article-title">Novel pyrazolopyrimidine urea derivatives: Synthesis, antiproliferative activity, VEGFR‐2 inhibition, and effects on the cell cycle profile. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2020,</strong> <em>353 </em>
                                    (4)
                                     , 1900319. <a href="https://doi.org/10.1002/ardp.201900319" title="DOI URL">https://doi.org/10.1002/ardp.201900319</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201900319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201900319%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DNovel%252Bpyrazolopyrimidine%252Burea%252Bderivatives%25253A%252BSynthesis%25252C%252Bantiproliferative%252Bactivity%25252C%252BVEGFR%2525E2%252580%2525902%252Binhibition%25252C%252Band%252Beffects%252Bon%252Bthe%252Bcell%252Bcycle%252Bprofile%26aulast%3DKassab%26aufirst%3DAsmaa%2BE.%26date%3D2020%26volume%3D353%26issue%3D4%26spage%3D1900319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marwa  Sharaky</span>, <span class="hlFld-ContribAuthor ">Marwa  Kamel</span>, <span class="hlFld-ContribAuthor ">Marwa A.  Aziz</span>, <span class="hlFld-ContribAuthor ">Mervat  Omran</span>, <span class="hlFld-ContribAuthor ">Monira M.  Rageh</span>, <span class="hlFld-ContribAuthor ">Khaled A. M.  Abouzid</span>, <span class="hlFld-ContribAuthor ">Samia A.  Shouman</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of a new thieno[2,3-
              d
              ]pyrimidine-based urea derivative with potential antitumor activity against tamoxifen sensitive and resistant breast cancer cell lines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2020,</strong> <em>35 </em>
                                    (1)
                                     , 1641-1656. <a href="https://doi.org/10.1080/14756366.2020.1804383" title="DOI URL">https://doi.org/10.1080/14756366.2020.1804383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2020.1804383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2020.1804383%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Ba%252Bnew%252Bthieno%25255B2%25252C3-%252Bd%252B%25255Dpyrimidine-based%252Burea%252Bderivative%252Bwith%252Bpotential%252Bantitumor%252Bactivity%252Bagainst%252Btamoxifen%252Bsensitive%252Band%252Bresistant%252Bbreast%252Bcancer%252Bcell%252Blines%26aulast%3DSharaky%26aufirst%3DMarwa%26date%3D2020%26date%3D2020%26volume%3D35%26issue%3D1%26spage%3D1641%26epage%3D1656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Baohui  Qi</span>, <span class="hlFld-ContribAuthor ">Xingwei  Xu</span>, <span class="hlFld-ContribAuthor ">Ying  Yang</span>, <span class="hlFld-ContribAuthor ">Yuting  Zhou</span>, <span class="hlFld-ContribAuthor ">Tao  Chen</span>, <span class="hlFld-ContribAuthor ">Guowei  Gong</span>, <span class="hlFld-ContribAuthor ">Xupeng  Yue</span>, <span class="hlFld-ContribAuthor ">Xin  Xu</span>, <span class="hlFld-ContribAuthor ">Liping  Hu</span>, <span class="hlFld-ContribAuthor ">Huan  He</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of thiazolidin-4-one urea analogues as novel multikinase inhibitors that potently inhibit FLT3 and VEGFR2. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (10)
                                     , 2127-2139. <a href="https://doi.org/10.1016/j.bmc.2019.03.049" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.03.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.03.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.03.049%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthiazolidin-4-one%252Burea%252Banalogues%252Bas%252Bnovel%252Bmultikinase%252Binhibitors%252Bthat%252Bpotently%252Binhibit%252BFLT3%252Band%252BVEGFR2%26aulast%3DQi%26aufirst%3DBaohui%26date%3D2019%26volume%3D27%26issue%3D10%26spage%3D2127%26epage%3D2139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Reem Fawaz  Abutayeh</span>, <span class="hlFld-ContribAuthor ">Mutasem O.  Taha</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel Flt3 inhibitory chemotypes through extensive ligand-based and new structure-based pharmacophore modelling methods. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2019,</strong> <em>88 </em>, 128-151. <a href="https://doi.org/10.1016/j.jmgm.2019.01.011" title="DOI URL">https://doi.org/10.1016/j.jmgm.2019.01.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2019.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2019.01.011%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DDiscovery%252Bof%252Bnovel%252BFlt3%252Binhibitory%252Bchemotypes%252Bthrough%252Bextensive%252Bligand-based%252Band%252Bnew%252Bstructure-based%252Bpharmacophore%252Bmodelling%252Bmethods%26aulast%3DAbutayeh%26aufirst%3DReem%2BFawaz%26date%3D2019%26volume%3D88%26spage%3D128%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fatima  Arshad</span>, <span class="hlFld-ContribAuthor ">Mohemmed Faraz  Khan</span>, <span class="hlFld-ContribAuthor ">Wasim  Akhtar</span>, <span class="hlFld-ContribAuthor ">Mohammad Mumtaz  Alam</span>, <span class="hlFld-ContribAuthor ">Lalit Mohan  Nainwal</span>, <span class="hlFld-ContribAuthor ">Sumit Kumar  Kaushik</span>, <span class="hlFld-ContribAuthor ">Mymoona  Akhter</span>, <span class="hlFld-ContribAuthor ">Suhel  Parvez</span>, <span class="hlFld-ContribAuthor ">Syed Misbahul  Hasan</span>, <span class="hlFld-ContribAuthor ">Mohammad  Shaquiquzzaman</span>. </span><span class="cited-content_cbyCitation_article-title">Revealing quinquennial anticancer journey of morpholine: A SAR based review. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>167 </em>, 324-356. <a href="https://doi.org/10.1016/j.ejmech.2019.02.015" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.02.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.02.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.02.015%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRevealing%252Bquinquennial%252Banticancer%252Bjourney%252Bof%252Bmorpholine%25253A%252BA%252BSAR%252Bbased%252Breview%26aulast%3DArshad%26aufirst%3DFatima%26date%3D2019%26volume%3D167%26spage%3D324%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniela  Zizioli</span>, <span class="hlFld-ContribAuthor ">Marina  Mione</span>, <span class="hlFld-ContribAuthor ">Marco  Varinelli</span>, <span class="hlFld-ContribAuthor ">Michele  Malagola</span>, <span class="hlFld-ContribAuthor ">Simona  Bernardi</span>, <span class="hlFld-ContribAuthor ">Elisa  Alghisi</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Borsani</span>, <span class="hlFld-ContribAuthor ">Dario  Finazzi</span>, <span class="hlFld-ContribAuthor ">Eugenio  Monti</span>, <span class="hlFld-ContribAuthor ">Marco  Presta</span>, <span class="hlFld-ContribAuthor ">Domenico  Russo</span>. </span><span class="cited-content_cbyCitation_article-title">Zebrafish disease models in hematology: Highlights on biological and translational impact. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease</span><span> <strong>2019,</strong> <em>1865 </em>
                                    (3)
                                     , 620-633. <a href="https://doi.org/10.1016/j.bbadis.2018.12.015" title="DOI URL">https://doi.org/10.1016/j.bbadis.2018.12.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbadis.2018.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbadis.2018.12.015%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Molecular%2520Basis%2520of%2520Disease%26atitle%3DZebrafish%252Bdisease%252Bmodels%252Bin%252Bhematology%25253A%252BHighlights%252Bon%252Bbiological%252Band%252Btranslational%252Bimpact%26aulast%3DZizioli%26aufirst%3DDaniela%26date%3D2019%26volume%3D1865%26issue%3D3%26spage%3D620%26epage%3D633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amna  Ghith</span>, <span class="hlFld-ContribAuthor ">Khairia M.  Youssef</span>, <span class="hlFld-ContribAuthor ">Nasser S.M.  Ismail</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and molecular modeling study of certain VEGFR-2 inhibitors based on thienopyrimidne scaffold as cancer targeting agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>83 </em>, 111-128. <a href="https://doi.org/10.1016/j.bioorg.2018.10.008" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.10.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.10.008%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bmolecular%252Bmodeling%252Bstudy%252Bof%252Bcertain%252BVEGFR-2%252Binhibitors%252Bbased%252Bon%252Bthienopyrimidne%252Bscaffold%252Bas%252Bcancer%252Btargeting%252Bagents%26aulast%3DGhith%26aufirst%3DAmna%26date%3D2019%26volume%3D83%26spage%3D111%26epage%3D128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhi-Ning  Huang</span>, <span class="hlFld-ContribAuthor ">Han  Liang</span>, <span class="hlFld-ContribAuthor ">Hong  Qiao</span>, <span class="hlFld-ContribAuthor ">Bao-Rui  Wang</span>, <span class="hlFld-ContribAuthor ">Ning  Qu</span>, <span class="hlFld-ContribAuthor ">Hua  Li</span>, <span class="hlFld-ContribAuthor ">Run-Run  Zhou</span>, <span class="hlFld-ContribAuthor ">Li-Juan  Wang</span>, <span class="hlFld-ContribAuthor ">Shan-Hua  Li</span>, <span class="hlFld-ContribAuthor ">Fu-Nan  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and structure–activity relationship of N-(piperidin-4-yl)benzamide derivatives as activators of hypoxia-inducible factor 1 pathways. </span><span class="cited-content_cbyCitation_journal-name">Archives of Pharmacal Research</span><span> <strong>2018,</strong> <em>41 </em>
                                    (12)
                                     , 1149-1161. <a href="https://doi.org/10.1007/s12272-018-1050-2" title="DOI URL">https://doi.org/10.1007/s12272-018-1050-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12272-018-1050-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12272-018-1050-2%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Pharmacal%2520Research%26atitle%3DSynthesis%252Band%252Bstructure%2525E2%252580%252593activity%252Brelationship%252Bof%252BN-%252528piperidin-4-yl%252529benzamide%252Bderivatives%252Bas%252Bactivators%252Bof%252Bhypoxia-inducible%252Bfactor%252B1%252Bpathways%26aulast%3DHuang%26aufirst%3DZhi-Ning%26date%3D2018%26date%3D2018%26volume%3D41%26issue%3D12%26spage%3D1149%26epage%3D1161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mai  Adel</span>, <span class="hlFld-ContribAuthor ">Rabah A.T.  Serya</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Khaled A.M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2018,</strong> <em>81 </em>, 612-629. <a href="https://doi.org/10.1016/j.bioorg.2018.09.001" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.09.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.09.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DIdentification%252Bof%252Bnew%252Bpyrrolo%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252Bpotent%252BVEGFR-2%252Btyrosine%252Bkinase%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bmolecular%252Bmodeling%26aulast%3DAdel%26aufirst%3DMai%26date%3D2018%26volume%3D81%26spage%3D612%26epage%3D629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jia  Wang</span>, <span class="hlFld-ContribAuthor ">Grace Qun  Gong</span>, <span class="hlFld-ContribAuthor ">Yan  Zhou</span>, <span class="hlFld-ContribAuthor ">Woo-Jeong  Lee</span>, <span class="hlFld-ContribAuthor ">Christina Maree  Buchanan</span>, <span class="hlFld-ContribAuthor ">William Alexander  Denny</span>, <span class="hlFld-ContribAuthor ">Gordon William  Rewcastle</span>, <span class="hlFld-ContribAuthor ">Jackie Diane  Kendall</span>, <span class="hlFld-ContribAuthor ">James Michael Jeremy  Dickson</span>, <span class="hlFld-ContribAuthor ">Jack Urquhart  Flanagan</span>, <span class="hlFld-ContribAuthor ">Peter Robin  Shepherd</span>, <span class="hlFld-ContribAuthor ">De-Hua  Yang</span>, <span class="hlFld-ContribAuthor ">Ming-Wei  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">High-throughput screening campaigns against a PI3Kα isoform bearing the H1047R mutation identified potential inhibitors with novel scaffolds. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2018,</strong> <em>39 </em>
                                    (11)
                                     , 1816-1822. <a href="https://doi.org/10.1038/s41401-018-0057-z" title="DOI URL">https://doi.org/10.1038/s41401-018-0057-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41401-018-0057-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41401-018-0057-z%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DHigh-throughput%252Bscreening%252Bcampaigns%252Bagainst%252Ba%252BPI3K%2525CE%2525B1%252Bisoform%252Bbearing%252Bthe%252BH1047R%252Bmutation%252Bidentified%252Bpotential%252Binhibitors%252Bwith%252Bnovel%252Bscaffolds%26aulast%3DWang%26aufirst%3DJia%26date%3D2018%26date%3D2018%26volume%3D39%26issue%3D11%26spage%3D1816%26epage%3D1822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ling-Ling  Yang</span>, <span class="hlFld-ContribAuthor ">Hua-Li  Wang</span>, <span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Chen  Yuan</span>, <span class="hlFld-ContribAuthor ">Si-Yu  Liu</span>, <span class="hlFld-ContribAuthor ">Zhu-Jun  Yu</span>, <span class="hlFld-ContribAuthor ">Sha  Liu</span>, <span class="hlFld-ContribAuthor ">Yu-Hang  Yan</span>, <span class="hlFld-ContribAuthor ">Chengyong  Wu</span>, <span class="hlFld-ContribAuthor ">Yuxi  Wang</span>, <span class="hlFld-ContribAuthor ">Zhouyu  Wang</span>, <span class="hlFld-ContribAuthor ">Yamei  Yu</span>, <span class="hlFld-ContribAuthor ">Qiang  Chen</span>, <span class="hlFld-ContribAuthor ">Guo-Bo  Li</span>. </span><span class="cited-content_cbyCitation_article-title">X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>155 </em>, 806-823. <a href="https://doi.org/10.1016/j.ejmech.2018.06.041" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.06.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.06.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.06.041%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DX-ray%252Bcrystal%252Bstructure%252Bguided%252Bdiscovery%252Bof%252Bnew%252Bselective%25252C%252Bsubstrate-mimicking%252Bsirtuin%252B2%252Binhibitors%252Bthat%252Bexhibit%252Bactivities%252Bagainst%252Bnon-small%252Bcell%252Blung%252Bcancer%252Bcells%26aulast%3DYang%26aufirst%3DLing-Ling%26date%3D2018%26volume%3D155%26spage%3D806%26epage%3D823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fang  Wang</span>, <span class="hlFld-ContribAuthor ">Thomas  Bank</span>, <span class="hlFld-ContribAuthor ">Gregory  Malnassy</span>, <span class="hlFld-ContribAuthor ">Maribel  Arteaga</span>, <span class="hlFld-ContribAuthor ">Na  Shang</span>, <span class="hlFld-ContribAuthor ">Annika  Dalheim</span>, <span class="hlFld-ContribAuthor ">Xianzhong  Ding</span>, <span class="hlFld-ContribAuthor ">Scott J.  Cotler</span>, <span class="hlFld-ContribAuthor ">Mitchell F.  Denning</span>, <span class="hlFld-ContribAuthor ">Michael I.  Nishimura</span>, <span class="hlFld-ContribAuthor ">Peter  Breslin</span>, <span class="hlFld-ContribAuthor ">Wei  Qiu</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of insulin‐like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival. </span><span class="cited-content_cbyCitation_journal-name">Hepatology Communications</span><span> <strong>2018,</strong> <em>2 </em>
                                    (6)
                                     , 732-746. <a href="https://doi.org/10.1002/hep4.1181" title="DOI URL">https://doi.org/10.1002/hep4.1181</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/hep4.1181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fhep4.1181%26sid%3Dliteratum%253Aachs%26jtitle%3DHepatology%2520Communications%26atitle%3DInhibition%252Bof%252Binsulin%2525E2%252580%252590like%252Bgrowth%252Bfactor%252B1%252Breceptor%252Benhances%252Bthe%252Befficacy%252Bof%252Bsorafenib%252Bin%252Binhibiting%252Bhepatocellular%252Bcarcinoma%252Bcell%252Bgrowth%252Band%252Bsurvival%26aulast%3DWang%26aufirst%3DFang%26date%3D2018%26date%3D2018%26volume%3D2%26issue%3D6%26spage%3D732%26epage%3D746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Conesa-Milián</span>, <span class="hlFld-ContribAuthor ">Eva  Falomir</span>, <span class="hlFld-ContribAuthor ">Juan  Murga</span>, <span class="hlFld-ContribAuthor ">Miguel  Carda</span>, <span class="hlFld-ContribAuthor ">Eef  Meyen</span>, <span class="hlFld-ContribAuthor ">Sandra  Liekens</span>, <span class="hlFld-ContribAuthor ">J.  Alberto Marco</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of carbamates derived from aminocombretastatin A-4 as vascular disrupting agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>147 </em>, 183-193. <a href="https://doi.org/10.1016/j.ejmech.2018.01.058" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.01.058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.01.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.01.058%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bcarbamates%252Bderived%252Bfrom%252Baminocombretastatin%252BA-4%252Bas%252Bvascular%252Bdisrupting%252Bagents%26aulast%3DConesa-Mili%25C3%25A1n%26aufirst%3DLaura%26date%3D2018%26volume%3D147%26spage%3D183%26epage%3D193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhongzhen  Yang</span>, <span class="hlFld-ContribAuthor ">Yong  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Chen</span>, <span class="hlFld-ContribAuthor ">Weijian  Li</span>, <span class="hlFld-ContribAuthor ">Guo-Bo  Li</span>, <span class="hlFld-ContribAuthor ">Yong  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Total Synthesis and Evaluation of B-Homo Palmatine and Berberine Derivatives as p300 Histone Acetyltransferase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>2018 </em>
                                    (8)
                                     , 1041-1052. <a href="https://doi.org/10.1002/ejoc.201701693" title="DOI URL">https://doi.org/10.1002/ejoc.201701693</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201701693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201701693%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DTotal%252BSynthesis%252Band%252BEvaluation%252Bof%252BB-Homo%252BPalmatine%252Band%252BBerberine%252BDerivatives%252Bas%252Bp300%252BHistone%252BAcetyltransferase%252BInhibitors%26aulast%3DYang%26aufirst%3DZhongzhen%26date%3D2018%26date%3D2018%26volume%3D2018%26issue%3D8%26spage%3D1041%26epage%3D1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sha  Liu</span>, <span class="hlFld-ContribAuthor ">Li  Jing</span>, <span class="hlFld-ContribAuthor ">Zhu-Jun  Yu</span>, <span class="hlFld-ContribAuthor ">Chengyong  Wu</span>, <span class="hlFld-ContribAuthor ">Yongxiang  Zheng</span>, <span class="hlFld-ContribAuthor ">En  Zhang</span>, <span class="hlFld-ContribAuthor ">Qiang  Chen</span>, <span class="hlFld-ContribAuthor ">Yamei  Yu</span>, <span class="hlFld-ContribAuthor ">Li  Guo</span>, <span class="hlFld-ContribAuthor ">Yong  Wu</span>, <span class="hlFld-ContribAuthor ">Guo-Bo  Li</span>. </span><span class="cited-content_cbyCitation_article-title">(( S )-3-Mercapto-2-methylpropanamido)acetic acid derivatives as metallo-β-lactamase inhibitors: Synthesis, kinetic and crystallographic studies. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>145 </em>, 649-660. <a href="https://doi.org/10.1016/j.ejmech.2018.01.032" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.01.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.01.032%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D%252528%252528%252BS%252B%252529-3-Mercapto-2-methylpropanamido%252529acetic%252Bacid%252Bderivatives%252Bas%252Bmetallo-%2525CE%2525B2-lactamase%252Binhibitors%25253A%252BSynthesis%25252C%252Bkinetic%252Band%252Bcrystallographic%252Bstudies%26aulast%3DLiu%26aufirst%3DSha%26date%3D2018%26volume%3D145%26spage%3D649%26epage%3D660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shu  Zhou</span>, <span class="hlFld-ContribAuthor ">Guo-Bo  Li</span>, <span class="hlFld-ContribAuthor ">Lin  Luo</span>, <span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Kai  Chen</span>, <span class="hlFld-ContribAuthor ">Hui  Li</span>, <span class="hlFld-ContribAuthor ">Xiao-Juan  Jiang</span>, <span class="hlFld-ContribAuthor ">Qi  Fu</span>, <span class="hlFld-ContribAuthor ">Xin  Long</span>, <span class="hlFld-ContribAuthor ">Jin-ku  Bao</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based discovery of new maternal embryonic leucine zipper kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (9)
                                     , 1489-1495. <a href="https://doi.org/10.1039/C7OB02344H" title="DOI URL">https://doi.org/10.1039/C7OB02344H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7OB02344H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7OB02344H%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DStructure-based%252Bdiscovery%252Bof%252Bnew%252Bmaternal%252Bembryonic%252Bleucine%252Bzipper%252Bkinase%252Binhibitors%26aulast%3DZhou%26aufirst%3DShu%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D9%26spage%3D1489%26epage%3D1495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jin  Luo</span>, <span class="hlFld-ContribAuthor ">Anlin  Zhao</span>, <span class="hlFld-ContribAuthor ">Caihua  Zheng</span>, <span class="hlFld-ContribAuthor ">Tao  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and herbicidal activity of novel 6-arylthio-3-methylthio-1
              H
              -pyrazolo[3,4-d]pyrimidin-4(5
              H
              )-ones. </span><span class="cited-content_cbyCitation_journal-name">Phosphorus, Sulfur, and Silicon and the Related Elements</span><span> <strong>2017,</strong> <em>192 </em>
                                    (10)
                                     , 1124-1126. <a href="https://doi.org/10.1080/10426507.2017.1333508" title="DOI URL">https://doi.org/10.1080/10426507.2017.1333508</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10426507.2017.1333508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10426507.2017.1333508%26sid%3Dliteratum%253Aachs%26jtitle%3DPhosphorus%252C%2520Sulfur%252C%2520and%2520Silicon%2520and%2520the%2520Related%2520Elements%26atitle%3DSynthesis%252Band%252Bherbicidal%252Bactivity%252Bof%252Bnovel%252B6-arylthio-3-methylthio-1%252BH%252B-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-4%2525285%252BH%252B%252529-ones%26aulast%3DLuo%26aufirst%3DJin%26date%3D2017%26date%3D2017%26volume%3D192%26issue%3D10%26spage%3D1124%26epage%3D1126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingling  Yang</span>, <span class="hlFld-ContribAuthor ">Xiaobo  Ma</span>, <span class="hlFld-ContribAuthor ">Chen  Yuan</span>, <span class="hlFld-ContribAuthor ">Yanying  He</span>, <span class="hlFld-ContribAuthor ">Ling  Li</span>, <span class="hlFld-ContribAuthor ">Sha  Fang</span>, <span class="hlFld-ContribAuthor ">Wei  Xia</span>, <span class="hlFld-ContribAuthor ">Tao  He</span>, <span class="hlFld-ContribAuthor ">Shan  Qian</span>, <span class="hlFld-ContribAuthor ">Zhihong  Xu</span>, <span class="hlFld-ContribAuthor ">Guobo  Li</span>, <span class="hlFld-ContribAuthor ">Zhouyu  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-((4,6-dimethylpyrimidin-2-yl)thio)- N -phenylacetamide derivatives as new potent and selective human sirtuin 2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>134 </em>, 230-241. <a href="https://doi.org/10.1016/j.ejmech.2017.04.010" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.04.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.04.010%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-%252528%2525284%25252C6-dimethylpyrimidin-2-yl%252529thio%252529-%252BN%252B-phenylacetamide%252Bderivatives%252Bas%252Bnew%252Bpotent%252Band%252Bselective%252Bhuman%252Bsirtuin%252B2%252Binhibitors%26aulast%3DYang%26aufirst%3DLingling%26date%3D2017%26volume%3D134%26spage%3D230%26epage%3D241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Fu</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Shanhe  Wan</span>, <span class="hlFld-ContribAuthor ">Zhonghuang  Li</span>, <span class="hlFld-ContribAuthor ">Guangfa  Wang</span>, <span class="hlFld-ContribAuthor ">Jiajie  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2017,</strong> <em>22 </em>
                                    (4)
                                     , 542. <a href="https://doi.org/10.3390/molecules22040542" title="DOI URL">https://doi.org/10.3390/molecules22040542</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules22040542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules22040542%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBisarylureas%252BBased%252Bon%252B1H-Pyrazolo%25255B3%25252C4-d%25255Dpyrimidine%252BScaffold%252Bas%252BNovel%252BPan-RAF%252BInhibitors%252Bwith%252BPotent%252BAnti-Proliferative%252BActivities%25253A%252BStructure-Based%252BDesign%25252C%252BSynthesis%25252C%252BBiological%252BEvaluation%252Band%252BMolecular%252BModelling%252BStudies%26aulast%3DFu%26aufirst%3DYu%26date%3D2017%26date%3D2017%26volume%3D22%26issue%3D4%26spage%3D542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongyu  Hu</span>, <span class="hlFld-ContribAuthor ">Chunrong  Lin</span>, <span class="hlFld-ContribAuthor ">Mingtao  Ao</span>, <span class="hlFld-ContribAuthor ">Yufen  Ji</span>, <span class="hlFld-ContribAuthor ">Bowen  Tang</span>, <span class="hlFld-ContribAuthor ">Xiaoxiao  Zhou</span>, <span class="hlFld-ContribAuthor ">Meijuan  Fang</span>, <span class="hlFld-ContribAuthor ">Jinzhang  Zeng</span>, <span class="hlFld-ContribAuthor ">Zhen  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 1-(2-(adamantane-1-yl)-1H-indol-5-yl)-3-substituted urea/thiourea derivatives as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2017,</strong> <em>7 </em>
                                    (81)
                                     , 51640-51651. <a href="https://doi.org/10.1039/C7RA08149A" title="DOI URL">https://doi.org/10.1039/C7RA08149A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7RA08149A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7RA08149A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B1-%2525282-%252528adamantane-1-yl%252529-1H-indol-5-yl%252529-3-substituted%252Burea%25252Fthiourea%252Bderivatives%252Bas%252Banticancer%252Bagents%26aulast%3DHu%26aufirst%3DHongyu%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D81%26spage%3D51640%26epage%3D51651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zrinka Rajić  Džolić</span>, <span class="hlFld-ContribAuthor ">Ivana  Perković</span>, <span class="hlFld-ContribAuthor ">Sandra Kraljević  Pavelić</span>, <span class="hlFld-ContribAuthor ">Mirela  Sedić</span>, <span class="hlFld-ContribAuthor ">Nataša  Ilić</span>, <span class="hlFld-ContribAuthor ">Dominique  Schols</span>, <span class="hlFld-ContribAuthor ">Branka  Zorc</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and cytostatic activity of novel pyrazine sorafenib analogs. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2016,</strong> <em>25 </em>
                                    (12)
                                     , 2729-2741. <a href="https://doi.org/10.1007/s00044-016-1667-y" title="DOI URL">https://doi.org/10.1007/s00044-016-1667-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-016-1667-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-016-1667-y%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bcytostatic%252Bactivity%252Bof%252Bnovel%252Bpyrazine%252Bsorafenib%252Banalogs%26aulast%3DD%25C5%25BEoli%25C4%2587%26aufirst%3DZrinka%2BRaji%25C4%2587%26date%3D2016%26date%3D2016%26volume%3D25%26issue%3D12%26spage%3D2729%26epage%3D2741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongyu  Hu</span>, <span class="hlFld-ContribAuthor ">Jun  Wu</span>, <span class="hlFld-ContribAuthor ">Mingtao  Ao</span>, <span class="hlFld-ContribAuthor ">Huiru  Wang</span>, <span class="hlFld-ContribAuthor ">Tongtong  Zhou</span>, <span class="hlFld-ContribAuthor ">Yuhua  Xue</span>, <span class="hlFld-ContribAuthor ">Yingkun  Qiu</span>, <span class="hlFld-ContribAuthor ">Meijuan  Fang</span>, <span class="hlFld-ContribAuthor ">Zhen  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, structure-activity relationship studies and biological evaluation of novel 2,5-disubstituted indole derivatives as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2016,</strong> <em>88 </em>
                                    (5)
                                     , 766-778. <a href="https://doi.org/10.1111/cbdd.12808" title="DOI URL">https://doi.org/10.1111/cbdd.12808</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12808%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DSynthesis%25252C%252Bstructure-activity%252Brelationship%252Bstudies%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B2%25252C5-disubstituted%252Bindole%252Bderivatives%252Bas%252Banticancer%252Bagents%26aulast%3DHu%26aufirst%3DHongyu%26date%3D2016%26date%3D2016%26volume%3D88%26issue%3D5%26spage%3D766%26epage%3D778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong  Li</span>, <span class="hlFld-ContribAuthor ">Ting-Ting  Cao</span>, <span class="hlFld-ContribAuthor ">Shanchun  Guo</span>, <span class="hlFld-ContribAuthor ">Qiu  Zhong</span>, <span class="hlFld-ContribAuthor ">Cai-Hu  Li</span>, <span class="hlFld-ContribAuthor ">Ying  Li</span>, <span class="hlFld-ContribAuthor ">Lin  Dong</span>, <span class="hlFld-ContribAuthor ">Shilong  Zheng</span>, <span class="hlFld-ContribAuthor ">Guangdi  Wang</span>, <span class="hlFld-ContribAuthor ">Shu-Fan  Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Allopurinol Derivatives with Anticancer Activity and Attenuated Xanthine Oxidase Inhibition. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2016,</strong> <em>21 </em>
                                    (6)
                                     , 771. <a href="https://doi.org/10.3390/molecules21060771" title="DOI URL">https://doi.org/10.3390/molecules21060771</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules21060771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules21060771%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDiscovery%252Bof%252BNovel%252BAllopurinol%252BDerivatives%252Bwith%252BAnticancer%252BActivity%252Band%252BAttenuated%252BXanthine%252BOxidase%252BInhibition%26aulast%3DLi%26aufirst%3DYong%26date%3D2016%26date%3D2016%26volume%3D21%26issue%3D6%26spage%3D771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wagdy M.  Eldehna</span>, <span class="hlFld-ContribAuthor ">Sahar M.  Abou-Seri</span>, <span class="hlFld-ContribAuthor ">Ahmed M.  El Kerdawy</span>, <span class="hlFld-ContribAuthor ">Rezk R.  Ayyad</span>, <span class="hlFld-ContribAuthor ">Abdallah M.  Hamdy</span>, <span class="hlFld-ContribAuthor ">Hazem A.  Ghabbour</span>, <span class="hlFld-ContribAuthor ">Mamdouh M.  Ali</span>, <span class="hlFld-ContribAuthor ">Dalal  A. Abou El Ella</span>. </span><span class="cited-content_cbyCitation_article-title">Increasing the binding affinity of VEGFR-2 inhibitors by extending their hydrophobic interaction with the active site: Design, synthesis and biological evaluation of 1-substituted-4-(4-methoxybenzyl)phthalazine derivatives. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>113 </em>, 50-62. <a href="https://doi.org/10.1016/j.ejmech.2016.02.029" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.02.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.02.029%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIncreasing%252Bthe%252Bbinding%252Baffinity%252Bof%252BVEGFR-2%252Binhibitors%252Bby%252Bextending%252Btheir%252Bhydrophobic%252Binteraction%252Bwith%252Bthe%252Bactive%252Bsite%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B1-substituted-4-%2525284-methoxybenzyl%252529phthalazine%252Bderivatives%26aulast%3DEldehna%26aufirst%3DWagdy%2BM.%26date%3D2016%26volume%3D113%26spage%3D50%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Yan</span>, <span class="hlFld-ContribAuthor ">Zhaoru  Huang</span>, <span class="hlFld-ContribAuthor ">Zhengyu  Wang</span>, <span class="hlFld-ContribAuthor ">Sufen  Cao</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Chen  Wang</span>, <span class="hlFld-ContribAuthor ">Lin  Zhou</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Cheng  Luo</span>, <span class="hlFld-ContribAuthor ">Jinpei  Zhou</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Wenhu  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 1,3-Diaryl-pyridones as Potent VEGFR-2 Inhibitors: Design, Synthesis, and Biological Evaluation. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2016,</strong> <em>87 </em>
                                    (5)
                                     , 694-703. <a href="https://doi.org/10.1111/cbdd.12703" title="DOI URL">https://doi.org/10.1111/cbdd.12703</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12703%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DDiscovery%252Bof%252B1%25252C3-Diaryl-pyridones%252Bas%252BPotent%252BVEGFR-2%252BInhibitors%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%26aulast%3DYan%26aufirst%3DWei%26date%3D2016%26date%3D2016%26volume%3D87%26issue%3D5%26spage%3D694%26epage%3D703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanyuan  Shan</span>, <span class="hlFld-ContribAuthor ">Chen  Wang</span>, <span class="hlFld-ContribAuthor ">Lin  Zhang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Wang</span>, <span class="hlFld-ContribAuthor ">Maoyi  Wang</span>, <span class="hlFld-ContribAuthor ">Yalin  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Expanding the structural diversity of diarylureas as multi-target tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (4)
                                     , 750-758. <a href="https://doi.org/10.1016/j.bmc.2015.12.038" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.12.038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.12.038%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DExpanding%252Bthe%252Bstructural%252Bdiversity%252Bof%252Bdiarylureas%252Bas%252Bmulti-target%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DShan%26aufirst%3DYuanyuan%26date%3D2016%26volume%3D24%26issue%3D4%26spage%3D750%26epage%3D758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuang  Ma</span>, <span class="hlFld-ContribAuthor ">Ling-Ling  Yang</span>, <span class="hlFld-ContribAuthor ">Ting  Niu</span>, <span class="hlFld-ContribAuthor ">Chuan  Cheng</span>, <span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Ming-Wu  Zheng</span>, <span class="hlFld-ContribAuthor ">Yu  Xiong</span>, <span class="hlFld-ContribAuthor ">Lin-Li  Li</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>, <span class="hlFld-ContribAuthor ">Li-Juan  Chen</span>, <span class="hlFld-ContribAuthor ">Qiao  Zhou</span>, <span class="hlFld-ContribAuthor ">Yu-Quan  Wei</span>, <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2015,</strong> <em>5 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/srep15646" title="DOI URL">https://doi.org/10.1038/srep15646</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/srep15646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fsrep15646%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DSKLB-677%25252C%252Ban%252BFLT3%252Band%252BWnt%25252F%2525CE%2525B2-catenin%252Bsignaling%252Binhibitor%25252C%252Bdisplays%252Bpotent%252Bactivity%252Bin%252Bmodels%252Bof%252BFLT3-driven%252BAML%26aulast%3DMa%26aufirst%3DShuang%26date%3D2015%26date%3D2015%26volume%3D5%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jin  Hou</span>, <span class="hlFld-ContribAuthor ">Wei  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhi-Ning  Huang</span>, <span class="hlFld-ContribAuthor ">Shao-Mei  Yang</span>, <span class="hlFld-ContribAuthor ">Li-Juan  Wang</span>, <span class="hlFld-ContribAuthor ">Yu  Jiang</span>, <span class="hlFld-ContribAuthor ">Zhong-Shi  Zhou</span>, <span class="hlFld-ContribAuthor ">Man-Yi  Zheng</span>, <span class="hlFld-ContribAuthor ">Ji-Li  Jiang</span>, <span class="hlFld-ContribAuthor ">Shan-Hua  Li</span>, <span class="hlFld-ContribAuthor ">Fu-Nan  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of Novel
              N
              -(piperidine-4-yl)benzamide Derivatives as Potential Cell Cycle Inhibitors in HepG2 Cells. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2015,</strong> <em>86 </em>
                                    (2)
                                     , 223-231. <a href="https://doi.org/10.1111/cbdd.12484" title="DOI URL">https://doi.org/10.1111/cbdd.12484</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.12484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.12484%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DEvaluation%252Bof%252BNovel%252BN%252B-%252528piperidine-4-yl%252529benzamide%252BDerivatives%252Bas%252BPotential%252BCell%252BCycle%252BInhibitors%252Bin%252BHepG2%252BCells%26aulast%3DHou%26aufirst%3DJin%26date%3D2015%26date%3D2014%26volume%3D86%26issue%3D2%26spage%3D223%26epage%3D231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guo-Bo  Li</span>, <span class="hlFld-ContribAuthor ">Sen  Ji</span>, <span class="hlFld-ContribAuthor ">Ling-Ling  Yang</span>, <span class="hlFld-ContribAuthor ">Rong-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Kai  Chen</span>, <span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Shuang  Ma</span>, <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">LEADOPT: An automatic tool for structure-based lead optimization, and its application in structural optimizations of VEGFR2 and SYK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>93 </em>, 523-538. <a href="https://doi.org/10.1016/j.ejmech.2015.02.019" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.02.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.02.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.02.019%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLEADOPT%25253A%252BAn%252Bautomatic%252Btool%252Bfor%252Bstructure-based%252Blead%252Boptimization%25252C%252Band%252Bits%252Bapplication%252Bin%252Bstructural%252Boptimizations%252Bof%252BVEGFR2%252Band%252BSYK%252Binhibitors%26aulast%3DLi%26aufirst%3DGuo-Bo%26date%3D2015%26volume%3D93%26spage%3D523%26epage%3D538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Athanasios  Papakyriakou</span>, <span class="hlFld-ContribAuthor ">Panagiotis  Kefalos</span>, <span class="hlFld-ContribAuthor ">Panagiotis  Sarantis</span>, <span class="hlFld-ContribAuthor ">Christos  Tsiamantas</span>, <span class="hlFld-ContribAuthor ">Kleanthis P.  Xanthopoulos</span>, <span class="hlFld-ContribAuthor ">Dionisios  Vourloumis</span>, <span class="hlFld-ContribAuthor ">Dimitris  Beis</span>. </span><span class="cited-content_cbyCitation_article-title">A Zebrafish
              In Vivo
              Phenotypic Assay to Identify 3-Aminothiophene-2-Carboxylic Acid-Based Angiogenesis Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ASSAY and Drug Development Technologies</span><span> <strong>2014,</strong> <em>12 </em>
                                    (9-10)
                                     , 527-535. <a href="https://doi.org/10.1089/adt.2014.606" title="DOI URL">https://doi.org/10.1089/adt.2014.606</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1089/adt.2014.606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1089%2Fadt.2014.606%26sid%3Dliteratum%253Aachs%26jtitle%3DASSAY%2520and%2520Drug%2520Development%2520Technologies%26atitle%3DA%252BZebrafish%252BIn%252BVivo%252BPhenotypic%252BAssay%252Bto%252BIdentify%252B3-Aminothiophene-2-Carboxylic%252BAcid-Based%252BAngiogenesis%252BInhibitors%26aulast%3DPapakyriakou%26aufirst%3DAthanasios%26date%3D2014%26volume%3D12%26issue%3D9-10%26spage%3D527%26epage%3D535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Konstantinos M.  Kasiotis</span>, <span class="hlFld-ContribAuthor ">Evangelia N.  Tzanetou</span>, <span class="hlFld-ContribAuthor ">Serkos A.  Haroutounian</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrazoles as potential anti-angiogenesis agents: a contemporary overview. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2014,</strong> <em>2 </em><a href="https://doi.org/10.3389/fchem.2014.00078" title="DOI URL">https://doi.org/10.3389/fchem.2014.00078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2014.00078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2014.00078%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DPyrazoles%252Bas%252Bpotential%252Banti-angiogenesis%252Bagents%25253A%252Ba%252Bcontemporary%252Boverview%26aulast%3DKasiotis%26aufirst%3DKonstantinos%2BM.%26date%3D2014%26date%3D2014%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0013.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Structure of compound <b>1</b>. (b) Schematic showing subgroups or atoms that were the focus of structural modifications.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) phosphorus oxychloride, DIEA, toluene, reflux, 56%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (b) triphosgene, Et<sub>3</sub>N, THF, rt; (c) RNH<sub>2</sub>, THF, 45 °C, 72–96% for two steps; (d) Fe, NH<sub>4</sub>Cl, EtOH, H<sub>2</sub>O, 91–98%; (e) HCl, 1-BuOH, 100 °C, 74–80%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (f) triphosgene, THF, Et<sub>3</sub>N, rt; 4-aminophenol, THF, 45 °C, 64–99%; (g) sodium hydroxide, H<sub>2</sub>O, THF, 60 °C, 21–34%; (h) 4-aminophenol, sodium hydroxide, H<sub>2</sub>O, THF, 60 °C, 32%; (i) substituted anilines, triphosgene, THF, Et<sub>3</sub>N, rt; acetonitrile, reflux, 61–84%; (j) HOBT, EDCI, DIEA, THF, rt to reflux, 66–73%.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (k) iodomethane (MeI), sodium hydroxide, DMF, rt, 65–70%.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (h) 3-aminophenol, sodium hydroxide, THF, H<sub>2</sub>O, 60 °C, 38%; (i) for <b>12</b> and <b>13</b>, substituted aniline, triphosgene, THF, Et<sub>3</sub>N, rt; acetonitrile, reflux, 87–89%; for <b>14</b> and <b>15</b>, HOBT, EDCI, DIEA, THF, rt to reflux, 71–74%; (m) HOBT, EDCI, DIEA, THF, rt to reflux, 79–86%.</p></p></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (n) amine, triphosgene, THF, Et<sub>3</sub>N, rt; acetonitrile, reflux, 44–77%.</p></p></figure><figure data-id="fig2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0014.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Preliminary in vivo anti-AML assays. Daily oral administration of compounds <b>9</b>, <b>27</b>, and <b>33</b> at concentrations of 5, 7.5, and 5 mg/kg/d, respectively, was initiated when the MV4-11 tumors reached approximately 400 mm<sup>3</sup> in volume (three mice per group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0015.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Growth inhibitory profile of compound <b>33</b> against MV4-11 cells using the MTT assay method. (b) A flow cytometry assay was performed to examine cell apoptosis. MV4-11 cells (1 × 10<sup>5</sup>) were harvested after treatment with various drug concentrations for 24 h. Cells were stained with an Annexin V & PI Kit and analyzed by flow cytometry. Percentages in the bottom right quadrants are the ratio of cells in early apoptosis (annexin V positive and PI negative). Percentages in the upper right quadrants are the ratio of cells in late apoptosis (Annexin V positive and PI positive). (c) Western blot analysis was used to examine the phosphorylation of FLT3 and downstream signals in MV4-11 cells treated with different doses of compound <b>33</b> for 20 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0016.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) 33hpf zebrafish embryos treated with blank control or 1.25, 2.5, or 5 μM <b>33</b>. ISV budding and outgrowth were almost completely inhibited by treatment with 5 μM <b>33</b>. (b) Statistics of ISV length in embryos treated with blank control and compound <b>33</b>. ISVs above the yolk extension were counted. Key: columns, mean; bars, SD (<i>n</i> = 11; ANOVA; **, <i>P</i> < 0.01 vs the control).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0017.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (a) Daily oral administration of compound <b>33</b> at concentrations of 1, 3, and 10 mg/kg/d and sorafenib at a dose of 3 mg/kg/d was initiated when the MV4-11 tumors reached approximately 500 mm<sup>3</sup> in volume (six mice per group). (b) Average body weights for <b>33</b>-treated mouse groups in the MV4-11 xenograft model. (c) Pharmacokinetics of compound <b>33</b> in SD rats (five rats per group). The rats were treated orally with 10 mg/kg/d of compound <b>33</b>, and plasma was collected via jugular vein cannulation. Finally, compound concentrations in the plasma were detected by liquid–liquid extraction followed by LC–MS detection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/medium/jm-2012-01537p_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0018.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Ki67, TUNEL, and p-STAT5 detection of MV4-11 tumor tissues after treatment with compound <b>33</b> for 72 or 96 h. At 24 h after the final dose of compound <b>33</b>, the tumor samples were collected for analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-4/jm301537p/production/images/large/jm-2012-01537p_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301537p&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02671" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02671" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 44 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Lowenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downing, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnett, A.</span><span> </span><span class="NLM_article-title">Acute myeloid leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">1051</span><span class="NLM_x">–</span> <span class="NLM_lpage">1062</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1056%2FNEJM199909303411407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=10502596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A280%3ADyaK1MvhslSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=1999&pages=1051-1062&author=B.+Lowenbergauthor=J.+R.+Downingauthor=A.+Burnett&title=Acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Acute myeloid leukemia</span></div><div class="casAuthors">Lowenberg B; Downing J R; Burnett A</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1051-62</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvdpRq9xav842y4bB4mnvYfW6udTcc2ebTi8XNpXaYzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1MvhslSrtg%253D%253D&md5=7cd5e8c3edc8a431afbad11822153c23</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJM199909303411407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199909303411407%26sid%3Dliteratum%253Aachs%26aulast%3DLowenberg%26aufirst%3DB.%26aulast%3DDowning%26aufirst%3DJ.%2BR.%26aulast%3DBurnett%26aufirst%3DA.%26atitle%3DAcute%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1999%26volume%3D341%26spage%3D1051%26epage%3D1062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Schlenk, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dohner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbacioglu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bullinger, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habdank, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spath, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlegelberger, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heil, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dohner, H.</span><span> </span><span class="NLM_article-title">German-Austrian Acute Myeloid Leukemia Study, G. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">358</span><span class="NLM_x">, </span> <span class="NLM_fpage">1909</span><span class="NLM_x">–</span> <span class="NLM_lpage">1918</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1056%2FNEJMoa074306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=18450602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1Ggu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2008&pages=1909-1918&author=R.+F.+Schlenkauthor=K.+Dohnerauthor=J.+Krauterauthor=S.+Frohlingauthor=A.+Corbaciogluauthor=L.+Bullingerauthor=M.+Habdankauthor=D.+Spathauthor=M.+Morganauthor=A.+Bennerauthor=B.+Schlegelbergerauthor=G.+Heilauthor=A.+Ganserauthor=H.+Dohner&title=German-Austrian+Acute+Myeloid+Leukemia+Study%2C+G.+Mutations+and+treatment+outcome+in+cytogenetically+normal+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia</span></div><div class="casAuthors">Schlenk, Richard F.; Doehner, Konstanze; Krauter, Jurgen; Frohling, Stefan; Corbacioglu, Andrea; Bullinger, Lars; Habdank, Marianne; Spith, Daniela; Morgan, Michael; Benner, Axel; Schlegelberger, Brigitte; Heil, Gerhard; Ganser, Arnold; Doehner, Hartmut; Schlimok, G.; Arnold, R.; Pezzutto, A.; Glasmacher, A.; Germing, U.; Heit, W.; Hoelzer, D.; Derigs, H. G.; Luebbert, M.; Pralle, H.; Runde, V.; Griesinger, F.; Fiedler, W.; Salwender, H.; Kirchner, H.; Hensel, M.; Hartmann, F.; Fischer, J. T.; Kneba, M.; Hinke, A.; Kremers, S.; Goetze, K.; Waterhouse, C.; del Valle, F.; Matzdorff, A.; Grimminger, W.; Mergenthaler, H. G.; Kirchen, H.; Brossart, P.; Bergmann, L.; Raghavachar, Aruna; Petzer, A.; Koller, E.; Neons, L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1909-1918</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations occur in several genes in cytogenetically normal acute myeloid leukemia (AML) cells: the nucleophosmin gene (NPM1), the fms-related tyrosine kinase 3 gene (FLT3), the CCAAT/enhancer binding protein a gene (CEPBA), the myeloid-lymphoid or mixed-lineage leukemia gene (MLL), and the neuroblastoma RAS viral oncogene homolog (NRAS).  We evaluated the assocns. of these mutations with clin. outcomes in patients.  We compared the mutational status of the NPM1, FLT3, CEBPA, MLL, and NRAS genes in leukemia cells with the clin. outcome in 872 adults younger than 60 years of age with cytogenetically normal AML.  Patients had been entered into one of four trials of therapy for AML.  In each study, patients with an HLA-matched related donor were assigned to undergo stem-cell transplantation.  A total of 53% of patients had NPM1 mutations, 31% had FLT3 internal tandem duplications (ITDs), 11% had FLT3 tyrosine kinase-domain mutations, 13% had CEBPA mutations, 7% had MLL partial tandem duplications (PTDs), and 13% had NRAS mutations.  The overall complete-remission rate was 77%.  The genotype of mutant NPM1 without FLT3-ITD, the mutant CEBPA genotype, and younger age were each significantly assocd. with complete remission.  Of the 663 patients who received postremission therapy, 150 underwent hematopoietic stem-cell transplantation from an HLA-matched related donor.  Significant assocns. were found between the risk of relapse or the risk of death during complete remission and the leukemia genotype of mutant NPM1 without FLT3-ITD (hazard ratio, 0.44; 95% confidence interval [CI], 0.32 to 0.61), the mutant CEBPA genotype (hazard ratio, 0.48; 95% CI, 0.30 to 0.75), and the MLL-PTD genotype (hazard ratio, 1.56; 95% CI, 1.00 to 2.43), as well as receipt of a transplant from an HLA-matched related donor (hazard ratio, 0.60; 95% CI, 0.44 to 0.82).  The benefit of the transplant was limited to the subgroup of patients with the prognostically adverse genotype FLT3-ITD or the genotype consisting of wild-type NPM1 and CEBPA without FLT3-ITD.  Genotypes defined by the mutational status of NPM1, FLT3, CEBPA, and MLL are assocd. with the outcome of treatment for patients with cytogenetically normal AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6JpbRc9OYmrVg90H21EOLACvtfcHk0ljUP8LabFEHog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1Ggu70%253D&md5=4109ec9d7141f2405163dfc31a9dd660</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa074306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa074306%26sid%3Dliteratum%253Aachs%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DDohner%26aufirst%3DK.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DFrohling%26aufirst%3DS.%26aulast%3DCorbacioglu%26aufirst%3DA.%26aulast%3DBullinger%26aufirst%3DL.%26aulast%3DHabdank%26aufirst%3DM.%26aulast%3DSpath%26aufirst%3DD.%26aulast%3DMorgan%26aufirst%3DM.%26aulast%3DBenner%26aufirst%3DA.%26aulast%3DSchlegelberger%26aufirst%3DB.%26aulast%3DHeil%26aufirst%3DG.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DDohner%26aufirst%3DH.%26atitle%3DGerman-Austrian%2520Acute%2520Myeloid%2520Leukemia%2520Study%252C%2520G.%2520Mutations%2520and%2520treatment%2520outcome%2520in%2520cytogenetically%2520normal%2520acute%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2008%26volume%3D358%26spage%3D1909%26epage%3D1918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Meshinchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonzo, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirewalt, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwaan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhardt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaspers, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerema, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerbing, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lange, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radich, J. P.</span><span> </span><span class="NLM_article-title">Clinical implications of FLT3 mutations in pediatric AML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3654</span><span class="NLM_x">–</span> <span class="NLM_lpage">3661</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3654-3661&author=S.+Meshinchiauthor=T.+A.+Alonzoauthor=D.+L.+Stirewaltauthor=M.+Zwaanauthor=M.+Zimmermanauthor=D.+Reinhardtauthor=G.+J.+Kaspersauthor=N.+A.+Heeremaauthor=R.+Gerbingauthor=B.+J.+Langeauthor=J.+P.+Radich&title=Clinical+implications+of+FLT3+mutations+in+pediatric+AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeshinchi%26aufirst%3DS.%26aulast%3DAlonzo%26aufirst%3DT.%2BA.%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26aulast%3DZwaan%26aufirst%3DM.%26aulast%3DZimmerman%26aufirst%3DM.%26aulast%3DReinhardt%26aufirst%3DD.%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DGerbing%26aufirst%3DR.%26aulast%3DLange%26aufirst%3DB.%2BJ.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26atitle%3DClinical%2520implications%2520of%2520FLT3%2520mutations%2520in%2520pediatric%2520AML%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3654%26epage%3D3661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholl, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wernig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernard, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">4788</span><span class="NLM_x">–</span> <span class="NLM_lpage">4796</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=4788-4796&author=M.+M.+Loriauxauthor=R.+L.+Levineauthor=J.+W.+Tynerauthor=S.+Frohlingauthor=C.+Schollauthor=E.+P.+Stoffregenauthor=G.+Wernigauthor=H.+Ericksonauthor=C.+A.+Eideauthor=R.+Bergerauthor=O.+A.+Bernardauthor=J.+D.+Griffinauthor=R.+M.+Stoneauthor=B.+Leeauthor=M.+Meyersonauthor=M.+C.+Heinrichauthor=M.+W.+Deiningerauthor=D.+G.+Gillilandauthor=B.+J.+Druker&title=High-throughput+sequence+analysis+of+the+tyrosine+kinome+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DFrohling%26aufirst%3DS.%26aulast%3DScholl%26aufirst%3DC.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DWernig%26aufirst%3DG.%26aulast%3DErickson%26aufirst%3DH.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DBerger%26aufirst%3DR.%26aulast%3DBernard%26aufirst%3DO.%2BA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DHigh-throughput%2520sequence%2520analysis%2520of%2520the%2520tyrosine%2520kinome%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D4788%26epage%3D4796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walters, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willis, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttropp, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oost, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">2238</span><span class="NLM_x">–</span> <span class="NLM_lpage">2245</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=2238-2245&author=J.+W.+Tynerauthor=D.+K.+Waltersauthor=S.+G.+Willisauthor=M.+Luttroppauthor=J.+Oostauthor=M.+Loriauxauthor=H.+Ericksonauthor=A.+S.+Corbinauthor=T.+O%E2%80%99Hareauthor=M.+C.+Heinrichauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=RNAi+screening+of+the+tyrosine+kinome+identifies+therapeutic+targets+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DWalters%26aufirst%3DD.%2BK.%26aulast%3DWillis%26aufirst%3DS.%2BG.%26aulast%3DLuttropp%26aufirst%3DM.%26aulast%3DOost%26aufirst%3DJ.%26aulast%3DLoriaux%26aufirst%3DM.%26aulast%3DErickson%26aufirst%3DH.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DRNAi%2520screening%2520of%2520the%2520tyrosine%2520kinome%2520identifies%2520therapeutic%2520targets%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D2238%26epage%3D2245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">The roles of FLT3 in hematopoiesis and leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">1532</span><span class="NLM_x">–</span> <span class="NLM_lpage">1542</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1182%2Fblood-2002-02-0492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=12176867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=1532-1542&author=D.+G.+Gillilandauthor=J.+D.+Griffin&title=The+roles+of+FLT3+in+hematopoiesis+and+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The roles of FLT3 in hematopoiesis and leukemia</span></div><div class="casAuthors">Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1532-1542</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">FLT3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system.  The ligand for FLT3 is expressed by marrow stromal cells and other cells and synergized with other growth factors to stimulate proliferation of stem cells, progenitor cells, dendritic cells, and natural killer cells.  Mutations of FLT3 have been detected in about 30% of patients with acute myelogenous leukemia and a small no. of patients with acute lymphocytic leukemia or myelodysplastic syndrome.  Patients with FLT3 mutations tend to have a poor prognosis.  The mutations most often involve small tandem duplications of amino acids within the juxtamembrane domain of the receptor and result in constitutive tyrosine kinase activity.  Expression of a mutant FLT3 receptor in murine marrow cells results in a lethal myeloproliferative syndrome and preliminary studies suggest that mutant FLT3 cooperates with other leukemia oncogenes to confer a more aggressive phenotype.  Taken together, these results suggest that FLT3 is an attractive therapeutic target for kinase inhibitors or other approaches for patients with mutations of this gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYQc2WkC8EQbVg90H21EOLACvtfcHk0liPKxkbgFiRSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslyhsLc%253D&md5=f6d04b227f5c5baf5c22cfba6e693ff1</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1182%2Fblood-2002-02-0492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2002-02-0492%26sid%3Dliteratum%253Aachs%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DThe%2520roles%2520of%2520FLT3%2520in%2520hematopoiesis%2520and%2520leukemia%26jtitle%3DBlood%26date%3D2002%26volume%3D100%26spage%3D1532%26epage%3D1542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Kottaridis, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frew, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langabeer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belton, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheatley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowen, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnett, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstone, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linch, D. C.</span><span> </span><span class="NLM_article-title">The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">1752</span><span class="NLM_x">–</span> <span class="NLM_lpage">1759</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=1752-1759&author=P.+D.+Kottaridisauthor=R.+E.+Galeauthor=M.+E.+Frewauthor=G.+Harrisonauthor=S.+E.+Langabeerauthor=A.+A.+Beltonauthor=H.+Walkerauthor=K.+Wheatleyauthor=D.+T.+Bowenauthor=A.+K.+Burnettauthor=A.+H.+Goldstoneauthor=D.+C.+Linch&title=The+presence+of+a+FLT3+internal+tandem+duplication+in+patients+with+acute+myeloid+leukemia+%28AML%29+adds+important+prognostic+information+to+cytogenetic+risk+group+and+response+to+the+first+cycle+of+chemotherapy%3A+analysis+of+854+patients+from+the+United+Kingdom+Medical+Research+Council+AML+10+and+12+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKottaridis%26aufirst%3DP.%2BD.%26aulast%3DGale%26aufirst%3DR.%2BE.%26aulast%3DFrew%26aufirst%3DM.%2BE.%26aulast%3DHarrison%26aufirst%3DG.%26aulast%3DLangabeer%26aufirst%3DS.%2BE.%26aulast%3DBelton%26aufirst%3DA.%2BA.%26aulast%3DWalker%26aufirst%3DH.%26aulast%3DWheatley%26aufirst%3DK.%26aulast%3DBowen%26aufirst%3DD.%2BT.%26aulast%3DBurnett%26aufirst%3DA.%2BK.%26aulast%3DGoldstone%26aufirst%3DA.%2BH.%26aulast%3DLinch%26aufirst%3DD.%2BC.%26atitle%3DThe%2520presence%2520of%2520a%2520FLT3%2520internal%2520tandem%2520duplication%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%2520adds%2520important%2520prognostic%2520information%2520to%2520cytogenetic%2520risk%2520group%2520and%2520response%2520to%2520the%2520first%2520cycle%2520of%2520chemotherapy%253A%2520analysis%2520of%2520854%2520patients%2520from%2520the%2520United%2520Kingdom%2520Medical%2520Research%2520Council%2520AML%252010%2520and%252012%2520trials%26jtitle%3DBlood%26date%3D2001%26volume%3D98%26spage%3D1752%26epage%3D1759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Andersson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitelman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billstrom, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fioretos, T.</span><span> </span><span class="NLM_article-title">Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients</span> <span class="citation_source-journal">Eur. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1111%2Fj.1600-0609.2004.00225.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=15059064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkt1Kgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2004&pages=307-313&author=A.+Anderssonauthor=B.+Johanssonauthor=C.+Lassenauthor=F.+Mitelmanauthor=R.+Billstromauthor=T.+Fioretos&title=Clinical+impact+of+internal+tandem+duplications+and+activating+point+mutations+in+FLT3+in+acute+myeloid+leukemia+in+elderly+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients</span></div><div class="casAuthors">Andersson, Anna; Johansson, Bertil; Lassen, Carin; Mitelman, Felix; Billstroem, Rolf; Fioretos, Thoas</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Haematology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">307-313</span>CODEN:
                <span class="NLM_cas:coden">EJHAEC</span>;
        ISSN:<span class="NLM_cas:issn">0902-4441</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The FLT3 gene is frequently mutated in acute myeloid leukemia (AML), either by an internal tandem duplication (ITD) of the juxtamembrane domain or by activating point mutations in the second tyrosine kinase domain (ATKD).  Only a few investigations have focused on the prognostic significance of FLT3 alterations in AML among the elderly, yielding conflicting results.  In the present study, the frequency and clin. relevance of FLT3 abnormalities were ascertained in a cohort of elderly AML patients.  A total of 109 AMLs, occurring in patients above the age of 60 yr (median 71.5), were investigated.  DNA was extd. from fresh bone marrow cells or from cells in fixative and investigated for the presence of ITD of exons 14 and 15 and the ATKD D835 in exon 20.  ITDs and ATKDs were identified in 20 (18%) and 11 (10%) of the cases, resp.  Three cases displayed both an ITD and an ATKD.  FLT3 abnormalities were assocd. with leukocytosis (ITD P < 0.01; ATKD P = 0.069), and the monocytic FAB subtypes M4 and M5 [ITD (P < 0.05), ATKD (P = 0.05)], and ITD and ATKD were significantly (P < 0.05) more common in cases with a normal karyotype.  There was no correlation between the presence of FLT3 abnormalities and complete remission rates or overall survival.  A correlation was obsd. between FLT3 abnormalities and leukocytosis, a normal karyotype, and the M4/M5 subtypes of leukemia.  However, no clear-cut prognostic impact of FLT3 abnormalities was identified in elderly AML patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqywfTjAtj3ULVg90H21EOLACvtfcHk0liPKxkbgFiRSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkt1Kgu74%253D&md5=1eb23898d331d2321b640467b1355ae2</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0609.2004.00225.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0609.2004.00225.x%26sid%3Dliteratum%253Aachs%26aulast%3DAndersson%26aufirst%3DA.%26aulast%3DJohansson%26aufirst%3DB.%26aulast%3DLassen%26aufirst%3DC.%26aulast%3DMitelman%26aufirst%3DF.%26aulast%3DBillstrom%26aufirst%3DR.%26aulast%3DFioretos%26aufirst%3DT.%26atitle%3DClinical%2520impact%2520of%2520internal%2520tandem%2520duplications%2520and%2520activating%2520point%2520mutations%2520in%2520FLT3%2520in%2520acute%2520myeloid%2520leukemia%2520in%2520elderly%2520patients%26jtitle%3DEur.%2520J.%2520Haematol.%26date%3D2004%26volume%3D72%26spage%3D307%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salerno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perl, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travers, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadt, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasarskis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span> </span><span class="NLM_article-title">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">485</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1038%2Fnature11016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=22504184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=485&publication_year=2012&pages=260-263&author=C.+C.+Smithauthor=Q.+Wangauthor=C.+S.+Chinauthor=S.+Salernoauthor=L.+E.+Damonauthor=M.+J.+Levisauthor=A.+E.+Perlauthor=K.+J.+Traversauthor=S.+Wangauthor=J.+P.+Huntauthor=P.+P.+Zarrinkarauthor=E.+E.+Schadtauthor=A.+Kasarskisauthor=J.+Kuriyanauthor=N.+P.+Shah&title=Validation+of+ITD+mutations+in+FLT3+as+a+therapeutic+target+in+human+acute+myeloid+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukemia</span></div><div class="casAuthors">Smith, Catherine C.; Wang, Qi; Chin, Chen-Shan; Salerno, Sara; Damon, Lauren E.; Levis, Mark J.; Perl, Alexander E.; Travers, Kevin J.; Wang, Susana; Hunt, Jeremy P.; Zarrinkar, Patrick P.; Schadt, Eric E.; Kasarskis, Andrew; Kuriyan, John; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">485</span>
        (<span class="NLM_cas:issue">7397</span>),
    <span class="NLM_cas:pages">260-263</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Effective targeted cancer therapeutic development depends upon distinguishing disease-assocd. driver' mutations, which have causative roles in malignancy pathogenesis, from passenger' mutations, which are dispensable for cancer initiation and maintenance.  Translational studies of clin. active targeted therapeutics can definitively discriminate driver from passenger lesions and provide valuable insights into human cancer biol.  Activating internal tandem duplication (ITD) mutations in FLT3 (FLT3-ITD) are detected in approx. 20% of acute myeloid leukemia (AML) patients and are assocd. with a poor prognosis.  Abundant scientific and clin. evidence, including the lack of convincing clin. activity of early FLT3 inhibitors, suggests that FLT3-ITD probably represents a passenger lesion.  Here we report point mutations at three residues within the kinase domain of FLT3-ITD that confer substantial in vitro resistance to AC220 (quizartinib), an active investigational inhibitor of FLT3, KIT, PDGFRA, PDGFRB and RET; evolution of AC220-resistant substitutions at two of these amino acid positions was obsd. in eight of eight FLT3-ITD-pos. AML patients with acquired resistance to AC220.  Our findings demonstrate that FLT3-ITD can represent a driver lesion and valid therapeutic target in human AML.  AC220-resistant FLT3 kinase domain mutants represent high-value targets for future FLT3 inhibitor development efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq0PeqhlWLObVg90H21EOLACvtfcHk0lgmCa8wbZcWSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D&md5=228dae85b08e65918f74ee8c5d20ddb0</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature11016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11016%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DChin%26aufirst%3DC.%2BS.%26aulast%3DSalerno%26aufirst%3DS.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DTravers%26aufirst%3DK.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DSchadt%26aufirst%3DE.%2BE.%26aulast%3DKasarskis%26aufirst%3DA.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DValidation%2520of%2520ITD%2520mutations%2520in%2520FLT3%2520as%2520a%2520therapeutic%2520target%2520in%2520human%2520acute%2520myeloid%2520leukaemia%26jtitle%3DNature%26date%3D2012%26volume%3D485%26spage%3D260%26epage%3D263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Thiede, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steudel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schakel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Platzbecker, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wermke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornhauser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ehninger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illmer, T.</span><span> </span><span class="NLM_article-title">Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">4326</span><span class="NLM_x">–</span> <span class="NLM_lpage">4335</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=4326-4335&author=C.+Thiedeauthor=C.+Steudelauthor=B.+Mohrauthor=M.+Schaichauthor=U.+Schakelauthor=U.+Platzbeckerauthor=M.+Wermkeauthor=M.+Bornhauserauthor=M.+Ritterauthor=A.+Neubauerauthor=G.+Ehningerauthor=T.+Illmer&title=Analysis+of+FLT3-activating+mutations+in+979+patients+with+acute+myelogenous+leukemia%3A+association+with+FAB+subtypes+and+identification+of+subgroups+with+poor+prognosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThiede%26aufirst%3DC.%26aulast%3DSteudel%26aufirst%3DC.%26aulast%3DMohr%26aufirst%3DB.%26aulast%3DSchaich%26aufirst%3DM.%26aulast%3DSchakel%26aufirst%3DU.%26aulast%3DPlatzbecker%26aufirst%3DU.%26aulast%3DWermke%26aufirst%3DM.%26aulast%3DBornhauser%26aufirst%3DM.%26aulast%3DRitter%26aufirst%3DM.%26aulast%3DNeubauer%26aufirst%3DA.%26aulast%3DEhninger%26aufirst%3DG.%26aulast%3DIllmer%26aufirst%3DT.%26atitle%3DAnalysis%2520of%2520FLT3-activating%2520mutations%2520in%2520979%2520patients%2520with%2520acute%2520myelogenous%2520leukemia%253A%2520association%2520with%2520FAB%2520subtypes%2520and%2520identification%2520of%2520subgroups%2520with%2520poor%2520prognosis%26jtitle%3DBlood%26date%3D2002%26volume%3D99%26spage%3D4326%26epage%3D4335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Sallmyr, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Datta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rassool, F.</span><span> </span><span class="NLM_article-title">Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">3173</span><span class="NLM_x">–</span> <span class="NLM_lpage">3182</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=3173-3182&author=A.+Sallmyrauthor=J.+Fanauthor=K.+Dattaauthor=K.+T.+Kimauthor=D.+Grosuauthor=P.+Shapiroauthor=D.+Smallauthor=F.+Rassool&title=Internal+tandem+duplication+of+FLT3+%28FLT3%2FITD%29+induces+increased+ROS+production%2C+DNA+damage%2C+and+misrepair%3A+implications+for+poor+prognosis+in+AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSallmyr%26aufirst%3DA.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DDatta%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DK.%2BT.%26aulast%3DGrosu%26aufirst%3DD.%26aulast%3DShapiro%26aufirst%3DP.%26aulast%3DSmall%26aufirst%3DD.%26aulast%3DRassool%26aufirst%3DF.%26atitle%3DInternal%2520tandem%2520duplication%2520of%2520FLT3%2520%2528FLT3%252FITD%2529%2520induces%2520increased%2520ROS%2520production%252C%2520DNA%2520damage%252C%2520and%2520misrepair%253A%2520implications%2520for%2520poor%2520prognosis%2520in%2520AML%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D3173%26epage%3D3182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">O’Farrell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngai, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smolich, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherrington, J. M.</span><span> </span><span class="NLM_article-title">SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">3597</span><span class="NLM_x">–</span> <span class="NLM_lpage">3605</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2003&pages=3597-3605&author=A.+M.+O%E2%80%99Farrellauthor=T.+J.+Abramsauthor=H.+A.+Yuenauthor=T.+J.+Ngaiauthor=S.+G.+Louieauthor=K.+W.+Yeeauthor=L.+M.+Wongauthor=W.+Hongauthor=L.+B.+Leeauthor=A.+Townauthor=B.+D.+Smolichauthor=W.+C.+Manningauthor=L.+J.+Murrayauthor=M.+C.+Heinrichauthor=J.+M.+Cherrington&title=SU11248+is+a+novel+FLT3+tyrosine+kinase+inhibitor+with+potent+activity+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Farrell%26aufirst%3DA.%2BM.%26aulast%3DAbrams%26aufirst%3DT.%2BJ.%26aulast%3DYuen%26aufirst%3DH.%2BA.%26aulast%3DNgai%26aufirst%3DT.%2BJ.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DYee%26aufirst%3DK.%2BW.%26aulast%3DWong%26aufirst%3DL.%2BM.%26aulast%3DHong%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DL.%2BB.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DSmolich%26aufirst%3DB.%2BD.%26aulast%3DManning%26aufirst%3DW.%2BC.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCherrington%26aufirst%3DJ.%2BM.%26atitle%3DSU11248%2520is%2520a%2520novel%2520FLT3%2520tyrosine%2520kinase%2520inhibitor%2520with%2520potent%2520activity%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2003%26volume%3D101%26spage%3D3597%26epage%3D3605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Lopes de Menezes, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, E. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shephard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldbeck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oei, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aukerman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C.</span><span> </span><span class="NLM_article-title">CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5281</span><span class="NLM_x">–</span> <span class="NLM_lpage">5291</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1158%2F1078-0432.CCR-05-0358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=16033847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmt12qurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=5281-5291&author=D.+E.+Lopes+de+Menezesauthor=J.+Pengauthor=E.+N.+Garrettauthor=S.+G.+Louieauthor=S.+H.+Leeauthor=M.+Wiesmannauthor=Y.+Tangauthor=L.+Shephardauthor=C.+Goldbeckauthor=Y.+Oeiauthor=H.+Yeauthor=S.+L.+Aukermanauthor=C.+Heise&title=CHIR-258%3A+a+potent+inhibitor+of+FLT3+kinase+in+experimental+tumor+xenograft+models+of+human+acute+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia</span></div><div class="casAuthors">Lopes de Menezes, Daniel E.; Peng, Jing; Garrett, Evelyn N.; Louie, Sharianne G.; Lee, Sang H.; Wiesmann, Marion; Tang, Yan; Shephard, Lee; Goldbeck, Cheryl; Oei, Yoko; Ye, Helen; Aukerman, Sharon L.; Heise, Carla</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5281-5291</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Fms-like tyrosine kinase 3 (FLT3) encodes a receptor tyrosine kinase (RTK) for which activating mutations have been identified in a proportion of acute myelogenous leukemia (AML) patients and assocd. with poor clin. prognosis.  Given the relevance of FLT3 mutations in AML, we investigated the activity of CHIR-258, an orally active, multitargeted small mol., with potent activity against FLT3 kinase and class III, IV, and V RTKs involved in endothelial and tumor cell proliferation in AML models.  Exptl. Design: CHIR-258 was tested on two human leukemic cell lines in vitro and in vivo with differing FLT3 mutational status [MV4;11 cells express FLT3 internal tandem duplications (ITD) vs. RS4;11 cells with wild-type (WT) FLT3].  Results: Antiproliferative activity of CHIR-258 against MV4;11 was ∼24-fold greater compared with RS4;11, indicating more potent inhibition against cells with constitutively activated FLT3 ITD.  Dose-dependent down modulation of receptor phosphorylation and downstream signaling [signal transducer and activator of transcription 5 (STAT5) and extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase] in MV4;11 cells with CHIR-258 confirmed the mol. mechanism of action.  Target modulation of phospho-FLT3, phospho-STAT5, and phospho-ERK in MV4;11 tumors was achieved at biol. active doses of CHIR-258.  Tumor regressions and eradication of AML cells from the bone marrow were shown in s.c. and bone marrow engraftment leukemic xenograft models.  Tumor responses were characterized by decreased cellular proliferation and pos. immunohistochem. staining for active caspase-3 and cleaved poly(ADP-ribose) polymerase, suggesting cell death was mediated in part via apoptosis.  Conclusions: These data indicate that CHIR-258 may be an effective therapy in FLT3-assocd. AML and warrants clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqguTG7oB17arVg90H21EOLACvtfcHk0lii3TrBITJuog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmt12qurc%253D&md5=81dc564d120f28420fdd69f685f877c2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0358%26sid%3Dliteratum%253Aachs%26aulast%3DLopes%2Bde%2BMenezes%26aufirst%3DD.%2BE.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DGarrett%26aufirst%3DE.%2BN.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DShephard%26aufirst%3DL.%26aulast%3DGoldbeck%26aufirst%3DC.%26aulast%3DOei%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DAukerman%26aufirst%3DS.%2BL.%26aulast%3DHeise%26aufirst%3DC.%26atitle%3DCHIR-258%253A%2520a%2520potent%2520inhibitor%2520of%2520FLT3%2520kinase%2520in%2520experimental%2520tumor%2520xenograft%2520models%2520of%2520human%2520acute%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D5281%26epage%3D5291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Angelo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galinsky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klimek, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebwohl, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial</span> <span class="citation_source-journal">Ann. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2004&pages=89-90&author=R.+M.+Stoneauthor=J.+De+Angeloauthor=I.+Galinskyauthor=E.+Esteyauthor=V.+Klimekauthor=W.+Grandinauthor=D.+Lebwohlauthor=A.+Yapauthor=P.+Cohenauthor=E.+Foxauthor=D.+Neubergauthor=J.+Clarkauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=PKC+412+FLT3+inhibitor+therapy+in+AML%3A+results+of+a+phase+II+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DDe%2BAngelo%26aufirst%3DJ.%26aulast%3DGalinsky%26aufirst%3DI.%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DKlimek%26aufirst%3DV.%26aulast%3DGrandin%26aufirst%3DW.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DYap%26aufirst%3DA.%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DFox%26aufirst%3DE.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DPKC%2520412%2520FLT3%2520inhibitor%2520therapy%2520in%2520AML%253A%2520results%2520of%2520a%2520phase%2520II%2520trial%26jtitle%3DAnn.%2520Hematol.%26date%3D2004%26volume%3D83%26spage%3D89%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beran, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauses, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allebach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">3669</span><span class="NLM_x">–</span> <span class="NLM_lpage">3676</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2004&pages=3669-3676&author=B.+D.+Smithauthor=M.+Levisauthor=M.+Beranauthor=F.+Gilesauthor=H.+Kantarjianauthor=K.+Bergauthor=K.+M.+Murphyauthor=T.+Dausesauthor=J.+Allebachauthor=D.+Small&title=Single-agent+CEP-701%2C+a+novel+FLT3+inhibitor%2C+shows+biologic+and+clinical+activity+in+patients+with+relapsed+or+refractory+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DBeran%26aufirst%3DM.%26aulast%3DGiles%26aufirst%3DF.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DBerg%26aufirst%3DK.%26aulast%3DMurphy%26aufirst%3DK.%2BM.%26aulast%3DDauses%26aufirst%3DT.%26aulast%3DAllebach%26aufirst%3DJ.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DSingle-agent%2520CEP-701%252C%2520a%2520novel%2520FLT3%2520inhibitor%252C%2520shows%2520biologic%2520and%2520clinical%2520activity%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2004%26volume%3D103%26spage%3D3669%26epage%3D3676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaney, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klisovic, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lecerf, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karol, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holford, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span> </span><span class="NLM_article-title">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3674</span><span class="NLM_x">–</span> <span class="NLM_lpage">3681</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1182%2Fblood-2006-02-005702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=16902153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=3674-3681&author=D.+J.+DeAngeloauthor=R.+M.+Stoneauthor=M.+L.+Heaneyauthor=S.+D.+Nimerauthor=R.+L.+Paquetteauthor=R.+B.+Klisovicauthor=M.+A.+Caligiuriauthor=M.+R.+Cooperauthor=J.+M.+Lecerfauthor=M.+D.+Karolauthor=S.+Shengauthor=N.+Holfordauthor=P.+T.+Curtinauthor=B.+J.+Drukerauthor=M.+C.+Heinrich&title=Phase+1+clinical+results+with+tandutinib+%28MLN518%29%2C+a+novel+FLT3+antagonist%2C+in+patients+with+acute+myelogenous+leukemia+or+high-risk+myelodysplastic+syndrome%3A+safety%2C+pharmacokinetics%2C+and+pharmacodynamics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</span></div><div class="casAuthors">DeAngelo, Daniel J.; Stone, Richard M.; Heaney, Mark L.; Nimer, Stephen D.; Paquette, Ronald L.; Klisovic, Rebecca B.; Caligiuri, Michael A.; Cooper, Michael R.; Lecerf, Jean-Michel; Karol, Michael D.; Sheng, Shihong; Holford, Nick; Curtin, Peter T.; Druker, Brian J.; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3674-3681</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptor (PDGFR), and KIT.  Because of the correlation between FLT3 internal tandem duplication (ITD) mutations and poor prognosis in acute myelogenous leukemia (AML), we conducted a phase 1 trial of tandutinib in 40 patients with either AML or high-risk myelodysplastic syndrome (MDS).  Tandutinib was given orally in doses ranging from 50 mg to 700 mg twice daily The principal dose-limiting toxicity (DLT) of tandutinib was reversible generalized muscular weakness, fatigue, or both, occurring at doses of 525 mg and 700 mg twice daily.  Tandutinib's pharmacokinetics were characterized by slow elimination, with achievement of steady-state plasma concns. requiring greater than 1 wk of dosing.  Western blotting showed that tandutinib inhibited phosphorylation of FLT3 in circulating leukemic blasts.  Eight patients had FLT3-ITD mutations; 5 of these were evaluable for assessment of tandutinib's antileukemic effect.  Two of the 5 patients, treated at 525 mg and 700 mg twice daily, showed evidence of antileukemic activity, with decreases in both peripheral and bone marrow blasts.  Tandutinib at the MTD (525 mg twice daily) should be evaluated more extensively in patients with AML with FLT3-ITD mutations to better define its antileukemic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraXRBv_Gv-TLVg90H21EOLACvtfcHk0lhvt7wPryv2ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Kgs7%252FM&md5=42c0b5a4c193955023198d6c6d12c463</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-02-005702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-02-005702%26sid%3Dliteratum%253Aachs%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStone%26aufirst%3DR.%2BM.%26aulast%3DHeaney%26aufirst%3DM.%2BL.%26aulast%3DNimer%26aufirst%3DS.%2BD.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKlisovic%26aufirst%3DR.%2BB.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DCooper%26aufirst%3DM.%2BR.%26aulast%3DLecerf%26aufirst%3DJ.%2BM.%26aulast%3DKarol%26aufirst%3DM.%2BD.%26aulast%3DSheng%26aufirst%3DS.%26aulast%3DHolford%26aufirst%3DN.%26aulast%3DCurtin%26aufirst%3DP.%2BT.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DPhase%25201%2520clinical%2520results%2520with%2520tandutinib%2520%2528MLN518%2529%252C%2520a%2520novel%2520FLT3%2520antagonist%252C%2520in%2520patients%2520with%2520acute%2520myelogenous%2520leukemia%2520or%2520high-risk%2520myelodysplastic%2520syndrome%253A%2520safety%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D3674%26epage%3D3681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brigham, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belli, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprankle, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armstrong, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S. S.</span><span> </span><span class="NLM_article-title">AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">2984</span><span class="NLM_x">–</span> <span class="NLM_lpage">2992</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=2984-2992&author=P.+P.+Zarrinkarauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=D.+Brighamauthor=B.+Belliauthor=M.+W.+Karamanauthor=K.+W.+Pratzauthor=G.+Pallaresauthor=Q.+Chaoauthor=K.+G.+Sprankleauthor=H.+K.+Patelauthor=M.+Levisauthor=R.+C.+Armstrongauthor=J.+Jamesauthor=S.+S.+Bhagwat&title=AC220+is+a+uniquely+potent+and+selective+inhibitor+of+FLT3+for+the+treatment+of+acute+myeloid+leukemia+%28AML%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DBelli%26aufirst%3DB.%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DPratz%26aufirst%3DK.%2BW.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DArmstrong%26aufirst%3DR.%2BC.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DAC220%2520is%2520a%2520uniquely%2520potent%2520and%2520selective%2520inhibitor%2520of%2520FLT3%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D2984%26epage%3D2992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Chao, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprankle, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunawardane, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cramer, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, S. S.</span><span> </span><span class="NLM_article-title">Identification of <i>N</i>-(5-<i>tert</i>-butylisoxazol-3-yl)-<i>N</i>′-{4-[7-(2-morpholin-4-ylethoxy)imidazo[2,1-<i>b</i>][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7808</span><span class="NLM_x">–</span> <span class="NLM_lpage">7816</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9007533" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7808-7816&author=Q.+Chaoauthor=K.+G.+Sprankleauthor=R.+M.+Grotzfeldauthor=A.+G.+Laiauthor=T.+A.+Carterauthor=A.+M.+Velascoauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=J.+Jamesauthor=P.+P.+Zarrinkarauthor=H.+K.+Patelauthor=S.+S.+Bhagwat&title=Identification+of+N-%285-tert-butylisoxazol-3-yl%29-N%E2%80%B2-%7B4-%5B7-%282-morpholin-4-ylethoxy%29imidazo%5B2%2C1-b%5D%5B1%2C3%5Dbenzothiazol-2-yl%5Dphenyl%7Durea+dihydrochloride+%28AC220%29%2C+a+uniquely+potent%2C+selective%2C+and+efficacious+FMS-like+tyrosine+kinase-3+%28FLT3%29+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm9007533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9007533%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DIdentification%2520of%2520N-%25285-tert-butylisoxazol-3-yl%2529-N%25E2%2580%25B2-%257B4-%255B7-%25282-morpholin-4-ylethoxy%2529imidazo%255B2%252C1-b%255D%255B1%252C3%255Dbenzothiazol-2-yl%255Dphenyl%257Durea%2520dihydrochloride%2520%2528AC220%2529%252C%2520a%2520uniquely%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520FMS-like%2520tyrosine%2520kinase-3%2520%2528FLT3%2529%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7808%26epage%3D7816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Kampen, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ter Elst, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bont, E. S.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor signaling in acute myeloid leukemia</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><div class="note"><p class="first last">in press</p></div><span class="refDoi"> DOI: 10.1007/s00018-012-1085-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1007%2Fs00018-012-1085-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=K.+R.+Kampenauthor=A.+Ter+Elstauthor=E.+S.+de+Bont&title=Vascular+endothelial+growth+factor+signaling+in+acute+myeloid+leukemia&doi=10.1007%2Fs00018-012-1085-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00018-012-1085-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-012-1085-3%26sid%3Dliteratum%253Aachs%26aulast%3DKampen%26aufirst%3DK.%2BR.%26aulast%3DTer%2BElst%26aufirst%3DA.%26aulast%3Dde%2BBont%26aufirst%3DE.%2BS.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520signaling%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2013%26doi%3D10.1007%2Fs00018-012-1085-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Ter Elst, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherpen, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Jonge, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douwes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierenga, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuringa, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamps, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bont, E. S.</span><span> </span><span class="NLM_article-title">Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">2761</span><span class="NLM_x">–</span> <span class="NLM_lpage">2771</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=2761-2771&author=A.+Ter+Elstauthor=B.+Maauthor=F.+J.+Scherpenauthor=H.+J.+de+Jongeauthor=J.+Douwesauthor=A.+T.+Wierengaauthor=J.+J.+Schuringaauthor=W.+A.+Kampsauthor=E.+S.+de+Bont&title=Repression+of+vascular+endothelial+growth+factor+expression+by+the+runt-related+transcription+factor+1+in+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTer%2BElst%26aufirst%3DA.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DScherpen%26aufirst%3DF.%2BJ.%26aulast%3Dde%2BJonge%26aufirst%3DH.%2BJ.%26aulast%3DDouwes%26aufirst%3DJ.%26aulast%3DWierenga%26aufirst%3DA.%2BT.%26aulast%3DSchuringa%26aufirst%3DJ.%2BJ.%26aulast%3DKamps%26aufirst%3DW.%2BA.%26aulast%3Dde%2BBont%26aufirst%3DE.%2BS.%26atitle%3DRepression%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520expression%2520by%2520the%2520runt-related%2520transcription%2520factor%25201%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D2761%26epage%3D2771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Savic, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cemerikic-Martinovic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dovat, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajic, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urosevic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekulic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kvrgic, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popovic, S.</span><span> </span><span class="NLM_article-title">Angiogenesis and survival in patients with myelodysplastic syndrome</span> <span class="citation_source-journal">Pathol. Oncol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">681</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1007%2Fs12253-012-9495-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=22270865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsF2msLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=681-690&author=A.+Savicauthor=V.+Cemerikic-Martinovicauthor=S.+Dovatauthor=N.+Rajicauthor=I.+Urosevicauthor=B.+Sekulicauthor=V.+Kvrgicauthor=S.+Popovic&title=Angiogenesis+and+survival+in+patients+with+myelodysplastic+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis and Survival in Patients with Myelodysplastic Syndrome</span></div><div class="casAuthors">Savic, Aleksandar; Cemerikic-Martinovic, Vesna; Dovat, Sinisa; Rajic, Nebojsa; Urosevic, Ivana; Sekulic, Borivoj; Kvrgic, Vanja; Popovic, Stevan</div><div class="citationInfo"><span class="NLM_cas:title">Pathology & Oncology Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">681-690</span>CODEN:
                <span class="NLM_cas:coden">POREFR</span>;
        ISSN:<span class="NLM_cas:issn">1219-4956</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Angiogenesis has been implicated in the pathogenesis and prognosis of myelodysplastic syndrome (MDS).  In this study, we investigated the relationship between microvessel d. (MVD), vascular endothelial growth factor (VEGF) expression, common morphol. and clin. factors, and survival in patients with MDS.  We examd. the MVD of paraffin-embedded bone marrow sections from 70 MDS patients and 31 controls.  VEGF expression was detd. in 50 patients and 20 controls.  The median MVD in MDS patients was significantly higher than that in controls (p = 0.025), whereas there was no difference in VEGF expression between MDS patients and controls.  In univariate anal., increased MVD was assocd. with a shorter survival time (p = 0.023).  However, in multivariate anal., MVD was not an independent predictor of survival.  The VEGF expression did not influence survival in univariate anal.  Survival was independently influenced by platelet count (p = 0.0073), cytogenetic risk category (p = 0.022), and transfusion dependence (p = 0.0073).  Neither MVD nor VEGF expression were predictors for progression to acute myeloid leukemia in univariate anal.  Progression to acute myeloid leukemia was independently influenced only by the cytogenetic risk category (p = 0.022).  This study confirmed increased MVD in MDS.  It does not support an independent prognostic role of angiogenesis in MDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBEH9qNr3gD7Vg90H21EOLACvtfcHk0lhKcaBoD5ZsLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsF2msLY%253D&md5=92901e8c2460b32e964195c734c23490</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs12253-012-9495-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12253-012-9495-y%26sid%3Dliteratum%253Aachs%26aulast%3DSavic%26aufirst%3DA.%26aulast%3DCemerikic-Martinovic%26aufirst%3DV.%26aulast%3DDovat%26aufirst%3DS.%26aulast%3DRajic%26aufirst%3DN.%26aulast%3DUrosevic%26aufirst%3DI.%26aulast%3DSekulic%26aufirst%3DB.%26aulast%3DKvrgic%26aufirst%3DV.%26aulast%3DPopovic%26aufirst%3DS.%26atitle%3DAngiogenesis%2520and%2520survival%2520in%2520patients%2520with%2520myelodysplastic%2520syndrome%26jtitle%3DPathol.%2520Oncol.%2520Res.%26date%3D2012%26volume%3D18%26spage%3D681%26epage%3D690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Padro, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bieker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steins, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Retzlaff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrera, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kienast, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Tidow, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serve, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdel, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesters, R. M.</span><span> </span><span class="NLM_article-title">Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1302</span><span class="NLM_x">–</span> <span class="NLM_lpage">1310</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=1302-1310&author=T.+Padroauthor=R.+Biekerauthor=S.+Ruizauthor=M.+Steinsauthor=S.+Retzlaffauthor=H.+Burgerauthor=T.+Buchnerauthor=T.+Kesslerauthor=F.+Herreraauthor=J.+Kienastauthor=C.+Muller-Tidowauthor=H.+Serveauthor=W.+E.+Berdelauthor=R.+M.+Mesters&title=Overexpression+of+vascular+endothelial+growth+factor+%28VEGF%29+and+its+cellular+receptor+KDR+%28VEGFR-2%29+in+the+bone+marrow+of+patients+with+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPadro%26aufirst%3DT.%26aulast%3DBieker%26aufirst%3DR.%26aulast%3DRuiz%26aufirst%3DS.%26aulast%3DSteins%26aufirst%3DM.%26aulast%3DRetzlaff%26aufirst%3DS.%26aulast%3DBurger%26aufirst%3DH.%26aulast%3DBuchner%26aufirst%3DT.%26aulast%3DKessler%26aufirst%3DT.%26aulast%3DHerrera%26aufirst%3DF.%26aulast%3DKienast%26aufirst%3DJ.%26aulast%3DMuller-Tidow%26aufirst%3DC.%26aulast%3DServe%26aufirst%3DH.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DMesters%26aufirst%3DR.%2BM.%26atitle%3DOverexpression%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520%2528VEGF%2529%2520and%2520its%2520cellular%2520receptor%2520KDR%2520%2528VEGFR-2%2529%2520in%2520the%2520bone%2520marrow%2520of%2520patients%2520with%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2002%26volume%3D16%26spage%3D1302%26epage%3D1310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Trujillo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cogle, C. R.</span><span> </span><span class="NLM_article-title">Angiogenesis in acute myeloid leukemia and opportunities for novel therapies</span> <span class="citation_source-journal">J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">9</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1155%2F2012%2F128608" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&pages=1-9&author=A.+Trujilloauthor=C.+McGeeauthor=C.+R.+Cogle&title=Angiogenesis+in+acute+myeloid+leukemia+and+opportunities+for+novel+therapies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1155%2F2012%2F128608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2012%252F128608%26sid%3Dliteratum%253Aachs%26aulast%3DTrujillo%26aufirst%3DA.%26aulast%3DMcGee%26aufirst%3DC.%26aulast%3DCogle%26aufirst%3DC.%2BR.%26atitle%3DAngiogenesis%2520in%2520acute%2520myeloid%2520leukemia%2520and%2520opportunities%2520for%2520novel%2520therapies%26jtitle%3DJ.%2520Oncol.%26date%3D2012%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Fiedler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graeven, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ergun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verago, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilic, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockschlader, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hossfeld, D. K.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">1870</span><span class="NLM_x">–</span> <span class="NLM_lpage">1875</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1997&pages=1870-1875&author=W.+Fiedlerauthor=U.+Graevenauthor=S.+Ergunauthor=S.+Veragoauthor=N.+Kilicauthor=M.+Stockschladerauthor=D.+K.+Hossfeld&title=Vascular+endothelial+growth+factor%2C+a+possible+paracrine+growth+factor+in+human+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DGraeven%26aufirst%3DU.%26aulast%3DErgun%26aufirst%3DS.%26aulast%3DVerago%26aufirst%3DS.%26aulast%3DKilic%26aufirst%3DN.%26aulast%3DStockschlader%26aufirst%3DM.%26aulast%3DHossfeld%26aufirst%3DD.%2BK.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%252C%2520a%2520possible%2520paracrine%2520growth%2520factor%2520in%2520human%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D1997%26volume%3D89%26spage%3D1870%26epage%3D1875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Deckers, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Bezooijen, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Horst, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoogendam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Der Bent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papapoulos, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowik, C. W.</span><span> </span><span class="NLM_article-title">Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A</span> <span class="citation_source-journal">Endocrinology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">143</span><span class="NLM_x">, </span> <span class="NLM_fpage">1545</span><span class="NLM_x">–</span> <span class="NLM_lpage">1553</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2002&pages=1545-1553&author=M.+M.+Deckersauthor=R.+L.+van+Bezooijenauthor=G.+van+der+Horstauthor=J.+Hoogendamauthor=C.+van+Der+Bentauthor=S.+E.+Papapoulosauthor=C.+W.+Lowik&title=Bone+morphogenetic+proteins+stimulate+angiogenesis+through+osteoblast-derived+vascular+endothelial+growth+factor+A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDeckers%26aufirst%3DM.%2BM.%26aulast%3Dvan%2BBezooijen%26aufirst%3DR.%2BL.%26aulast%3Dvan%2Bder%2BHorst%26aufirst%3DG.%26aulast%3DHoogendam%26aufirst%3DJ.%26aulast%3Dvan%2BDer%2BBent%26aufirst%3DC.%26aulast%3DPapapoulos%26aufirst%3DS.%2BE.%26aulast%3DLowik%26aufirst%3DC.%2BW.%26atitle%3DBone%2520morphogenetic%2520proteins%2520stimulate%2520angiogenesis%2520through%2520osteoblast-derived%2520vascular%2520endothelial%2520growth%2520factor%2520A%26jtitle%3DEndocrinology%26date%3D2002%26volume%3D143%26spage%3D1545%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Kodama, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshiko, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohama, K.</span><span> </span><span class="NLM_article-title">Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice</span> <span class="citation_source-journal">J. Bone Miner. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">200</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1359%2FJBMR.0301229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=14969389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1emu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2004&pages=200-206&author=I.+Kodamaauthor=S.+Niidaauthor=M.+Sanadaauthor=Y.+Yoshikoauthor=M.+Tsudaauthor=N.+Maedaauthor=K.+Ohama&title=Estrogen+regulates+the+production+of+VEGF+for+osteoclast+formation+and+activity+in+op%2Fop+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice</span></div><div class="casAuthors">Kodama, Ichiro; Niida, Shumpei; Sanada, Mitsuhiro; Yoshiko, Yuji; Tsuda, Mikio; Maeda, Norihiko; Ohama, Koso</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bone and Mineral Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">200-206</span>CODEN:
                <span class="NLM_cas:coden">JBMREJ</span>;
        ISSN:<span class="NLM_cas:issn">0884-0431</span>.
    
            (<span class="NLM_cas:orgname">American Society for Bone and Mineral Research</span>)
        </div><div class="casAbstract">Op/op mice have a severe deficiency of osteoclasts because of lacking functional M-CSF that is an essential factor of osteoclast differentiation and function.  The authors now report that OVX induces osteoclast formation and cures osteopetrosis by increasing the VEGF that regulates osteoclast formation in these mice.  The authors have found that estrogen deficiency induced by ovariectomy (OVX) upregulated osteoclast formation in op/op mice.  The authors have recently demonstrated that vascular endothelial growth factor (VEGF) could substitute for macrophage colony-stimulating factor (M-CSF) in the support of osteoclastic bone resorption in these mice.  Therefore, in this study, the authors wished to assess the effects of VEGF on bone loss induced by OVX in these mice.  Eight-week-old op/op mice were bilateral OVX or sham-operated.  Mice were killed at 8, 10, and 12 wk of age, and femurs were removed for prepns.  Some OVX mice were treated with three consecutive injections of 120 μl/body of VEGF-neutralizing antibody at 12-h intervals starting from 36 h before death at 4 wk after OVX.  VEGFR-1/Fc chimeric protein (600 μg/kg/day) or 17β-estradiol (0.16 μg/day) was administered in a dorsal s.c. pocket of the mice at the time of OVX.  These mice were killed 2 wk after surgery.  Changes of serum levels of VEGF were measured by ELISA.  Changes of mRNA levels of VEGF, Flt-1, interleukin-6, and osteoclast differentiation factor (ODF/TRANCE/RANKL) in bone tissue were measured by reverse transcriptase-polymerase chain reaction.  In OVX op/op mice, trabecular bone vol. of the femur was decreased, and the no. of osteoclasts was significantly increased.  Serum levels of VEGF were demonstrated to be higher in OVX mice than in sham-operated mice.  VEGF mRNA, Flt-1 mRNA, interleukin-6 mRNA, and RANKL mRNA levels in bone tissue were elevated in OVX mice over that in sham-operated mice.  The increase in osteoclast no. was inhibited by VEGF antagonist treatment in OVX mice.  Thus, the authors have demonstrated that the prodn. of VEGF and RANKL stimulated by OVX results in increased osteoclast formation in op/op mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNdUCvdWoEv7Vg90H21EOLACvtfcHk0liJLxme2cyQCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1emu7o%253D&md5=d61bdc6a122829993f4ff2843ebda085</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1359%2FJBMR.0301229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1359%252FJBMR.0301229%26sid%3Dliteratum%253Aachs%26aulast%3DKodama%26aufirst%3DI.%26aulast%3DNiida%26aufirst%3DS.%26aulast%3DSanada%26aufirst%3DM.%26aulast%3DYoshiko%26aufirst%3DY.%26aulast%3DTsuda%26aufirst%3DM.%26aulast%3DMaeda%26aufirst%3DN.%26aulast%3DOhama%26aufirst%3DK.%26atitle%3DEstrogen%2520regulates%2520the%2520production%2520of%2520VEGF%2520for%2520osteoclast%2520formation%2520and%2520activity%2520in%2520op%252Fop%2520mice%26jtitle%3DJ.%2520Bone%2520Miner.%2520Res.%26date%3D2004%26volume%3D19%26spage%3D200%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Knowles, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Athanasou, N. A.</span><span> </span><span class="NLM_article-title">Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF</span> <span class="citation_source-journal">J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">215</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">66</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1002%2Fpath.2319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=18283716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtFKrsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=2008&pages=56-66&author=H.+J.+Knowlesauthor=N.+A.+Athanasou&title=Hypoxia-inducible+factor+is+expressed+in+giant+cell+tumour+of+bone+and+mediates+paracrine+effects+of+hypoxia+on+monocyte-osteoclast+differentiation+via+induction+of+VEGF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF</span></div><div class="casAuthors">Knowles, H. J.; Athanasou, N. A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">215</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-66</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Hypoxia is an important regulator of bone biol. and stimulates osteoclast differentiation from monocytic precursors.  Hypoxia-inducible factor (HIF) is a key pro-tumorigenic transcription factor mediating pathways of hypoxia-inducible gene expression.  We have described expression of HIF-1α and HIF-2α in the multi-nucleated, osteoclast-like giant cells and the mononuclear stromal component of giant cell tumor of bone (GCTB), a locally osteolytic primary bone tumor.  HIF induction was obsd. in culture in the osteoblastic MG-63 cell line, primary GCTB stromal cells, and monocyte-derived osteoclasts following stimulation with hypoxia (0.1% O2) or the osteoclastogenic cytokines hepatocyte growth factor (HGF) and macrophage colony-stimulating factor (M-CSF).  This was accompanied by increased expression of the downstream target genes Bcl-2/adenovirus E1B 19 kD-interacting protein 3 (BNIP3), Glut-1, and vascular endothelial growth factor (VEGF).  As VEGF can substitute for M-CSF to support osteoclastogenesis in the presence of receptor activator for nuclear factor κB ligand (RANKL), we assessed the effect of MG-63 hypoxic conditioned media on osteoclast differentiation.  In the presence of RANKL, hypoxic conditioned media induced the formation of active osteoclasts, as assessed from the nos. of TRAP-pos. multi-nucleated cells and the area of lacunar bone resorption, which was inhibited by co-incubation with a neutralizing anti-VEGF antibody.  Targeted siRNA ablated HIF-1α and/or HIF-2α expression in MG-63 cells and reduced hypoxic secretion of VEGF.  Hypoxic conditioned media from cells treated with siRNA for (HIF-1α + HIF-2α) produced a significant decrease in osteoclast no. (p < 0.005) and activity (p < 0.05) in comparison with the scrambled siRNA control.  These results suggest that local hypoxia could indirectly influence osteoclastogenesis via autocrine and paracrine secretion of VEGF under the control of HIF.  This is potentially an important mechanism of pathogenesis for GCTB and other osteolytic lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhbgp3zroAPbVg90H21EOLACvtfcHk0liJLxme2cyQCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtFKrsr8%253D&md5=9b7490c27469b2d52e4c4e50f23701a3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fpath.2319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.2319%26sid%3Dliteratum%253Aachs%26aulast%3DKnowles%26aufirst%3DH.%2BJ.%26aulast%3DAthanasou%26aufirst%3DN.%2BA.%26atitle%3DHypoxia-inducible%2520factor%2520is%2520expressed%2520in%2520giant%2520cell%2520tumour%2520of%2520bone%2520and%2520mediates%2520paracrine%2520effects%2520of%2520hypoxia%2520on%2520monocyte-osteoclast%2520differentiation%2520via%2520induction%2520of%2520VEGF%26jtitle%3DJ.%2520Pathol.%26date%3D2008%26volume%3D215%26spage%3D56%26epage%3D66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Z. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyce, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, L.</span><span> </span><span class="NLM_article-title">VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">13491</span><span class="NLM_x">–</span> <span class="NLM_lpage">13499</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=13491-13499&author=Q.+Zhangauthor=R.+Guoauthor=Y.+Luauthor=L.+Zhaoauthor=Q.+Zhouauthor=E.+M.+Schwarzauthor=J.+Huangauthor=D.+Chenauthor=Z.+G.+Jinauthor=B.+F.+Boyceauthor=L.+Xing&title=VEGF-C%2C+a+lymphatic+growth+factor%2C+is+a+RANKL+target+gene+in+osteoclasts+that+enhances+osteoclastic+bone+resorption+through+an+autocrine+mechanism"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGuo%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DSchwarz%26aufirst%3DE.%2BM.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DJin%26aufirst%3DZ.%2BG.%26aulast%3DBoyce%26aufirst%3DB.%2BF.%26aulast%3DXing%26aufirst%3DL.%26atitle%3DVEGF-C%252C%2520a%2520lymphatic%2520growth%2520factor%252C%2520is%2520a%2520RANKL%2520target%2520gene%2520in%2520osteoclasts%2520that%2520enhances%2520osteoclastic%2520bone%2520resorption%2520through%2520an%2520autocrine%2520mechanism%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D13491%26epage%3D13499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Holzer, P.; Imbach, P.; Furet, P.; Schmiedeberg, N.</span><span> </span><span class="NLM_article-title">3-(Substituted amino)-pyrazolo[3,4-d]pyrimidines as Ephb and VEGFR2 Kinase Inhibitors</span>. PCT WO 2007/062805 A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=P.+Holzer&author=P.+Imbach&author=P.+Furet&author=N.+Schmiedeberg&title=3-%28Substituted+amino%29-pyrazolo%5B3%2C4-d%5Dpyrimidines+as+Ephb+and+VEGFR2+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHolzer%26aufirst%3DP.%26atitle%3D3-%2528Substituted%2520amino%2529-pyrazolo%255B3%252C4-d%255Dpyrimidines%2520as%2520Ephb%2520and%2520VEGFR2%2520Kinase%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Bannen, L. C.; Chan, D. S.; Dalrymple, L. E.; Jammalamadaka, V.; Khoury, R. G.; Mac, M. B.; Mann, G.; Mann, L. W.; Nuss, J. M.; Parks, J. J.; Wang, Y.; Xu, W.</span><span> </span><span class="NLM_article-title">C-met Modulators and Method of Use</span>. PCT WO 2006/014325 A2,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=L.+C.+Bannen&author=D.+S.+Chan&author=L.+E.+Dalrymple&author=V.+Jammalamadaka&author=R.+G.+Khoury&author=M.+B.+Mac&author=G.+Mann&author=L.+W.+Mann&author=J.+M.+Nuss&author=J.+J.+Parks&author=Y.+Wang&author=W.+Xu&title=C-met+Modulators+and+Method+of+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBannen%26aufirst%3DL.%2BC.%26atitle%3DC-met%2520Modulators%2520and%2520Method%2520of%2520Use%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Kubo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohyama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murooka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasegawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Izawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isoe, T.</span><span> </span><span class="NLM_article-title">Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure–activity relationships, and antitumor activities of <i>N</i>-phenyl-<i>N</i>′-{4-(4-quinolyloxy)phenyl}ureas</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1359</span><span class="NLM_x">–</span> <span class="NLM_lpage">1366</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030427r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1359-1366&author=K.+Kuboauthor=T.+Shimizuauthor=S.+Ohyamaauthor=H.+Murookaauthor=A.+Iwaiauthor=K.+Nakamuraauthor=K.+Hasegawaauthor=Y.+Kobayashiauthor=N.+Takahashiauthor=K.+Takahashiauthor=S.+Katoauthor=T.+Izawaauthor=T.+Isoe&title=Novel+potent+orally+active+selective+VEGFR-2+tyrosine+kinase+inhibitors%3A+synthesis%2C+structure%E2%80%93activity+relationships%2C+and+antitumor+activities+of+N-phenyl-N%E2%80%B2-%7B4-%284-quinolyloxy%29phenyl%7Dureas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm030427r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030427r%26sid%3Dliteratum%253Aachs%26aulast%3DKubo%26aufirst%3DK.%26aulast%3DShimizu%26aufirst%3DT.%26aulast%3DOhyama%26aufirst%3DS.%26aulast%3DMurooka%26aufirst%3DH.%26aulast%3DIwai%26aufirst%3DA.%26aulast%3DNakamura%26aufirst%3DK.%26aulast%3DHasegawa%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DN.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DS.%26aulast%3DIzawa%26aufirst%3DT.%26aulast%3DIsoe%26aufirst%3DT.%26atitle%3DNovel%2520potent%2520orally%2520active%2520selective%2520VEGFR-2%2520tyrosine%2520kinase%2520inhibitors%253A%2520synthesis%252C%2520structure%25E2%2580%2593activity%2520relationships%252C%2520and%2520antitumor%2520activities%2520of%2520N-phenyl-N%25E2%2580%25B2-%257B4-%25284-quinolyloxy%2529phenyl%257Dureas%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1359%26epage%3D1366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Yang, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Q. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S. Y.</span><span> </span><span class="NLM_article-title">Discovery of N6-phenyl-1<i>H</i>-pyrazolo[3,4-d]pyrimidine-3,6- diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">30</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=30-38&author=L.+L.+Yangauthor=G.+B.+Liauthor=H.+X.+Yanauthor=Q.+Z.+Sunauthor=S.+Maauthor=P.+Jiauthor=Z.+R.+Wangauthor=S.+Fengauthor=J.+Zouauthor=S.+Y.+Yang&title=Discovery+of+N6-phenyl-1H-pyrazolo%5B3%2C4-d%5Dpyrimidine-3%2C6-+diamine+derivatives+as+novel+CK1+inhibitors+using+common-feature+pharmacophore+model+based+virtual+screening+and+hit-to-lead+optimization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%2BL.%26aulast%3DLi%26aufirst%3DG.%2BB.%26aulast%3DYan%26aufirst%3DH.%2BX.%26aulast%3DSun%26aufirst%3DQ.%2BZ.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DJi%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%2BR.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DZou%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DDiscovery%2520of%2520N6-phenyl-1H-pyrazolo%255B3%252C4-d%255Dpyrimidine-3%252C6-%2520diamine%2520derivatives%2520as%2520novel%2520CK1%2520inhibitors%2520using%2520common-feature%2520pharmacophore%2520model%2520based%2520virtual%2520screening%2520and%2520hit-to-lead%2520optimization%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D56%26spage%3D30%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Garofalo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farce, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemoine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Six, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chavatte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goossens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depreux, P.</span><span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1189</span><span class="NLM_x">–</span> <span class="NLM_lpage">1204</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm2013453" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1189-1204&author=A.+Garofaloauthor=A.+Farceauthor=S.+Ravezauthor=A.+Lemoineauthor=P.+Sixauthor=P.+Chavatteauthor=L.+Goossensauthor=P.+Depreux&title=Synthesis+and+structure%E2%80%93activity+relationships+of+%28aryloxy%29quinazoline+ureas+as+novel%2C+potent%2C+and+selective+vascular+endothelial+growth+factor+receptor-2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm2013453&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2013453%26sid%3Dliteratum%253Aachs%26aulast%3DGarofalo%26aufirst%3DA.%26aulast%3DFarce%26aufirst%3DA.%26aulast%3DRavez%26aufirst%3DS.%26aulast%3DLemoine%26aufirst%3DA.%26aulast%3DSix%26aufirst%3DP.%26aulast%3DChavatte%26aufirst%3DP.%26aulast%3DGoossens%26aufirst%3DL.%26aulast%3DDepreux%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520%2528aryloxy%2529quinazoline%2520ureas%2520as%2520novel%252C%2520potent%252C%2520and%2520selective%2520vascular%2520endothelial%2520growth%2520factor%2520receptor-2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1189%26epage%3D1204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Quentmeier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reinhardt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaborski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drexler, H. G.</span><span> </span><span class="NLM_article-title">FLT3 mutations in acute myeloid leukemia cell lines</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">120</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2003&pages=120-124&author=H.+Quentmeierauthor=J.+Reinhardtauthor=M.+Zaborskiauthor=H.+G.+Drexler&title=FLT3+mutations+in+acute+myeloid+leukemia+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DQuentmeier%26aufirst%3DH.%26aulast%3DReinhardt%26aufirst%3DJ.%26aulast%3DZaborski%26aufirst%3DM.%26aulast%3DDrexler%26aufirst%3DH.%2BG.%26atitle%3DFLT3%2520mutations%2520in%2520acute%2520myeloid%2520leukemia%2520cell%2520lines%26jtitle%3DLeukemia%26date%3D2003%26volume%3D17%26spage%3D120%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Li, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Q. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S. Y.</span><span> </span><span class="NLM_article-title">Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-<i>p</i>-tolylurea and its anti-acute myeloid leukemia (AML) activities <i>in vitro</i> and <i>in vivo</i></span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3852</span><span class="NLM_x">–</span> <span class="NLM_lpage">3866</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300042x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3852-3866&author=W.+W.+Liauthor=X.+Y.+Wangauthor=R.+L.+Zhengauthor=H.+X.+Yanauthor=Z.+X.+Caoauthor=L.+Zhongauthor=Z.+R.+Wangauthor=P.+Jiauthor=L.+L.+Yangauthor=L.+J.+Wangauthor=Y.+Xuauthor=J.+J.+Liuauthor=J.+Yangauthor=C.+H.+Zhangauthor=S.+Maauthor=S.+Fengauthor=Q.+Z.+Sunauthor=Y.+Q.+Weiauthor=S.+Y.+Yang&title=Discovery+of+the+novel+potent+and+selective+FLT3+inhibitor+1-%7B5-%5B7-%283-+morpholinopropoxy%29quinazolin-4-ylthio%5D-%5B1%2C3%2C4%5Dthiadiazol-2-yl%7D-3-p-tolylurea+and+its+anti-acute+myeloid+leukemia+%28AML%29+activities+in+vitro+and+in+vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm300042x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300042x%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%2BW.%26aulast%3DWang%26aufirst%3DX.%2BY.%26aulast%3DZheng%26aufirst%3DR.%2BL.%26aulast%3DYan%26aufirst%3DH.%2BX.%26aulast%3DCao%26aufirst%3DZ.%2BX.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%2BR.%26aulast%3DJi%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DL.%2BL.%26aulast%3DWang%26aufirst%3DL.%2BJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%2BJ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DQ.%2BZ.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DDiscovery%2520of%2520the%2520novel%2520potent%2520and%2520selective%2520FLT3%2520inhibitor%25201-%257B5-%255B7-%25283-%2520morpholinopropoxy%2529quinazolin-4-ylthio%255D-%255B1%252C3%252C4%255Dthiadiazol-2-yl%257D-3-p-tolylurea%2520and%2520its%2520anti-acute%2520myeloid%2520leukemia%2520%2528AML%2529%2520activities%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3852%26epage%3D3866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Davies, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forster, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnost, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choquette, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galullo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henkel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidary, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuver-Moody, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namchuk, M.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of a novel dual FMS-like tyrosine kinase 3/stem cell factor receptor (FLT3/c-KIT) inhibitor for the treatment of acute myelogenous leukemia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7184</span><span class="NLM_x">–</span> <span class="NLM_lpage">7192</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200712h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7184-7192&author=R.+J.+Daviesauthor=A.+C.+Pierceauthor=C.+Forsterauthor=R.+Greyauthor=J.+Xuauthor=M.+Arnostauthor=D.+Choquetteauthor=V.+Galulloauthor=S.+K.+Tianauthor=G.+Henkelauthor=G.+Chenauthor=D.+K.+Heidaryauthor=J.+Maauthor=C.+Stuver-Moodyauthor=M.+Namchuk&title=Design%2C+synthesis%2C+and+evaluation+of+a+novel+dual+FMS-like+tyrosine+kinase+3%2Fstem+cell+factor+receptor+%28FLT3%2Fc-KIT%29+inhibitor+for+the+treatment+of+acute+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm200712h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200712h%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DR.%2BJ.%26aulast%3DPierce%26aufirst%3DA.%2BC.%26aulast%3DForster%26aufirst%3DC.%26aulast%3DGrey%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DArnost%26aufirst%3DM.%26aulast%3DChoquette%26aufirst%3DD.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DTian%26aufirst%3DS.%2BK.%26aulast%3DHenkel%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DHeidary%26aufirst%3DD.%2BK.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DStuver-Moody%26aufirst%3DC.%26aulast%3DNamchuk%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520a%2520novel%2520dual%2520FMS-like%2520tyrosine%2520kinase%25203%252Fstem%2520cell%2520factor%2520receptor%2520%2528FLT3%252Fc-KIT%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520acute%2520myelogenous%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7184%26epage%3D7192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Bavetsias, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crumpler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avery, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atrash, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faisal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmopoulou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldrake, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bush, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayliss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linardopoulos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, J.</span><span> </span><span class="NLM_article-title">Optimization of imidazo[4,5-<i>b</i>]pyridine-based kinase inhibitors: identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8721</span><span class="NLM_x">–</span> <span class="NLM_lpage">8734</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300952s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8721-8734&author=V.+Bavetsiasauthor=S.+Crumplerauthor=C.+Sunauthor=S.+Averyauthor=B.+Atrashauthor=A.+Faisalauthor=A.+S.+Mooreauthor=M.+Kosmopoulouauthor=N.+Brownauthor=P.+W.+Sheldrakeauthor=K.+Bushauthor=A.+Henleyauthor=G.+Boxauthor=M.+Valentiauthor=A.+de+Haven+Brandonauthor=F.+I.+Raynaudauthor=P.+Workmanauthor=S.+A.+Ecclesauthor=R.+Baylissauthor=S.+Linardopoulosauthor=J.+Blagg&title=Optimization+of+imidazo%5B4%2C5-b%5Dpyridine-based+kinase+inhibitors%3A+identification+of+a+dual+FLT3%2Faurora+kinase+inhibitor+as+an+orally+bioavailable+preclinical+development+candidate+for+the+treatment+of+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm300952s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300952s%26sid%3Dliteratum%253Aachs%26aulast%3DBavetsias%26aufirst%3DV.%26aulast%3DCrumpler%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DAvery%26aufirst%3DS.%26aulast%3DAtrash%26aufirst%3DB.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DA.%2BS.%26aulast%3DKosmopoulou%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DN.%26aulast%3DSheldrake%26aufirst%3DP.%2BW.%26aulast%3DBush%26aufirst%3DK.%26aulast%3DHenley%26aufirst%3DA.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DBayliss%26aufirst%3DR.%26aulast%3DLinardopoulos%26aufirst%3DS.%26aulast%3DBlagg%26aufirst%3DJ.%26atitle%3DOptimization%2520of%2520imidazo%255B4%252C5-b%255Dpyridine-based%2520kinase%2520inhibitors%253A%2520identification%2520of%2520a%2520dual%2520FLT3%252Faurora%2520kinase%2520inhibitor%2520as%2520an%2520orally%2520bioavailable%2520preclinical%2520development%2520candidate%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8721%26epage%3D8734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span> </span><span class="NLM_article-title">SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">4439</span><span class="NLM_x">–</span> <span class="NLM_lpage">4450</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm301537p&amp;key=10.1158%2F1078-0432.CCR-10-3109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm301537p&amp;key=21622720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm301537p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1SmtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=4439-4450&author=S.+Zhangauthor=Z.+Caoauthor=H.+Tianauthor=G.+Shenauthor=Y.+Maauthor=H.+Xieauthor=Y.+Liuauthor=C.+Zhaoauthor=S.+Dengauthor=Y.+Yangauthor=R.+Zhengauthor=W.+Liauthor=N.+Zhangauthor=S.+Liuauthor=W.+Wangauthor=L.+Daiauthor=S.+Shiauthor=L.+Chengauthor=Y.+Panauthor=S.+Fengauthor=X.+Zhaoauthor=H.+Dengauthor=S.+Yangauthor=Y.+Wei&title=SKLB1002%2C+a+novel+potent+inhibitor+of+VEGF+receptor+2+signaling%2C+inhibits+angiogenesis+and+tumor+growth+in+vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth In Vivo</span></div><div class="casAuthors">Zhang, Shuang; Cao, Zhixing; Tian, Hongwei; Shen, Guobo; Ma, Yongping; Xie, Huanzhang; Liu, Yalin; Zhao, Chengjian; Deng, Senyi; Yang, Yang; Zheng, Renlin; Li, Weiwei; Zhang, Na; Liu, Shengyong; Wang, Wei; Dai, Lixia; Shi, Shuai; Cheng, Lin; Pan, Youli; Feng, Shan; Zhao, Xia; Deng, Hongxin; Yang, Shengyong; Wei, Yuquan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4439-4450</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: VEGF receptor 2 (VEGFR2) inhibitors, as efficient antiangiogenesis agents, have been applied in the cancer treatment.  However, currently most of these anticancer drugs suffer some adverse effects.  Discovery of novel VEGFR2 inhibitors as anticancer drug candidates is still needed.  Exptl. Design: In this investigation, we adopted a restricted de novo design method to design VEGFR2 inhibitors.  We selected the most potent compd. SKLB1002 and analyzed its inhibitory effects on human umbilical vein endothelial cells (HUVEC) in vitro.  Tumor xenografts in zebrafish and athymic mice were used to examine the in vivo activity of SKLB1002.  RESULTS: The use of the restricted de novo design method indeed led to a new potent VEGFR2 inhibitor, SKLB1002, which could significantly inhibit HUVEC proliferation, migration, invasion, and tube formation.  Western blot anal. was conducted, which indicated that SKLB1002 inhibited VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal-regulated kinase, focal adhesion kinase, and Src.  In vivo zebrafish model expts. showed that SKLB1002 remarkably blocked the formation of intersegmental vessels in zebrafish embryos.  It was further found to inhibit a new microvasculature in zebrafish embryos induced by inoculated tumor cells.  Finally, compared with the solvent control, administration of 100 mg/kg/d SKLB1002 reached more than 60% inhibition against human tumor xenografts in athymic mice.  The antiangiogenic effect was indicated by CD31 immunohistochem. staining and alginate-encapsulated tumor cell assay.  CONCLUSIONS: Our findings suggest that SKLB1002 inhibits angiogenesis and may be a potential drug candidate in anticancer therapy.  Clin Cancer Res; 17(13); 4439-50.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIgqK6UNG6yrVg90H21EOLACvtfcHk0lhCAR_q3HrTCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1SmtLo%253D&md5=a15e4fe2fd1e62134a8c48cf2d4a2547</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-3109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-3109%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DDeng%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DDai%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26atitle%3DSKLB1002%252C%2520a%2520novel%2520potent%2520inhibitor%2520of%2520VEGF%2520receptor%25202%2520signaling%252C%2520inhibits%2520angiogenesis%2520and%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D4439%26epage%3D4450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Song, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y.</span><span> </span><span class="NLM_article-title">A critical role of vascular endothelial growth factor D in zebrafish embryonic vasculogenesis and angiogenesis</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">357</span><span class="NLM_x">, </span> <span class="NLM_fpage">924</span><span class="NLM_x">–</span> <span class="NLM_lpage">930</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2007&pages=924-930&author=M.+Songauthor=H.+Yangauthor=S.+Yaoauthor=F.+Maauthor=Z.+Liauthor=Y.+Dengauthor=H.+Dengauthor=Q.+Zhouauthor=S.+Linauthor=Y.+Wei&title=A+critical+role+of+vascular+endothelial+growth+factor+D+in+zebrafish+embryonic+vasculogenesis+and+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DY.%26atitle%3DA%2520critical%2520role%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520D%2520in%2520zebrafish%2520embryonic%2520vasculogenesis%2520and%2520angiogenesis%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2007%26volume%3D357%26spage%3D924%26epage%3D930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Cao, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S. Y.</span><span> </span><span class="NLM_article-title">SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1892</span><span class="NLM_x">–</span> <span class="NLM_lpage">1895</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=1892-1895&author=Z.+X.+Caoauthor=J.+J.+Liuauthor=R.+L.+Zhengauthor=J.+Yangauthor=L.+Zhongauthor=Y.+Xuauthor=L.+J.+Wangauthor=C.+H.+Zhangauthor=B.+L.+Wangauthor=S.+Maauthor=Z.+R.+Wangauthor=H.+Z.+Xieauthor=Y.+Q.+Weiauthor=S.+Y.+Yang&title=SKLB1028%2C+a+novel+oral+multikinase+inhibitor+of+EGFR%2C+FLT3+and+Abl%2C+displays+exceptional+activity+in+models+of+FLT3-driven+AML+and+considerable+potency+in+models+of+CML+harboring+Abl+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DZ.%2BX.%26aulast%3DLiu%26aufirst%3DJ.%2BJ.%26aulast%3DZheng%26aufirst%3DR.%2BL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%2BJ.%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DWang%26aufirst%3DB.%2BL.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%2BR.%26aulast%3DXie%26aufirst%3DH.%2BZ.%26aulast%3DWei%26aufirst%3DY.%2BQ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26atitle%3DSKLB1028%252C%2520a%2520novel%2520oral%2520multikinase%2520inhibitor%2520of%2520EGFR%252C%2520FLT3%2520and%2520Abl%252C%2520displays%2520exceptional%2520activity%2520in%2520models%2520of%2520FLT3-driven%2520AML%2520and%2520considerable%2520potency%2520in%2520models%2520of%2520CML%2520harboring%2520Abl%2520mutants%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D1892%26epage%3D1895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Tran, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sneed, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haider, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blavo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aiyejorun, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baranowski, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubinstein, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doan, T. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dingledine, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandberg, E. M.</span><span> </span><span class="NLM_article-title">Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">11386</span><span class="NLM_x">–</span> <span class="NLM_lpage">11392</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11386-11392&author=T.+C.+Tranauthor=B.+Sneedauthor=J.+Haiderauthor=D.+Blavoauthor=A.+Whiteauthor=T.+Aiyejorunauthor=T.+C.+Baranowskiauthor=A.+L.+Rubinsteinauthor=T.+N.+Doanauthor=R.+Dingledineauthor=E.+M.+Sandberg&title=Automated%2C+quantitative+screening+assay+for+antiangiogenic+compounds+using+transgenic+zebrafish"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTran%26aufirst%3DT.%2BC.%26aulast%3DSneed%26aufirst%3DB.%26aulast%3DHaider%26aufirst%3DJ.%26aulast%3DBlavo%26aufirst%3DD.%26aulast%3DWhite%26aufirst%3DA.%26aulast%3DAiyejorun%26aufirst%3DT.%26aulast%3DBaranowski%26aufirst%3DT.%2BC.%26aulast%3DRubinstein%26aufirst%3DA.%2BL.%26aulast%3DDoan%26aufirst%3DT.%2BN.%26aulast%3DDingledine%26aufirst%3DR.%26aulast%3DSandberg%26aufirst%3DE.%2BM.%26atitle%3DAutomated%252C%2520quantitative%2520screening%2520assay%2520for%2520antiangiogenic%2520compounds%2520using%2520transgenic%2520zebrafish%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11386%26epage%3D11392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Nourry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dijkstra, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaulon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suijkerbuijk, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedlos, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span> </span><span class="NLM_article-title">BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1964</span><span class="NLM_x">–</span> <span class="NLM_lpage">1978</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901509a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1964-1978&author=A.+Nourryauthor=A.+Zambonauthor=L.+Daviesauthor=I.+Niculescu-Duvazauthor=H.+P.+Dijkstraauthor=D.+Menardauthor=C.+Gaulonauthor=D.+Niculescu-Duvazauthor=B.+M.+Suijkerbuijkauthor=F.+Friedlosauthor=H.+A.+Manneauthor=R.+Kirkauthor=S.+Whittakerauthor=R.+Maraisauthor=C.+J.+Springer&title=BRAF+inhibitors+based+on+an+imidazo%5B4%2C5%5Dpyridin-2-one+scaffold+and+a+meta+substituted+middle+ring"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm901509a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901509a%26sid%3Dliteratum%253Aachs%26aulast%3DNourry%26aufirst%3DA.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DL.%26aulast%3DNiculescu-Duvaz%26aufirst%3DI.%26aulast%3DDijkstra%26aufirst%3DH.%2BP.%26aulast%3DMenard%26aufirst%3DD.%26aulast%3DGaulon%26aufirst%3DC.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DSuijkerbuijk%26aufirst%3DB.%2BM.%26aulast%3DFriedlos%26aufirst%3DF.%26aulast%3DManne%26aufirst%3DH.%2BA.%26aulast%3DKirk%26aufirst%3DR.%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26atitle%3DBRAF%2520inhibitors%2520based%2520on%2520an%2520imidazo%255B4%252C5%255Dpyridin-2-one%2520scaffold%2520and%2520a%2520meta%2520substituted%2520middle%2520ring%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1964%26epage%3D1978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Vizirianakis, I. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatzopoulou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonovolias, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolaou, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demopoulos, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsiftsoglou, A. S.</span><span> </span><span class="NLM_article-title">Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6779</span><span class="NLM_x">–</span> <span class="NLM_lpage">6810</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100189a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6779-6810&author=I.+S.+Vizirianakisauthor=M.+Chatzopoulouauthor=I.+D.+Bonovoliasauthor=I.+Nicolaouauthor=V.+J.+Demopoulosauthor=A.+S.+Tsiftsoglou&title=Toward+the+development+of+innovative+bifunctional+agents+to+induce+differentiation+and+to+promote+apoptosis+in+leukemia%3A+clinical+candidates+and+perspectives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm100189a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100189a%26sid%3Dliteratum%253Aachs%26aulast%3DVizirianakis%26aufirst%3DI.%2BS.%26aulast%3DChatzopoulou%26aufirst%3DM.%26aulast%3DBonovolias%26aufirst%3DI.%2BD.%26aulast%3DNicolaou%26aufirst%3DI.%26aulast%3DDemopoulos%26aufirst%3DV.%2BJ.%26aulast%3DTsiftsoglou%26aufirst%3DA.%2BS.%26atitle%3DToward%2520the%2520development%2520of%2520innovative%2520bifunctional%2520agents%2520to%2520induce%2520differentiation%2520and%2520to%2520promote%2520apoptosis%2520in%2520leukemia%253A%2520clinical%2520candidates%2520and%2520perspectives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6779%26epage%3D6810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Metzelder, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gotze, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Linn, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salih, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinicke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuhlmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giagounidis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vohringer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schafer-Eckart, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultheis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldus, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burchert, A.</span><span> </span><span class="NLM_article-title">High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">2353</span><span class="NLM_x">–</span> <span class="NLM_lpage">2359</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=2353-2359&author=S.+K.+Metzelderauthor=T.+Schroederauthor=A.+Finckauthor=S.+Schollauthor=M.+Feyauthor=K.+Gotzeauthor=Y.+C.+Linnauthor=M.+Krogerauthor=A.+Reiterauthor=H.+R.+Salihauthor=T.+Heinickeauthor=R.+Stuhlmannauthor=L.+Mullerauthor=A.+Giagounidisauthor=R.+G.+Meyerauthor=W.+Bruggerauthor=M.+Vohringerauthor=P.+Dregerauthor=M.+Moriauthor=N.+Basaraauthor=K.+Schafer-Eckartauthor=B.+Schultheisauthor=C.+Baldusauthor=A.+Neubauerauthor=A.+Burchert&title=High+activity+of+sorafenib+in+FLT3-ITD-positive+acute+myeloid+leukemia+synergizes+with+allo-immune+effects+to+induce+sustained+responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMetzelder%26aufirst%3DS.%2BK.%26aulast%3DSchroeder%26aufirst%3DT.%26aulast%3DFinck%26aufirst%3DA.%26aulast%3DScholl%26aufirst%3DS.%26aulast%3DFey%26aufirst%3DM.%26aulast%3DGotze%26aufirst%3DK.%26aulast%3DLinn%26aufirst%3DY.%2BC.%26aulast%3DKroger%26aufirst%3DM.%26aulast%3DReiter%26aufirst%3DA.%26aulast%3DSalih%26aufirst%3DH.%2BR.%26aulast%3DHeinicke%26aufirst%3DT.%26aulast%3DStuhlmann%26aufirst%3DR.%26aulast%3DMuller%26aufirst%3DL.%26aulast%3DGiagounidis%26aufirst%3DA.%26aulast%3DMeyer%26aufirst%3DR.%2BG.%26aulast%3DBrugger%26aufirst%3DW.%26aulast%3DVohringer%26aufirst%3DM.%26aulast%3DDreger%26aufirst%3DP.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DBasara%26aufirst%3DN.%26aulast%3DSchafer-Eckart%26aufirst%3DK.%26aulast%3DSchultheis%26aufirst%3DB.%26aulast%3DBaldus%26aufirst%3DC.%26aulast%3DNeubauer%26aufirst%3DA.%26aulast%3DBurchert%26aufirst%3DA.%26atitle%3DHigh%2520activity%2520of%2520sorafenib%2520in%2520FLT3-ITD-positive%2520acute%2520myeloid%2520leukemia%2520synergizes%2520with%2520allo-immune%2520effects%2520to%2520induce%2520sustained%2520responses%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D2353%26epage%3D2359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i43"><a href="/doi/suppl/10.1021/jm301537p">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_17848"></div></div></div></div></div><hr /></hr><p class="last">Table S1 listing the binding affinities of compound <b>33</b> with various kinases, Figure S1 showing the TREE<i>spot</i> interaction maps for compound <b>33</b>, experimental details of the synthesis and analytical characterization of compounds <b>2</b>–<b>5</b>, <b>7</b>, <b>8</b>, <b>11</b>, <b>13</b>–<b>17</b>, <b>19</b>–<b>26</b>, and <b>28</b>–<b>32</b> described in this paper, and purity data for the final compounds. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm301537p/suppl_file/jm301537p_si_001.pdf">jm301537p_si_001.pdf (289.52 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm301537p&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm301537p%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-4%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm301537p" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b36072c9ad95a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
